
CITATION REPORT List of articles citing



DOI: 10.1096/fasebj.13.1.9 FASEB Journal, 1999, 13, 9-22.

Source: https://exaly.com/paper-pdf/29990757/citation-report.pdf

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF		Citations
2338	The effects of nitrous oxide on vascular endothelial growth factor (VEGF) and its soluble receptor 1 (VEGFR1) in patient undergoing urological surgery. 2014 , 30, 45-9		1
2337	Increased growth factor expression after hepatic and pancreatic resection. 1994 , 20, 1527		1
2336	Angiogenesis in Ischemic Disease. 1999 , 82, 44-52		88
2335	Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. 1999 , 277, H2205	-11	80
2334	Quantitative RT-PCR Assay for VEGF Mrna in Human Tumors of the Kidney. 1999 , 14, 247-250		10
2333	Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. 1999 , 190, 293-8		349
2332	Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. 1999 , 274, 25130-5		367
2331	Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. 1999 , 13, 806-11		158
2330	Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. 1999 , 274, 30896-905		159
2329	Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. 1999 , 274, 33057-63		234
2328	Development of a method for measuring myocardial contractility with gated myocardial SPECT and arterial tonometry. 1999 , 6, 657-63		8
2327	Molecular angiogenesis. 1999 , 6, R217-24		193
2326	New paradigms of signaling in the vasculature: ephrins and metalloproteases. 1999 , 10, 536-40		13
2325	Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. 1999 , 113, 1047-53		91
2324	Role of vascular endothelial growth factor in the regulation of angiogenesis. 1999 , 56, 794-814		547
2323	Glomerular endothelial cell development. 1999 , 56, 1597-8		4
2322	Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. 1999 , 5, 495-502		559

2321	Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene. 1999 , 18, 4200-10	19
2320	Growth factor signaling pathways in vascular development. 1999 , 18, 7917-32	90
2319	Soluble VEGF receptors. 1999 , 3, 33-9	45
2318	Role of endothelial cell survival and death signals in angiogenesis. 1999 , 3, 101-16	45
2317	Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. 1999 , 18, 473-81	71
2316	Tyrosine kinase inhibitors in preclinical development. 1999 , 17, 213-26	39
2315	Dual effects of heparin on VEGF binding to VEGF receptor-1 and transduction of biological responses. 1999 , 3, 159-66	21
2314	Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. 1999 , 18, 6240-8	184
2313	Molecular and biological properties of vascular endothelial growth factor. 1999 , 77, 527-43	880
2312	Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis. 1999 , 435, 20-31	31
2311	On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). 1999 , 232, 121-9	72
2310	Vascular endothelial growth factor stimulates Schwann cell invasion and neovascularization of acellular nerve grafts. 1999 , 846, 219-28	165
2309	Inhibierung der Angiogenese in vivo durch ets-1-Antisense-Oligonucleotide [Hemmung der Expression des Ets-1-Transkriptionsfaktors durch das Antibiotikum Fumagillin. 1999 , 111, 3432-3435	6
2308	Vascular endothelial growth factor upregulation in transient global ischemia induced by cardiac arrest and resuscitation in rat brain. 1999 , 74, 83-90	46
2307	Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. 1999 , 146, 233-42	406
2306	Levels of vascular endothelial growth factor are elevated in patients with ectopic pregnancy: is this a novel marker?. 1999 , 72, 1013-7	51
2305	Signaling via vascular endothelial growth factor receptors. 1999 , 253, 117-30	225
2304	Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. 1999 , 264, 781-8	300

2303	Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. 1999 , 274, 35172-8	141
2302	Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. 1999 , 13, 1055-66	611
2301	Vascular endothelial growth factor stimulates dephosphorylation of the catenins p120 and p100 in endothelial cells. 2000 , 346, 209	17
2300	The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. 2000 , 347, 501-9	33
2299	Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. 2000 , 348, 273	19
2298	Multiple isoforms of the ryanodine receptor are expressed in rat pancreatic acinar cells. 2000 , 351, 265-71	40
2297	The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. 2000 , 347, 501-509	61
2296	Multiple isoforms of the ryanodine receptor are expressed in rat pancreatic acinar cells. 2000 , 351, 265-271	51
2295	Vascular endothelial growth factor stimulates dephosphorylation of the catenins p120 and p100 in endothelial cells. 2000 , 346, 209-216	34
2294	Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. 2000 , 348, 273-280	48
2293	Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. 2000 , 15, 1087-93	150
2292	Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke. 2000 , 31, 1863-70	192
2291	Vascular endothelial growth factor is efficiently synthesized in spite of low transfection efficiency of pSG5VEGF plasmids in vascular smooth muscle cells. 2000 , 5, 33-40	14
2290	Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor. 2000 , 20, 1512-20	125
2289	Molecular aspects of fracture healing. 2000 , 11, 367-371	3
2288	Is angiogenesis inhibition the Holy Grail of cancer therapy?. 2000 , 12, 89-94	20
2287	Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. 2000 , 86, 174-81	117
2286	Transgenic mouse models in angiogenesis and cardiovascular disease. 2000 , 190, 387-405	97

(2000-2000)

2285	Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castration. 2000 , 43, 184-94	29
2284	ATP site-directed competitive and irreversible inhibitors of protein kinases. 2000 , 20, 28-57	95
2283	Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. 2000 , 192, 150-8	283
2282	Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. 2000 , 45, 216-24	95
2281	VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. 2000 , 219, 341-52	102
2280	Placental defects in ARNT-knockout conceptus correlate with localized decreases in VEGF-R2, Ang-1, and Tie-2. 2000 , 219, 526-38	59
2279	Expression and regulation of neuropilin-1 in human astrocytomas. 2000 , 88, 584-92	65
2278	Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells. 2000 , 184, 246-54	15
2277	ACTH-regulated expression of vascular endothelial growth factor in the adult bovine adrenal cortex: a possible role in the maintenance of the microvasculature. 2000 , 185, 226-34	31
2276	Vascular endothelial growth factor production in polymyalgia rheumatica. 2000 , 43, 2472-80	21
2275	Diabetic neuropathya continuing enigma. 2000 , 16, 408-33	135
2274	Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. 2000 , 2, 279-88	46
2273	Placenta growth factor is induced in human keratinocytes during wound healing. 2000, 115, 388-95	75
2272	Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. 2000 , 115, 1000-7	128
2271	Enhanced vascularization of cultured skin substitutes genetically modified to overexpress vascular endothelial growth factor. 2000 , 114, 5-13	95
2270	Active hair growth (anagen) is associated with angiogenesis. 2000 , 114, 909-16	171
2269	Role of vascular endothelial growth factor in diabetic nephropathy. 2000 , 77, S104-12	91
2268	Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. 2000 , 121, 426-9	36

2267	Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. 2000 , 12, 4243-54	297
2266	AngiogenBe´: mcanismes ghfaux et implications au cours de la polyarthrite rhumatoffe. 2000 , 67, 573-592	1
2265	Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. 2000 , 20, 1174-89	81
2264	Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. 2000 , 19, 4611-20	170
2263	Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. 2000 , 19, 5598-605	337
2262	The protein tyrosine kinase family of the human genome. 2000 , 19, 5548-57	819
2261	Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. 2000 , 19, 6122-9	212
2260	Alterations of the rat mesentery vasculature in experimental diabetes. 2000 , 80, 1171-84	15
2259	Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. 2000 , 80, 1195-205	136
2258	Controlled growth factor release from synthetic extracellular matrices. 2000 , 408, 998-1000	415
2257	VEGF: an update on biological and therapeutic aspects. 2000 , 11, 617-24	315
2256	Angiogenesis in ovarian cancer. 2000 , 14, 901-18	40
2255	Endometrial angiogenesis. 2000 , 14, 919-36	23
2254	New thoughts on new vessels: therapy for angiogenesis-dependent diseases. 2000 , 6, 104-105	
2253	Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. 2000 , 28, 91-101	136
2252	Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells. 2000 , 36, 81-8	18
2251	Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts: involvement of p38 mitogen-activated protein kinase. 2000 , 12, 375-80	31
2250	Studying vascular development in the zebrafish. 2000 , 10, 352-60	30

2249 Integra	ting the VEGF signals leading to actin-based motility in vascular endothelial cells. 2000 , 10, 321-7	106
2248 Vascul	ar growth factors as an adjunct to surgical revascularization. 2000 , 9, 43-46	
	ation between the Ca(2+) signal and tube formation induced by vascular endothelial growth in bovine aortic endothelial cells. <i>European Journal of Pharmacology</i> , 2000 , 398, 19-29	8
2246 Growtl	n factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. 2000 , 50, 121-37	169
2245 Physio	ogy of angiogenesis. 2000 , 50, 17-35	52
	prevents apoptosis of rat sinusoidal endothelial cells caused by deprivation of vascular elial growth factor. 2000 , 32, 542-6	42
	1 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic ther splice variants in vivo. 2000 , 83, 63-8	126
	on of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on rating endothelial cells. 2000 , 83, 1077-83	35
2241 The co	ntrols of microvascular survival. 2000 , 19, 75-81	34
2240 Neuro	pilin is a mediator of angiogenesis. 2000 , 19, 29-37	80
<u> </u>	pilin is a mediator of angiogenesis. 2000 , 19, 29-37 Denesis in the corpus luteum. 2000 , 12, 1-9	189
2239 Angiog		
2239 Angiog 2238 Effects TGF-al	enesis in the corpus luteum. 2000 , 12, 1-9 of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR,	189
2239 Angiog 2238 Effects TGF-all The VE 2237 2000, 2	denesis in the corpus luteum. 2000 , 12, 1-9 To of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, pha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets. 2000 , 43, 763-72 GF splice variants: properties, receptors, and usage for the treatment of ischemic diseases.	189 72
2239 Angiog 2238 Effects TGF-all 2237 The VE 2000, 2	denesis in the corpus luteum. 2000, 12, 1-9 of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, pha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets. 2000, 43, 763-72 GF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. 25, 126-9 Deutic neoangiogenesis of peripheral arteries]. 2000, 25, 600-10 Detection of vascular endothelial growth factor and its receptor KDR on gastric carcinoma MGC803 cell line and stimulation of exogenous VEGF(165) to MGC803 cells. 2000,	189 72
2239 Angiog 2238 Effects TGF-all 2237 2000, 2 2236 [Thera Coexplanded adenoted as a second secon	denesis in the corpus luteum. 2000, 12, 1-9 of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, pha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets. 2000, 43, 763-72 GF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. 25, 126-9 Deutic neoangiogenesis of peripheral arteries]. 2000, 25, 600-10 Detection of vascular endothelial growth factor and its receptor KDR on gastric carcinoma MGC803 cell line and stimulation of exogenous VEGF(165) to MGC803 cells. 2000,	189 72 43
2239 Angiog 2238 Effects TGF-all 2237 2000, 2 2236 [Thera Coexpladence 43, 88- 2234 Vascul multip	renesis in the corpus luteum. 2000, 12, 1-9 of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, cha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets. 2000, 43, 763-72 GF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. 25, 126-9 peutic neoangiogenesis of peripheral arteries]. 2000, 25, 600-10 ression of vascular endothelial growth factor and its receptor KDR on gastric carcinoma MGC803 cell line and stimulation of exogenous VEGF(165) to MGC803 cells. 2000, 95 ar endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in	189 72 43

2231	Determinants of Endothelial Cell Phenotype in Venules. 2000 , 7, 67-80	46
2230	Inhibition of angiogenesis decreases alveolarization in the developing rat lung. 2000 , 279, L600-7	477
2229	Roles of the podocyte in glomerular function. 2000 , 278, F173-9	97
2228	Coexpression of neuropilin-1, Flk1, and VEGF(164) in developing and mature mouse kidney glomeruli. 2000 , 279, F275-82	78
2227	EORTC Receptor and Biomarker Study Group Report: A Sandwich Enzyme-Linked Immunosorbent Assay for Vascular Endothelial Growth Factor in Blood and Tumor Tissue Extracts. 2000 , 15, 184-191	29
2226	VEGF and ATP act by different mechanisms to increase microvascular permeability and endothelial [Ca(2+)](i). 2000 , 279, H1625-34	39
2225	Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. 2000 , 275, 33189-92	103
2224	Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. 2000 , 97, 2573-8	257
2223	Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. 2000 , 164, 5922-7	124
2222	c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells. 2000 , 164, 1169-74	34
2221	1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. 2000 , 87, 214-20	350
2220	Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. 2000 , 275, 18040-5	308
2219	Angiopoietin/Tie receptor system: emerging targets for therapeutic angiogenesis and anti-angiogenic therapy. 2000 , 4, 323-332	1
2218	Changes in expression of vascular endothelial growth factor and angiopoietin-1 and -2 in the macaque corpus luteum during the menstrual cycle. 2000 , 6, 993-8	51
2217	Vascular endothelial growth factor release following coronary artery bypass surgery: extracorporeal circulation versus 'beating heart' surgery. 2000 , 21, 1708-13	15
2216	Vascular endothelial growth factor and coronary artery surgery: implications for improved endothelial protection!. 2000 , 21, 1649-51	1
2215	Percutaneous mitral balloon commissurotomy: a useful and necessary treatment for the western population. 2000 , 21, 1651-2	3
2214	Signaling pathways induced by vascular endothelial growth factor (review). 2000 , 5, 447-56	81

2213	Rat sponge implant model: a new system for evaluating angiogenic gene transfer. 2000 , 6, 645-53	3
2212	Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells. 2000 , 16, 253-60	27
2211	Molecular biology of the VEGF and the VEGF receptor family. 2000 , 26, 561-9	133
2210	Vascular endothelial growth factor and transforming growth factor-beta1 regulate the expression of insulin-like growth factor-binding protein-3, -4, and -5 in large vessel endothelial cells. 2000 , 141, 2062-7	32
2209	Current status of viral gene therapy for brain tumours. 2000 , 9, 713-26	11
2208	Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. 2000 , 141, 1667-74	448
2207	VEGF receptor signaling in tumor angiogenesis. 2000 , 5 Suppl 1, 3-10	394
2206	The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. 2000 , 10, 349-57	87
2205	Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. 2000 , 97, 10242-7	585
2204	Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. 2000 , 20, 7282-91	211
2203	Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. <i>FASEB Journal</i> , 2000 , 14, 2532-9	255
2202	Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. 2000 , 275, 21695-702	160
2201	Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. 2000 , 275, 16986-92	176
2200	Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. 2000 , 5 Suppl 1, 45-50	69
2199	The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB Journal, 2000, 14, 2373-6	144
2198	Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. 2000 , 102, 3098-103	195
2197	Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. 2000 , 275, 40725-31	187
2196	VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. 2000 , 275, 6059-62	91

2195	Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. 2000 , 102, 2262-8	117
2194	Mouse flt-1 promoter directs endothelial-specific expression in the embyroid body model of embryogenesis. 2000 , 276, 1089-99	16
2193	Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. 2000 , 12, 1232-5	611
2192	The zebrafish floating head mutant demonstrates podocytes play an important role in directing glomerular differentiation. 2000 , 222, 147-57	53
2191	Loss of chromosome 13 in cultured human vascular endothelial cells. 2000 , 260, 357-64	28
2190	Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. 2000 , 301, 1179-90	182
2189	Interaction of angiogenesis inhibitor TNP-470 with basic fibroblast growth factor receptors. 2000 , 92, 18-22	12
2188	Mechanism-based target identification and drug discovery in cancer research. 2000 , 287, 1969-73	381
2187	Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. 2000 , 157, 7-14	37
2186	In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. 2000 , 157, 103-10	70
2185	Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. 2000 , 156, 939-50	102
2184	Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. 2000 , 156, 965-76	561
2183	Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. 2000 , 156, 1337-44	117
2182	Cardiovascular gene therapy. 2000 , 355, 213-22	327
2181	Mechanism of transforming growth factor-beta1-induced expression of vascular endothelial growth factor in murine osteoblastic MC3T3-E1 cells. 2000 , 1497, 69-76	45
2180	Induction of neuronal apoptosis by Semaphorin3A-derived peptide. 2000, 83, 81-93	35
2179	Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. 2000 , 26, 11-27	54
2178	Parathyroid-induced angiogenesis is VEGF-dependent. 2000 , 128, 458-64	36

(2001-2000)

2177	Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. 2000 , 32, 269-88	309
2176	Vascular developmental biology: getting nervous. 2000 , 10, 536-42	81
2175	Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. 2000 , 477, 258-62	284
2174	Altered expressions of VEGF mRNA splice variants during progression of uterine-peritoneal adhesions in the rat. 2000 , 43, 299-304	40
2173	Endothelial cells in culture: a model for studying vascular functions. 2000 , 42, 9-19	83
2172	Respiratory syncytial virus stimulation of vascular endothelial cell growth Factor/Vascular permeability factor. 2000 , 23, 662-9	45
2171	Determinants of Endothelial Cell Phenotype in Venules. 2000 , 7, 67-80	39
2170	Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats. 2000 , 68, 5991-7	38
2169	Monomeric midkine induces tumor cell proliferation in the absence of cell-surface proteoglycan binding. 2000 , 39, 5977-87	13
2168	Gene Therapy in Peripheral Vascular Disease. 2000 , 11, 431-433	
2167	Applications of magnetic resonance in model systems: tumor biology and physiology. 2000 , 2, 139-51	100
2166	Vasculogenesis and Angiogenesis. 2000 , 11, 427-430	
2165	Potential Applications of PET Imaging in Developing Novel Cancer Therapies. 2000, 11, 433-441	1
2164	Prospects for genetic therapy of cardiovascular disease. 2000 , 84, 199-213	17
2163	Vascular morphogenesis in the ovary. 2000 , 14, 867-82	34
2162	The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. 2000 , 1 Suppl 1, S80-4	59
2161	Expression of vascular endothelial growth factor mRNA in human preimplantation embryos derived from tripronuclear zygotes. 2000 , 74, 1220-6	38
2160	Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells. <i>FASEB Journal</i> , 2001 , 15, 1318-20	16

2159	Peritoneal mesothelial hypoxia during pneumoperitoneum is a cofactor in adhesion formation in a laparoscopic mouse model. 2001 , 76, 560-7	113
2158	Endothelial cells contain a glycine-gated chloride channel. 2001 , 40, 197-204	42
2157	The hemostatic system and angiogenesis in malignancy. 2001 , 3, 371-84	91
2156	Isoform-specific expression of VEGF-B in normal tissues and tumors. 2001 , 19, 49-59	48
2155	Functionally active VEGF fusion proteins. 2001 , 23, 1-7	28
2154	Endogenous production of nitric oxide by vascular endothelial growth factor down-regulates proliferation of choriocarcinoma cells. 2001 , 282, 1061-6	19
2153	New isoforms of VEGF are translated from alternative initiation CUG codons located in its 5'UTR. 2001 , 282, 1053-60	44
2152	Enhanced stimulation of Akt-3/protein kinase B-gamma in human aortic smooth muscle cells. 2001 , 283, 158-63	36
2151	Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. 2001 , 283, 164-73	39
2150	Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. 2001 , 283, 469-79	44
2149	Vascular endothelial growth factor and angiopoietin in liver regeneration. 2001 , 287, 209-15	53
2148	Study of the murine allantois by allantoic explants. 2001 , 233, 347-64	43
2147	Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. 2001 , 264, 169-84	447
2146	Increased vascular endothelial growth factor expression in human hearts with microvascular fibrin. 2001 , 33, 175-84	14
2145	Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. 2001 , 33, 295-305	41
2144	Morphine sulfate inhibits hypoxia-induced vascular endothelial growth factor expression in endothelial cells and cardiac myocytes. 2001 , 33, 2179-87	54
2143	Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. 2001 , 159, 651-9	84
2142	Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. 2001 , 159, 893-903	329

(2001-2001)

2141	Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. 2001 , 159, 993-1008	242
2140	Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma. 2001 , 6, 59-65	8
2139	Apoptosis in atherosclerosis: pathological and pharmacological implications. 2001 , 44, 59-71	26
2138	A molecular analysis of matrix remodeling and angiogenesis during long bone development. 2001 , 100, 245-50	134
2137	Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. 2001 , 106, 97-106	286
2136	The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development. 2001 , 108, 29-43	168
2135	Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. 2001 , 56, 607-20	197
2134	Aerogenous spread of primary lung adenocarcinoma induces ultrastructural remodeling of the alveolar capillary endothelium. 2001 , 32, 1050-8	14
2133	Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers. 2001 , 130, 593-600; discussion 600-1	29
2132	Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes. 2001 , 174, 71-6	38
2131	The Drosophila VEGF receptor homolog is expressed in hemocytes. 2001 , 109, 69-77	89
2130	EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. 2001 , 30, 355-68	220
2129	Vascular endothelial growth factor-A activates Ca2+ -activated K+ channels in human endothelial cells in culture. 2001 , 33, 337-46	35
2128	Angiogenesis in dermatology. 2001 , 13, 183-192	
2127	A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. 2001, 494, 150-6	26
2126	The future of human gene therapy. 2001 , 22, 113-42	108
2125	VASCULAR ENDOTHELIAL GROWTH FACTOR PROMOTES PROLIFERATION AND MIGRATION OF CAVERNOUS SMOOTH MUSCLE CELLS. 2001 , 166, 354-360	45
2124	Anti-angiogenesis: A new potential strategy to inhibit restenosis. 2001 , 4, 3-6	12

2123	Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000 - September 2000. 2001 , 11, 77-114	4
2122	Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. 2001 , 12, 1066-73	43
2121	Vascular endothelial growth factor (VEGF) mRNA splice variants are differentially expressed in human blastocysts. 2001 , 7, 57-63	45
2120	Relationship between placental vascular endothelial growth factor expression and placental/endometrial vascularity in the pig. 2001 , 64, 1821-5	74
2119	Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. 2001 , 281, L582-90	49
2118	Role of vascular endothelial growth factor in regulation of physiological angiogenesis. 2001 , 280, C1358-66	773
2117	Osteoblast expression of vascular endothelial growth factor is modulated by the extracellular microenvironment. 2001 , 280, C72-80	70
2116	Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle and their modification in muscle pathology. 2001 , 6, d75-89	10
2115	Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. 2001 , 280, C1375-86	241
2114	Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi?. 2001 , 280, H1923-7	23
2113	rhVEGF and Experimental Rat Skin Flaps: Systemic or Local Administration and Morphological Characteristics. 2001 , 24, 743-751	7
2112	Specific Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor (VEGF) Splice Variants by LightCycler Technology. 2001 , 47, 654-660	81
2111	Pitfalls in the Measurement of Circulating Vascular Endothelial Growth Factor. 2001 , 47, 617-623	267
2110	What Happens to the Peritoneal Membrane in Long-Term Peritoneal Dialysis?. 2001 , 21, 9-18	37
2109	Molecular Mechanisms of Peritoneal Permeability Research in Growth Factors. 2001, 21, 19-23	5
2108	Treatment of Ovarian Hyperstimulation Syndrome. 2001 , 200-226	
2107	The Contribution of Proangiogenic Factors to the Progression of Malignant Disease: Role of Vascular Endothelial Growth Factor and Its Receptors. 2001 , 10, 339-356	20
2106	Compartmentalization of Vascular Endothelial Growth Factor to the Epithelial Surface of the Human Lung. 2001 , 7, 240-246	100

(2001-2001)

2105	Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. 2001 , 6, D75-89	64
2104	Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies. 2001 , 6, D776-84	4
2103	Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor. 2001 , 21, 3332-41	189
2102	Controlled Growth Factor Delivery By Mechanical Stimulation. 2001 , 711, 1	
2101	Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations. 2001 , 48, 359-67; discussion 367-8	75
2100	Gene expression of VEGF and its receptors Flk-1/KDR and Flt-1 in cultured and transplanted rat islets. 2001 , 71, 924-35	83
2099	Expression of Endothelial Cell Angiogenesis Receptors in Human Cerebrovascular Malformations. 2001 , 48, 359-368	65
2098	Role of angiogenesis in the progression and treatment of prostate cancer. 2001 , 19, 181-91	26
2097	Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrow. 2001 , 19, 1-17	17
2096	Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. 2001 , 12, 1353-7	54
2095	Vascular endothelial growth factor-induced prostacyclin production is mediated by a protein kinase C (PKC)-dependent activation of extracellular signal-regulated protein kinases 1 and 2 involving PKC-delta and by mobilization of intracellular Ca2+. 2001 , 353, 503-12	46
2094	Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. 2001 , 360, 255-64	106
2093	Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. 2001 , 360, 255-264	163
2092	Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. 2001 , 100, 567-575	36
2091	Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo. 2001 , 101, 439-446	37
2090	Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. 2001 , 100, 567	12
2089	Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo. 2001 , 101, 439	20
2088	Vascular endothelial growth factor-induced prostacyclin production is mediated by a protein kinase C (PKC)-dependent activation of extracellular signal-regulated protein kinases 1 and 2 involving PKC-land by mobilization of intracellular Ca2+. 2001 , 353, 503-512	86

2087	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. 2001 , 98, 428-35	358
2086	Pathophysiology of Ovarian Hyperstimulation Syndrome. 2001 , 43-78	
2085	Clinical implications of circulating angiogenic factors in cancer patients. 2001 , 19, 1207-25	491
2084	Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. 2001 , 107, 1395-402	1460
2083	Progress toward understanding vascular malformations. 2001 , 107, 1509-23	63
2082	The endothelial response to oxygen deprivation: biology and clinical implications. 2001 , 27, 19-31	119
2081	Mechanistic insights on the inhibition of tumor angiogenesis. 2001 , 78, 663-72	49
2080	Clinical applications of vascular gene therapy. 2001 , 3, 29-36	18
2079	Angiozyme: a novel angiogenesis inhibitor. 2001 , 3, 141-6	93
2078	Vascular endothelial growth factor (VEGF) induces human Langerhans cell migration. 2001 , 293, 26-8	12
2077	VEGF expression in skin warts. Relevance to angiogenesis and vasodilation. 2001, 293, 233-8	8
2076	Control of glomerular capillary development by growth factor/receptor kinases. 2001, 16, 294-301	31
2075	Quantitative variation in vascular endothelial growth factor mRNA expression during early flexor tendon healing: an investigation in a canine model. 2001 , 19, 869-72	94
2074	Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity. 2001 , 34, 143-55	45
2073	Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic. 2001 , 31, 651-66	58
2072	Identification and cloning of an 85-kDa protein homologous to RING3 that is upregulated in proliferating endothelial cells. 2001 , 268, 4398-407	7
2071	Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1. 2001 , 39, 179-86	41
2070	Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. 2001 , 39, 409-15	150

(2001-1999)

2069	New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders. 1999 , 80, 235-50	37
2068	Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease12-month follow-up: angiogenic gene therapy. 2001 , 250, 373-81	60
2067	VEGF mRNA is unaltered in decidual and placental tissues in preeclampsia at delivery. 2001 , 80, 93-8	30
2066	Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. 2001 , 193, 468-75	290
2065	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. 2001 , 36, 601-4	51
2064	In vivo activities of mutants of vascular endothelial growth factor (VEGF) with differential in vitro activities. 2001 , 91, 327-333	3
2063	Neuropilin-1 expression in osteogenic cells: down-regulation during differentiation of osteoblasts into osteocytes. 2001 , 81, 82-92	60
2062	Involvement of p70 S6 kinase in bone morphogenetic protein signaling: vascular endothelial growth factor synthesis by bone morphogenetic protein-4 in osteoblasts. 2001 , 81, 430-6	62
2061	Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer. 2001 , 66, 59-61	21
2060	Coexpression of endothelial PAS protein 1 with essential angiogenic factors suggests its involvement in human vascular development. 2001 , 222, 377-88	35
2059	Vascular regression is required for mesenchymal condensation and chondrogenesis in the developing limb. 2001 , 222, 522-33	59
2058	Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. 2001 , 92, 545-50	82
2057	Involvement of p38 MAP kinase in TGF-beta-stimulated VEGF synthesis in aortic smooth muscle cells. 2001 , 82, 591-8	50
2056	Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix. 2001 , 83, 259-70	25
2055	The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. 2001 , 44, 1082-8	154
2054	Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. 2001 , 44, 2055-64	208
2053	Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts. 2001 , 44, 2512-24	55
2052	Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. 2001 , 6 Suppl 5, 24-31	66

2051	Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. 2001 , 89, 779-86	185
2050	Expression of vascular endothelial growth factor in normal and tumour oral tissues assessed with different antibodies. 2001 , 33, 287-94	12
2049	Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. 2001 , 16, 1077-91	107
2048	Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. 2001 , 6, 253-73	57
2047	Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. 2001 , 224, 81-9	40
2046	Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. 2001 , 4, 123-31	70
2045	Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. 2001 , 4, 143-54	83
2044	Protein and angiogenic dose-response expression of phVEGF-A(165) gene in rat myocardium. 2001 , 12, 151-6	3
2043	VEGF as a mediator of tumor-associated immunodeficiency. 2001 , 23, 263-72	265
2042	The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. 2001 , 33, 841-7	44
2041	Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis. 2001 , 34, 487-93	28
2040	Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver. 2001 , 34, 1135-48	126
2039	Dynamic modules and heterogeneity of function: a lesson from tyrosine kinase receptors in endothelial cells. 2001 , 2, 763-7	24
2038	The angiogenic peptide vascular endothelial growth factor is expressed in foetal and ruptured tendons. 2001 , 439, 579-85	98
2037	Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis. 2001 , 81, 1669-81	100
2036	Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. 2001 , 7, 192-8	1383
2035	Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. 2001 , 7, 575-83	1346
2034	Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. 2001 , 111, 1834-41	47

(2001-2001)

2033	Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch. 2001 , 132, 1342-8	11
2032	Inducible nitric oxide synthase (iNOS) activity promotes ischaemic skin flap survival. 2001 , 132, 1631-8	53
2031	The adapter protein, Grb10, is a positive regulator of vascular endothelial growth factor signaling. 2001 , 20, 3959-68	29
2030	Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. 2001 , 87, 1160-3	106
2029	TerplexDNA gene carrier system targeting artery wall cells. 2001 , 72, 179-89	18
2028	VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. 2001 , 74, 173-81	45
	Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2. 2001 , 74, 349-55	15
2026	Angiogenesis and leukemia. 2001 , 25, 639-45	38
2025	Regulation and action of angiogenic factors in the primate ovary. 2001 , 32, 567-75	131
2024	Increased expression of angiotensin-converting enzyme in retinas of diabetic rats. 2001 , 45, 585-91	16
2023	Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. 2001, 11, 70-82	49
	Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. 2001 , 184, 1267-72	189
2021	Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological, and pathological study in 12 patients monitored for 10 years. 2001 , 68, 493-8	16
2020	Development of the primate retinal vasculature. 2001 , 20, 799-821	258
2019	Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo. 2001, 37, 369-78	11
2018	Signal transduction by VEGF receptor-1 wild type and mutant proteins. 2001 , 13, 849-54	31
2017	Common origins of blood and blood vessels in adults?. 2001 , 68, 186-92	27
2016	The role of semaphorins in lung cancer. 2001 , 3, 145-50	10

2015	Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. 2001 , 276, 5281-6		37
2014	Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species. 2001 , 21, 1550-5		57
2013	Transforming growth factor-beta 1-mediated inhibition of the flk-1/KDR gene is mediated by a 5'-untranslated region palindromic GATA site. 2001 , 276, 5395-402		57
2012	Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. 2001 , 75, 9828-35		157
2011	Angiogenesis in lymphoproliferative disorders. 2001 , 106, 184-9		20
2010	VEGF protects against oxidized LDL toxicity to endothelial cells by an intracellular glutathione-dependent mechanism through the KDR receptor. 2001 , 21, 765-70		27
2009	Focal vascular endothelial growth factor correlates with angiogenesis in human endometrium. Role of intravascular neutrophils. 2001 , 16, 1065-75		69
2008	Differential effects of vascular endothelial growth factor-C and placental growth factor-1 on the hydraulic conductivity of frog mesenteric capillaries. 2001 , 38, 176-86		43
2007	The time course of tumor necrosis factor-alpha, inducible nitric oxide synthase and vascular endothelial growth factor expression in an experimental model of chronic myocardial infarction in rats. 2001 , 38, 288-300		53
2006	Glucotoxicity of the peritoneal membrane: the case for VEGF. 2001 , 16, 2299-302		14
2005	Angiogenesis Protocols. 2001 ,		8
2004	Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. 2001 , 20, 185-94		75
2003	Somatic gene therapy in the cardiovascular system. 2001 , 63, 427-50		38
2002	Cell-cell interactions in vascular development. 2001 , 52, 107-49		91
2001	The basic helix-loop-helix transcription factor HESR1 regulates endothelial cell tube formation. 2001 , 276, 6169-76		114
2000	Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism. <i>FASEB Journal</i> , 2001 , 15, 2548-50	0.9	144
1999	Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. 2001 , 98, 7481-6		62
1998	Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. <i>FASEB Journal</i> , 2001 , 15, 1218-1220	0.9	225

1997	Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. 2001 , 276, 18688-94	102
1996	Expression and hypoxic regulation of angiopoietins in human astrocytomas. 2001 , 3, 1-10	43
1995	Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). 2001 , 276, 25520-31	222
1994	Building better vasculature. 2001 , 15, 2497-502	65
1993	HIV-1 Tat protein stimulates in vivo vascular permeability and lymphomononuclear cell recruitment. 2001 , 166, 1380-8	42
1992	Matrix as a modulator of hepatic fibrogenesis. 2001 , 21, 351-72	404
1991	Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. 2001 , 163, 737-44	560
1990	Microvessel endothelial cells from human adipose tissues : isolation, identification, and culture. 2001 , 46, 213-6	1
1989	[Therapeutic neoangiogenesis. Alternative or adjuvant option in the treatment of advanced coronary and peripheral ischemic vascular disease]. 2001 , 126, 1053-7	1
	Delayed muscle injusies in asterial insufficiency, contrast enhanced MR imaging and 21B	
1988	Delayed muscle injuries in arterial insufficiency: contrast-enhanced MR imaging and 31P spectroscopy in rats. 2001 , 220, 413-9	8
1988		357
	spectroscopy in rats. 2001 , 220, 413-9	357
1987	Angiogenesis in the placenta. 2001 , 64, 1033-40 Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may	357
1987 1986	Angiogenesis in the placenta. 2001 , 64, 1033-40 Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. <i>FASEB Journal</i> , 2001 , 15, 1428-30 Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the Bothrops insularis pit viper. A new member of the VEGF family of proteins. 2001 ,	357 84
1987 1986 1985	Angiogenesis in the placenta. 2001 , 64, 1033-40 Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. <i>FASEB Journal</i> , 2001 , 15, 1428-30 Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the Bothrops insularis pit viper. A new member of the VEGF family of proteins. 2001 , 276, 39836-42	357 84 69
1987 1986 1985 1984	Angiogenesis in the placenta. 2001, 64, 1033-40 Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB Journal, 2001, 15, 1428-30 Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the Bothrops insularis pit viper. A new member of the VEGF family of proteins. 2001, 276, 39836-42 Novel pharmacological agents in clinical development for solid tumours. 2001, 10, 2059-88 Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.	357 84 69
1987 1986 1985 1984	Angiogenesis in the placenta. 2001, 64, 1033-40 Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB Journal, 2001, 15, 1428-30 Molecular cloning and expression of a functional snake venom vascular endothelium growth factor (VEGF) from the Bothrops insularis pit viper. A new member of the VEGF family of proteins. 2001, 276, 39836-42 Novel pharmacological agents in clinical development for solid tumours. 2001, 10, 2059-88 Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. 2001, 16, 359-70	357 84 69 12

1979	The role of angiogenesis in hematologic malignancies. 2002 , 11, 49-68		7
1978	Regulation of endothelial cell survival and apoptosis during angiogenesis. 2002 , 22, 887-93		208
1977	Development of the coronary vessel system. 2002 , 91, 761-8		183
1976	Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. 2002 , 277, 18069-76		177
1975	Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. 2002 , 277, 11410-5		213
1974	The Wilms' tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction. <i>FASEB Journal</i> , 2002 , 16, 1117-9	0.9	100
1973	Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. 2002 , 165, 67-70		177
1972	Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. 2002 , 99, 10470-5		176
1971	Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. 2002 , 105, 2524-30		116
1970	Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. <i>FASEB Journal</i> , 2002 , 16, 1471-3	0.9	112
1969	Characteristic gene expression profile of primary human cerebral endothelial cells. <i>FASEB Journal</i> , 2002 , 16, 589-91	0.9	87
1968	Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. 2002 , 9, 83-7		132
1967	Improved expression by cytomegalovirus promoter/enhancer and behavior of vascular endothelial growth factor gene after myocardial injection of naked DNA. 2002 , 34, 278-84		2
1966	A woman's right to choose…counselling!. 2002 , 28, 174-5		2
1965	Shear stress-induced endothelial cell migration involves integrin signaling via the fibronectin receptor subunits alpha(5) and beta(1). 2002 , 22, 69-75		125
1964	Microarray analysis of VEGF-responsive genes in myometrial endothelial cells. 2002 , 8, 855-63		42
1963	Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. 2002 , 16, 2684-98		674
1962	Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. <i>FASEB Journal</i> , 2002 , 16, 261-3	0.9	76

(2002-2002)

1961	of endostatin. <i>FASEB Journal</i> , 2002 , 16, 706-8	0.9	118
1960	Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. 2002 , 277, 2028-32		94
1959	Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. 2002 , 15, 310-26		96
1958	Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. 2002 , 277, 3101-8		298
1957	Effects of Boron in Wound Healing. 2002 , 1061-1065		4
1956	Differential involvement of MMP-2 and VEGF during muscle stretch- versus shear stress-induced angiogenesis. 2002 , 283, H1430-8		125
1955	Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. 2002 , 20, 509		1
1954	Vascular endothelial growth factor (VEGF) and discrimination between abnormal intrauterine and ectopic pregnancy. 2002 , 17, 3231-4		13
1953	Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. 2002 , 165, 88-94		78
1952	Pancreatic Cancer. 2002,		1
1952 1951	Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. 2002 , 143, 4339-48		138
	Vascular endothelial growth factor receptor-2 activation induces vascular permeability in		
1951	Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. 2002 , 143, 4339-48 B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. 2002 ,		138
1951 1950	Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. 2002 , 143, 4339-48 B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. 2002 , 16, 911-9 Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the		138
1951 1950 1949	Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. 2002, 143, 4339-48 B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. 2002, 16, 911-9 Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. 2002, 143, 420-5 VEGF plasma pattern in ovulation induction: evidence for an episodic secretion and lack of		138 109 118
1951 1950 1949 1948	Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. 2002, 143, 4339-48 B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. 2002, 16, 911-9 Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. 2002, 143, 420-5 VEGF plasma pattern in ovulation induction: evidence for an episodic secretion and lack of immediate effect of hCG. 2002, 110, 130-3 Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. 2002, 9, 631-41		138 109 118
1951 1950 1949 1948	Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. 2002, 143, 4339-48 B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. 2002, 16, 911-9 Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. 2002, 143, 420-5 VEGF plasma pattern in ovulation induction: evidence for an episodic secretion and lack of immediate effect of hCG. 2002, 110, 130-3 Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. 2002, 9, 631-41 Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in		138 109 118 12

1943	Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. 2002 , 94, 1484-93		246
1942	Antiangiogenesis therapeutic strategies in prostate cancer. 2002 , 317-330		
1941	Mechanisms and regulations of endometrial angiogenesis. 2002 , 10, 45-61		9
1940	Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. <i>FASEB Journal</i> , 2002 , 16, 219-21	0.9	284
1939	In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. 2002 , 99, 7866-71		126
1938	Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. 2002 , 277, 10445-51		141
1937	Essential role of calcium in vascular endothelial growth factor A-induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole. <i>FASEB Journal</i> , 2002 , 16, 1805-7	0.9	88
1936	Prostate Cancer: New Horizons in Research and Treatment. 2002,		
1935	Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells. 2002 , 282, G1088-96		37
1934	Hypoxia-inducible factor-1alpha/vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta. 2002 , 39, 46-50		87
1933	Nucleotide sequence and expression of the feline vascular endothelial growth factor. 2002 , 64, 453-6		7
1932	Vascular endothelial growth factor as a target opportunity in hematological malignancies. 2002 , 14, 649	-56	9
1931	Vascular endothelial growth factor: the key mediator in pleural effusion formation. 2002 , 8, 294-301		103
1930	Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth. 2002 , 131, 619-26		32
1929	New insights in the molecular mechanisms regulating peritoneal permeability. 2002, 17, 548-51		30
1928	Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. 2002 , 99, 2397-407		134
1927	Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. 2002 , 99, 3383-9		53
1926	BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. 2002 , 100, 3767-75		249

1925	proliferator-activated receptors in bladder cancer cells. 2002 , 277, 23534-43	88
1924	Expression of Vascular Endothelial Growth Factor Receptor-2/Flk-1/ KDR in Breast Carcinoma. 2002 , 249-257	
1923	Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. 2002 , 283, L585-95	113
1922	Vascular gene therapy: a reality of the 21st century. 2002 , 137, 854-61	9
1921	VEGF-RII influences the prognosis of pancreatic cancer. 2002 , 236, 738-49; discussion 749	69
1920	Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. 2002 , 51, 3090-4	259
1919	Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. 2002, 133, 693-8	89
1918	Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. 2002 , 160, 1405-23	495
1917	Neuropilin-1 participates in wound angiogenesis. 2002 , 160, 289-96	44
1916	Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. 2002 , 161, 1429-37	114
1915	Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. 2002 , 79, 278-84	57
1914	PDGF(BB) increases myocardial production of VEGF: shift in VEGF mRNA splice variants after direct injection of bFGF, PDGF(BB), and PDGF(AB). 2002 , 107, 203-9	19
1913	1,25-dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. 2002 , 398, 1-6	53
1912	Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. 2002 , 292, 860-8	61
1911	Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. 2002 , 13, 39-53	202
1910	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. 2002 , 45, 5687-93	97
1909	Vascular Endothelial Growth Factors. 2002 , 883-XXXV	
1908	VEGF and imaging of vessels in rheumatoid arthritis. 2002 , 4 Suppl 3, S99-107	85

1907	Angiogenesis in rheumatoid arthritis. 2002 , 4 Suppl 3, S81-90	213
1906	Angiogenesis in non-small cell lung cancer. A new target for therapy. 2002 , 1, 325-38	4
1905	Composition options for tissue-engineered bone. 2002 , 8, 529-39	97
1904	VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. 2002 , 99, 2532-40	215
1903	Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. 2002 , 11, 1447-65	30
1902	Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. 2002 , 99, 13837-42	164
1901	Adeno-associated virus-mediated vascular endothelial growth factor gene therapy in skeletal muscle before transplantation promotes revascularization of regenerating muscle. 2002 , 8, 879-91	20
1900	Identification of functional VEGF receptors on human platelets. 2002 , 512, 107-10	36
1899	An attempt to promote neo-vascularization by employing a newly synthesized inhibitor of protein tyrosine phosphatase. 2002 , 524, 54-8	28
1898	The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells. 2002 , 45, 21-5	6
1897	Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. 2002 , 111, 61-73	356
1896	Growth index is independent of microvessel density in non-small-cell lung carcinomas. 2002 , 33, 812-8	16
1895	Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. 2002 , 33, 863-70	90
1894	Adenovirus vector-mediated transfer of the vascular endothelial growth factor cDNA to healing abdominal fascia enhances vascularity and bursting strength in mice with normal and impaired wound healing. 2002 , 131, 219-27	17
1893	The blood-brain barrier and cerebral angiogenesis: lessons from the cold-injury model. 2002 , 8, 38-44	111
1892	Characterization of platelet-derived growth factor-C (PDGF-C): expression in normal and tumor cells, biological activity and chromosomal localization. 2002 , 34, 414-26	17
1891	The ephrins and Eph receptors in angiogenesis. 2002 , 13, 75-85	279
1890	A novel gene encoding a putative transmembrane protein with two extracellular CUB domains and a low-density lipoprotein class A module: isolation of alternatively spliced isoforms in retina and brain. 2002 , 286, 223-31	55

(2002-2002)

1889	vascular endothelial growth ractor and signaling in the prostate: more than anglogenesis. 2002 , 189, 169-79	43
1888	Co-expression of vascular endothelial growth factor and neuropilin-1 in ovine feto-placental artery endothelial cells. 2002 , 196, 95-106	19
1887	Signaling pathways in vascular development. 2002 , 18, 541-73	152
1886	Cytokine and growth factor network in human endometrium. 2002 , 22, 529-543	
1885	Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. 2002 , 4, 204-17	48
1884	Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. 2002 , 90, 95-102	24
1883	Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. 2002 , 22, 6401-7	252
1882	Compensatory glomerular growth after unilateral nephrectomy is VEGF dependent. 2002, 283, E362-6	42
1881	Glomerular remodelling: novel therapeutic approaches derived from the apparently chaotic growth factor network. 2002 , 91, 582-7	8
1880	Gene expression profiling in inflammatory airway disease associated with elevated adenosine. 2002 , 282, L169-82	31
1879	Interesting news in peritoneal dialysis. 2002 , 92, 763-71	
1878	Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors. 2002 , 282, H194-204	33
1877	Microvessel formation from mouse embryonic aortic explants is oxygen and VEGF dependent. 2002 , 283, R487-95	15
1876	Endometrial angiogenesis: physiology and clinical implications. 2002 , 28, 173-4	7
1875	Gene responses to hyperglycaemia. 2002 , 10, 120-9	3
1874	Antiangiogenic Strategies in Pancreatic Cancer. 2002 , 357-367	2
1873	Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. 2002 , 9, 36-44	206
1872	Effect of Helicobacter pylori on delay in ulcer healing induced by aspirin in rats. <i>European Journal of Pharmacology</i> , 2002 , 451, 191-202	5

1871	Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. 2002 , 132, 93-8	152
1870	Viral mediated gene transfer to sprouting blood vessels during angiogenesis. 2002 , 105, 1-11	7
1869	VEGF analysis induced by endothelialized gas-plasma treated D,L-PLA scaffolds. 2002 , 3, 176-82	13
1868	Regulation of vascular permeability by vascular endothelial growth factors. 2002 , 39, 225-37	264
1867	The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. 2002 , 12, 13-9	263
1866	VEGF gene delivery for treatment of ischemic cardiovascular disease. 2002 , 12, 108-14	54
1865	Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. 2002 , 46, 2587-97	210
1864	VEGF isoforms and mutations in human colorectal cancer. 2002 , 101, 32-6	36
1863	Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth. 2002 , 97, 313-22	47
1862	Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. 2002 , 97, 393-9	119
1861	Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. 2002 , 95, 1963-70	75
1860	Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. 2002 , 193, 299-318	183
1859	Inhibition of vascular endothelial growth factor in the treatment of solid tumors. 2002 , 4, 20-8	24
1858	New molecular targets of breast cancer therapy. 2002 , 178, 123-33	17
1857	[Role of receptor tyrosine kinase in the angiogenesis]. 2002 , 53, 629-42	1
1856	Considerations for successful transplantation of encapsulated pancreatic islets. 2002 , 45, 159-73	214
1855	Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. 2002 , 29, 699-709	26
1854	Angiogenesis in fetal tendon development: spatial and temporal expression of the angiogenic peptide vascular endothelial cell growth factor. 2002 , 205, 263-70	43

1853	Experimental angiogenesis of arterial vasa vasorum. 2002 , 307, 303-13	36
1852	Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. 2002 , 309, 387-92	75
1851	Characterization of the vascular endothelial growth factor-receptor interaction and determination of the recombinant protein by an optical receptor sensor. 2002 , 17, 983-91	29
1850	Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. 2002 , 6, 159-66; discussion 166	27
1849	Angiogenesis in the female reproductive organs: pathological implications. 2002, 83, 151-63	123
1848	Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. 2002 , 61, 375-86	67
1847	High protein-induced glomerular hypertrophy is vascular endothelial growth factor-dependent. 2002 , 61, 1600-4	34
1846	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. 2002 , 61, 1696-706	40
1845	Ischemic rat brain extracts induce human marrow stromal cell growth factor production. 2002 , 22, 275-9	333
1844	Regulation of microvascular permeability by vascular endothelial growth factors. 2002 , 200, 581-97	209
1843	Expression of VEGF121 and VEGF165 in hypertrophic chondrocytes of the human growth plate and epiphyseal cartilage. 2002 , 201, 153-7	53
1842	VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia. 2002 , 196, 220-7	43
1841	Calponin h1 suppresses tumor growth of Src-induced transformed 3Y1 cells in association with a decrease in angiogenesis. 2002 , 93, 935-43	11
1840	Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. 2002 , 16, 1302-10	160
1839	Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. 2002 , 21, 427-36	358
1838	Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo. 2002 , 21, 2822-8	45
1837	Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. 2002 , 21, 8817-29	51
1836	Molecular interactions and functional interference between vitronectin and transforming growth factor-beta. 2002 , 82, 37-46	48

1835	Design of a variant of vascular endothelial growth factor-A (VEGF-A) antagonizing KDR/Flk-1 and Flt-1. 2002 , 82, 473-81	16
1834	VEGF and the quest for tumour angiogenesis factors. 2002 , 2, 795-803	1204
1833	Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. 2002 , 2, 826-35	599
1832	The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. 2002 , 87, 772-8	72
1831	Tissue factor expression and angiogenesis in human glioma. 2002 , 35, 321-5	81
1830	Increased expression of vascular endothelial growth factor in human skeletal muscle in response to short-term one-legged exercise training. 2002 , 444, 752-9	80
1829	Antiangiogenesis therapeutic strategies in prostate cancer. 2002 , 21, 93-106	6
1828	Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents. 2002 , 5, 45-51	39
1827	Anti-angiogenic therapy: rationale, challenges and clinical studies. 2002 , 5, 237-56	108
1826	Characterization of a new alternatively spliced neuropilin-1 isoform. 2003 , 6, 39-45	16
1825	Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumors. 2003 , 6, 225-31	10
1824	Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. 2003 , 6, 295-301	40
1823	VEGF and endostatin levels in wound fluid and plasma after breast surgery. 2003, 6, 255-7	44
1822	Modeling the early stages of vascular network assembly. 2003 , 22, 1771-9	236
1821	Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles. 2003 , 18, 1573-83	48
1820	Antiangiogenic effects of butyric acid involve inhibition of VEGF/KDR gene expression and endothelial cell proliferation. 2003 , 243, 107-12	25
1819	Discrete types of osteoclast precursors can be generated from embryonic stem cells. 2003 , 21, 670-80	13
1818	Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. 2003 , 82, 19-23	50

1817	Growth factors and the development of diabetic nephropathy. 2003 , 3, 485-90	35
1816	Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. 2003 , 51, 321-7	54
1815	Angiogenesis factors in gliomas: a new key to tumour therapy?. 2003 , 90, 385-94	40
1814	Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis. 2003 , 90, 433-48	15
1813	Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. 2003 , 46, 1483-8	174
1812	Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits. 2003 , 18, 142-9	36
1811	The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed during the remodeling of free tendon grafts in sheep. 2003 , 123, 168-74	57
1810	The splice variants 120 and 164 of the angiogenic peptide vascular endothelial cell growth factor (VEGF) are expressed during Achilles tendon healing. 2003 , 123, 475-80	35
1809	Hypoxia and PDGF have a synergistic effect that increases the expression of the angiogenetic peptide vascular endothelial growth factor in Achilles tendon fibroblasts. 2003 , 123, 485-8	34
1808	Comparative effects of polyphenols from green tea (EGCG) and soybean (genistein) on VEGF and IL-8 release from normal human keratinocytes stimulated with the proinflammatory cytokine TNFalpha. 2003 , 295, 112-6	59
1807	Expression of the VEGF receptor-3 in osteoarthritic chondrocytes: stimulation by interleukin-1 beta and association with beta 1-integrins. 2003 , 120, 235-41	14
1806	VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. 2003 , 314, 5-14	118
1805	Genesis and pathogenesis of lymphatic vessels. 2003 , 314, 69-84	79
1804	Innovative therapies in wound healing. 2003 , 7, 217-24	16
1803	Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. 2003 , 197, 408-18	58
1802	Co-expression of vascular endothelial growth factor and its receptor, neuropilin-1, in a B cell lymphoma cell line (OHK) with primary effusion lymphoma immunophenotype. 2003 , 53, 649-51	2
1801	Recent data on the role for angiogenesis in rheumatoid arthritis. 2003, 70, 321-6	71
1800	Vascular endothelial growth factors and angiogenesis in eye disease. 2003 , 22, 1-29	711

1799	Retinal vascular development and oxygen-induced retinopathy: a role for adenosine. 2003, 22, 95-111		68
1798	Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. 2003 , 27, 229-38		56
1797	Pulmonary vascular endothelial growth factor and nitric oxide interaction during total cardiopulmonary bypass in neonatal pigs. 2003 , 125, 1050-7		13
1796	Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. 2003 , 82, 163-73		142
1795	Serum-derived factors weaken the barrier properties of cultured porcine brain capillary endothelial cells in vitro. 2003 , 981, 30-40		68
1794	Cerebral angiogenesis and expression of VEGF after subarachnoid hemorrhage (SAH) in rats. 2003 , 981, 58-69		47
1793	KR-31372 inhibits KDR/Flk-1 tyrosine phosphorylation via K+(ATP) channel opening in its antiangiogenic effect. <i>European Journal of Pharmacology</i> , 2003 , 465, 219-28	5.3	3
1792	Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. 2003 , 87, 49-56		143
1791	Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. 2003 , 98, 720-9		96
1790	Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. 2003 , 25, 464-74		92
1789	Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. 2003 , 107, 535-40		68
1788	Endothelial cell functions. 2003, 196, 430-43		479
1787	Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole. 2003, 197, 139-48		16
1786	Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. 2003 , 197, 453-62		140
1785	Effects of major liver resection, with or without recombinant bactericidal/permeability-increasing protein (rBPI21), on the angiogenic profile of patients with metastatic colorectal carcinoma. 2003 , 84, 137-42		5
1784	Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide. 2003 , 73, 481-96		60
1783	Placenta: regularization of neovascularization. Microvascularization pattern of the rabbit term placenta. 2003 , 60, 38-45		6
1782	Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. 2003, 60, 107-14		477

1	1781	Angiogenesis of the heart. 2003 , 60, 138-58	38
1	1780	Tumor angiogenesis of non-small cell lung cancer. 2003 , 60, 186-98	37
1	1779	Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. 2003 , 60, 208-24	31
1	1778	Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood. 2003 , 41, 516-26	22
1	¹ 777	Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. 2003 , 48, 2660-9	105
1	1776	Distribution of Flk-1 and Flt-1 receptors in neonatal and adult rat brains. 2003 , 274, 851-6	52
1	¹ 775	From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. 2003 , 69, 363-74	48
1	1774	Growth factors in the treatment of diabetic foot ulcers. 2003 , 90, 133-46	234
1	1773	Mechanical factors influence the expression of endostatinan inhibitor of angiogenesisin tendons. 2003 , 21, 610-6	46
1	1772	Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. 2003 , 7, 220-7; discussion 227-8	20
1	1771	Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behët's syndrome. 2003 , 42, 870-5	82
1	1770	The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. 2003 , 43, 33-9	55
1	1769	Non-endothelial KDR/flk-1 expression is associated with increased survival of patients with urothelial bladder carcinomas. 2003 , 43, 272-9	9
1	1768	Why should an angiogenic factor modulate tubular structure in diabetic nephropathy? Some answers, more questions. 2003 , 64, 758-9	2
1	1767	Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. 2003 , 1, 1356-70	279
1	1766	A tissue-engineered endothelialized dermis to study the modulation of angiogenic and angiostatic molecules on capillary-like tube formation in vitro. 2003 , 148, 1094-104	114
1	1765	Stromal cell-derived factor 1alpha (SDF-1alpha) induces gene-expression of early growth response-1 (Egr-1) and VEGF in human arterial endothelial cells and enhances VEGF induced cell proliferation. 2003 , 36, 75-86	61
1	1764	The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed in chronic sacral pressure ulcers. 2003 , 200, 130-6	26

1763	The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. 2003 , 200, 183-94	166
1762	Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. 2003 , 200, 577-88	40
1761	Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis. 2003, 140, 620-6	29
1760	Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. 2003 , 17, 604-11	150
1759	Vascular endothelial growth factor and its receptors in multiple myeloma. 2003, 17, 1961-6	60
1758	Expression of VEGF and its receptors by myeloma cells. 2003 , 17, 2025-31	118
1757	Molecular basis of angiogenesis and cancer. 2003 , 22, 6549-56	237
1756	The biology of VEGF and its receptors. 2003 , 9, 669-76	7480
1755	Gene transfer as a tool to induce therapeutic vascular growth. 2003 , 9, 694-701	346
1754	Basement membranes: structure, assembly and role in tumour angiogenesis. 2003 , 3, 422-33	12 90
1754 1753	Basement membranes: structure, assembly and role in tumour angiogenesis. 2003 , 3, 422-33 Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?. 2003 , 995, 200-7	1290
	Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?. 2003 , 995, 200-7	Ý
1753	Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?. 2003, 995, 200-7 Growth factors in wound healing. 2003, 83, 531-45, vi	38
1753 1752	Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?. 2003 , 995, 200-7 Growth factors in wound healing. 2003 , 83, 531-45, vi	38
1753 1752 1751	Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?. 2003, 995, 200-7 Growth factors in wound healing. 2003, 83, 531-45, vi Tyrosine kinases as targets in cancer therapy - successes and failures. 2003, 7, 215-34 A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the Role of vascular endothelial growth factor and placental growth factor in basal adhesion formation	38 88 171
1753 1752 1751 1750	Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?. 2003, 995, 200-7 Growth factors in wound healing. 2003, 83, 531-45, vi Tyrosine kinases as targets in cancer therapy - successes and failures. 2003, 7, 215-34 A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the Role of vascular endothelial growth factor and placental growth factor in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. 2003, 80 Suppl 2, 803-11	38 88 171 73
1753 1752 1751 1750 1749	Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems?. 2003, 995, 200-7 Growth factors in wound healing. 2003, 83, 531-45, vi Tyrosine kinases as targets in cancer therapy - successes and failures. 2003, 7, 215-34 A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the Role of vascular endothelial growth factor and placental growth factor in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. 2003, 80 Suppl 2, 803-11	38 88 171 73 48

(2003-2003)

1745	Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. 2003 , 26, 23-8	100
1744	Expression of neuropilin-1 in choroidal neovascular membranes. 2003 , 38, 41-5	5
1743	Altered expression of vascular endothelial growth factor and its receptors in normal saphenous vein and in arterialized and stenotic vein grafts. 2003 , 186, 561-8	13
1742	Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. 2003 , 114, 354-8	109
1741	Temporal and spatial regulation of VEGF-A controls vascular patterning in the embryonic lung. 2003 , 264, 443-55	107
1740	Lymphangiogenic growth factors, receptors and therapies. 2003 , 90, 167-84	107
1739	Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cells. 2003 , 309, 952-60	13
1738	Inhalant nitrite exposure alters mouse hepatic angiogenic gene expression. 2003, 310, 439-45	12
1737	Angiogenesis as a new target for cancer control. 2003 , 1, 1-12	16
1736	Significance of heparin-binding growth factor expression on cells of solid pediatric tumors. 2003 , 38, 1296-304	12
1735	Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells. 2003 , 109, 16-23	57
1734	Inhibition of endothelial cell activation by the homeobox gene Gax. 2003, 111, 91-9	59
1733	Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. 2003, 113, 133-8	70
1732	Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. 2003 , 34, 756-63	103
1731	Vascular endothelial growth factor in children with congenital heart disease. 2003 , 75, 1523-6	32
1730	Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. 2003 , 301, 198-203	28
1729	Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. 2003 , 308, 474-9	147
1728	Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats. 2003 , 52, 675-8	16

1727	Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor. 2003 , 283, 247-55	31
1726	A new view of diabetic retinopathy: a neurodegenerative disease of the eye. 2003 , 27, 283-90	417
1725	Regulation of embryonic implantation. 2003 , 110 Suppl 1, S2-9	93
1724	Expression of vascular endothelial growth factor and its receptors in rat neural stem cells. 2003 , 344, 165-8	111
1723	Vascular endothelial growth factor inhibits outward delayed-rectifier potassium currents in acutely isolated hippocampal neurons. 2003 , 118, 59-67	39
1722	VEGF receptors are differentially expressed by neuroblastoma cells in culture. 2003 , 38, 514-21	15
1721	The role of vascular endothelial growth factor in wound healing. 2003 , 2, 107-20	89
1720	Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence. 2003 , 29, 497-505	22
1719	Rponses du rseau capillaire du muscle squelettique Îlantraßement. 2003 , 18, 1-10	4
1718	Therapeutic angiogenesis: review of current concepts and future directions. 2003 , 22, 370-82	16
1717	Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. 2003 , 5, 45-57	584
1716	Expression of HIF-1alpha, VEGF and VEGF receptors in the carotid body of chronically hypoxic rat. 2003 , 138, 143-54	39
1715	Vascular endothelial growth factor is involved in neoangiogenesis in Hirudo medicinalis (Annelida, Hirudinea). 2003 , 22, 168-79	26
1714	Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. 2003, 38, 1106-12	46
1713	Peptides with anticancer use or potential. 2003 , 25, 1-40	48
1712	Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. 2003 , 11, 53-9	21
1711	Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. 2003 , 10, 839-51	34
1710	Angiogenesis: basic pathophysiology and implications for disease. 2003 , 24, 586-603	106

(2003-2003)

1709	Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. 2003 , 278, 5277-84		162
1708	VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. 2003 , 278, 17164-9		42
1707	Antiangiogenic effect of KR-31372 by apoptosis via mediation of mitochondrial KATP channel opening and the phosphatase and tensin homolog deleted from chromosome 10 phosphorylation. 2003 , 305, 1142-9		3
1706	Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor. 2003 , 42, 62-70		21
1705	Isolation and characterization of human thyroid endothelial cells. 2003, 284, E168-76		25
1704	Perlecan and tumor angiogenesis. 2003 , 51, 1393-410		110
1703	Differential expression of angiopoietins 1 and 2 and their receptor Tie-2 in human endometrium. 2003 , 9, 663-9		28
1702	VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. 2003 , 116, 665-74		182
1701	Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. 2003 , 44, 839-47		64
1700	Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. 2003 , 3, 95-117		148
1699	Lung injury after thoracotomy. 2003 , 91, 132-42		89
1698	Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. 2003 , 8, 9-13		58
1697	Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. 2003 , 278, 48848-60		163
1696	Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. 2003 , 95, 437-48		265
1695	Induction of follicular development by direct single injection of vascular endothelial growth factor gene fragments into the ovary of miniature gilts. 2003 , 69, 1388-93		79
1694	Inhibition of hypoxia-induced angiogenesis by cigarette smoke exposure: impairment of the HIF-1alpha/VEGF pathway. <i>FASEB Journal</i> , 2003 , 17, 1150-2	0.9	107
1693	Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. <i>FASEB Journal</i> , 2003 , 17, 2006-13	0.9	66
1692	Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure. 2003 , 89, 207-8		24

1691	Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. <i>FASEB Journal</i> , 2003 , 17, 163-74	0.9	99
1690	Angiogenesis in hypersensitivity pneumonitis. 2003 , 111, 365-8		11
1689	The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy. 2003 , 12, 577-92		1
1688	Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice. 2003 , 89, 215-21		9
1687	Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. 2003 , 7, 450-9		112
1686	Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. 2003 , 88, 237-44		125
1685	Regulation of vascular endothelial growth factor synthesis by nitric oxide: facts and controversies. 2003 , 5, 123-32		105
1684	Angiogenic capacity of endothelial cells in islets of Langerhans. FASEB Journal, 2003, 17, 881-3	0.9	80
1683	WEB TOP 10. 2003 , 89, 208-208		
1682	Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review. 2003 , 5, 27-34		17
1681	Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. 2003 , 171, 4853-9		111
1680	ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. 2003 , 278, 23656-65		189
1679	Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. 2003 , 278, 35564-73		100
1678	Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. 2003 , 278, 40026-31		140
1677	Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. <i>FASEB Journal</i> , 2003 , 17, 1147-9	0.9	66
1676	Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart. 2003 , 108, 2414-22		40
1675	Neuropilin: From Nervous System to Vascular and Tumor Biology. 2003,		1
1674	Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia. 2003 , 24, 785-93		16

1673	Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. 2003 , 41, 1118-23	75
1672	Imbalance between vascular endothelial growth factor and endostatin in emphysema. 2003 , 22, 609-12	18
1671	Angiogenesis in Hypersensitivity Pneumonitis. 2003 , 111, 365-368	
1670	Novel Anticancer Agents in Clinical Development. 2003 , 2, 4-14	20
1669	Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. 2003 , 22, 339-43	9
1668	Expression of vascular endothelial growth factor receptors in experimental otitis media in the rat. 2003 , 123, 559-63	11
1667	The emerging role of VEGF in diabetic kidney disease. 2003 , 18, 1427-30	32
1666	Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. 2003 , 167, 1250-6	150
1665	Clinical Significance of Angiogenesis in Hepatocellular Carcinoma. 2003, 01, 167-178	1
1664	Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. 2003 , 21, 4356-63	66
1663	Positron emission tomographic imaging of angiogenesis and vascular function. 2003 , 76 Spec No 1, S50-9	29
1662	Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. 2003 , 35, 675-84	50
1661	Polymers for induction of revascularization in the rat fascial flap: application of vascular endothelial growth factor and pancreatic islet cells. 2003 , 12, 769-78	42
1660	Tumor angiogenesis: a potential target in cancer control by phytochemicals. 2003 , 3, 205-17	59
1659	The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. 2003, 12, 1087-95	28
1658	Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. 2003 , 88, 2695-8	51
1657	Expression of basic fibroblast growth factor, vascular endothelial growth factor, and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas. 2003 , 30, 306-13	12
1656	Alternative Splicing: Genetic Complexity in Cancer. 2003 , 277-297	1

1655	Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. 2003 , 10, 136-41	133
1654	Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma. 2003 , 129, 882-8	54
1653	Midazolam stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of the mitogen-activated protein kinase superfamily. 2003 , 98, 1147-54	10
1652	The effect of age on gene expression in adult and juvenile rats following femoral fracture. 2003 , 17, 689-98	35
1651	Vascular endothelial growth factor expression in pig latissimus dorsi myocutaneous flaps after ischemia reperfusion injury. 2003 , 111, 775-80	21
1650	Unique structural features that influence neutrophil emigration into the lung. 2003, 83, 309-36	238
1649	Mild hypoxia impairs alveolarization in the endothelial nitric oxide synthase-deficient mouse. 2003 , 284, L964-71	95
1648	Etiology and pathogenesis of uterine leiomyomas: a review. 2003 , 111, 1037-54	365
1647	Differential expression of VEGF receptors in adrenal atrophy induced by dexamethasone: a protective role of ACTH. 2003 , 284, E156-67	21
1646	Expression of VEGF and angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. 2003 , 285, H352-8	79
1645	Innovative Therapies in Wound Healing. 2003 , 7, 217-224	20
1644	Targeting Retroviral Vectors Using Molecular Bridges. 2003 , 253-266	
1643	A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. 2003 , 101, 1155-63	506
1642	VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. 2003 , 101, 168-72	315
1641	Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. 2003 , 101, 1316-23	128
1640	Map kinase signaling pathways and hematologic malignancies. 2003 , 101, 4667-79	361
1639	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. 2003 , 102, 4399-406	70
1638	Vascular endothelial growth factor and the risk of smoking-related COPD. 2003 , 124, 323-7	36

(2004-2003)

1637	Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation. 2003 , 89, 169-176	63
1636	Targeted drugs in oncology: New names, new mechanisms, new paradigm. 2003 , 60, 1233-1243	6
1635	Role of VEGF and CD44v6 in differentiating benign from malignant ascites. 2003 , 9, 2596-600	31
1634	p38 MAP kinase regulates BMP-4-stimulated VEGF synthesis via p70 S6 kinase in osteoblasts. 2003 , 284, E1202-9	32
1633	Ascorbic acid blocks the growth inhibitory effect of tumor necrosis factor-alpha on endothelial cells. 2003 , 228, 855-65	33
1632	Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. 2003 , 44, 3186-93	266
1631	Endogenous vascular remodeling in ischemic skeletal muscle: a role for nitric oxide. 2003 , 94, 935-40	16
1630	Molecular-targeted agents in pancreatic cancer. 2004 , 11, 32-8	23
1629	Circulating Levels of Vegf-A, VEGF-D and soluble VEGF-A Receptor (sFlt-1) in Human Breast Cancer. 2004 , 19, 229-235	14
1628	Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. 2004 , 91, 595-605	152
1627	Angiogenesis: a target for cancer therapy. 2004 , 10, 11-26	61
1626	Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. 2004 , 19, 879-86	62
1625	Resistance to anti-VEGF agents. 2004 , 10, 51-64	20
1624	Prostate cancer prevention by silibinin. 2004 , 4, 1-11	100
1623	A case of hypertrophic osteoarthropathy associated with epithelioid hemangioendothelioma. 2004 , 19, 484-6	12
1622	HIF-1alpha: a valid therapeutic target for tumor therapy. 2004 , 36, 343-53	55
1621	Vascular Endothelial Growth Factor (Vegf) and Other Common Tissue Prognostic Indicators in Breast Cancer: A Case-Control Study. 2004 , 19, 275-281	7
1620	Involvement and Consequences of Blood Brain Barrier Permeability After Minimal Injury in Rat Cerebral Cortex. 2004 , 533-545	2

1619	Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. 2004 , 10, 7965-71	196
1618	Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia. 2004 , 52, 117-64	24
1617	Wiring the vascular circuitry: from growth factors to guidance cues. 2004 , 62, 87-126	2
1616	Novel approaches for targeted cancer therapy. 2004 , 4, 313-26	71
1615	Interferon-alpha: regulatory effects on cell cycle and angiogenesis. 2004 , 80 Suppl 1, 85-93	50
1614	Biological bypass in cardiovascular surgery. 2004 , 52, 237-48	3
1613	Ischemic preconditioning mediated angiogenic response in the heart. 2004 , 6, 413-21	12
1612	Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. 2004 , 45, 1887-97	33
1611	Senescent impairment in synergistic cytokine pathways that provide rapid cardioprotection in the rat heart. 2004 , 199, 797-804	40
1610	Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. 2004 , 64, 5212-24	201
1609	Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. 2004 , 57, 504-12	104
1608	Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. 2004 , 10, 3327-32	108
1607	Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. 2004 , 64, 4601-10	44
1606	Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. 2004 , 101 Suppl 2, 14615-21	129
1605	Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. 2004 , 10, 581-90	82
1604	Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization. 2004 , 110, 3699-707	96
1603	Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. 2004 , 64, 3508-16	96
1602	AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. 2004 , 64, 4931-41	293

(2004-2004)

via vessel co-option. 2004 , 10, 6222-30	194
Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries. 2004 , 57, 266-72	31
Systemic inflammatory response after cardiac surgery: Is extracorporeal circulation the main culprit?. 2004 , 31-47	
A hierarchical order of factors in the generation of FLK1- and SCL-expressing hematopoietic and endothelial progenitors from embryonic stem cells. 2004 , 131, 2749-62	186
Extra-embryonic vasculature development is regulated by the transcription factor HAND1. 2004 , 131, 2195-204	66
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. 2004 , 64, 7822-35	370
Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. 2004 , 279, 36148-57	63
Structural and functional characterization of oversulfated chondroitin sulfate/dermatan sulfate hybrid chains from the notochord of hagfish. Neuritogenic and binding activities for growth factors and neurotrophic factors. 2004 , 279, 50799-809	103
The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. 2004 , 64, 2774-81	128
The role of vascular endothelial growth factor in the kidney in health and disease. 2004 , 98, p73-9	24
Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. 2004 , 64, 5712-9	36
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. 2004 , 10, 3365-70	84
Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. 2004 , 10, 4150-7	86
Effects of histamine and the h2 receptor antagonist ranitidine on ischemia-induced acute renal failure: involvement of IL-6 and vascular endothelial growth factor. 2004 , 27, 105-13	10
A quantitative high-throughput endothelial cell migration assay. 2004 , 9, 712-8	33
Vascular endothelial growth factor and its receptors in embryonic zebrafish blood vessel development. 2004 , 62, 127-52	24
Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. 2004 , 279, 33213-9	47
Genetics in zebrafish, mice, and humans to dissect congenital heart disease: insights in the role of VEGF. 2004 , 62, 189-224	27
	Localisation of members of the vascular endothelial growth factor (VECF) family and their receptors in human atherosclerotic arteries. 2004, 57, 266-72 Systemic inflammatory response after cardiac surgery: Is extracorporeal circulation the main culprit?. 2004, 31-47 A hierarchical order of factors in the generation of FLK1- and SCL-expressing hematopoietic and endothelial progenitors from embryonic stem cells. 2004, 131, 2749-62 Extra-embryonic vasculature development is regulated by the transcription factor HAND1. 2004, 131, 2195-204 VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. 2004, 64, 7822-35 Vascular endothelial growth factor (VECF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. 2004, 279, 36148-57 Structural and functional characterization of oversulfated chondroitin sulfate/dermatan sulfate hybrid chains from the notochord of hagrish. Neurtogenic and binding activities for growth factors and neurotrophic factors. 2004, 279, 50799-809 The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. 2004, 64, 2774-81 The role of vascular endothelial growth factor in the kidney in health and disease. 2004, 98, p73-9 Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. 2004, 64, 5712-9 A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. 2004, 10, 3365-70 Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. 2004, 10, 4150-7 Effects of histamine and the h2 receptor antagonist rantitidine on ischemia-induced acute renal failure: involvement of IL-6 and vascular endothelial growth factor. 2004, 27, 105-13 A quantitative high-throughput endothelial cell migration assay. 2004, 9, 712-8 Va

1583	Expression of placental growth factor gene in lung cancer. 2004 , 25, 1-6	16
1582	The pro- and anti-inflammatory markers in patients with acute myocardial infarction and chronic stable angina. 2004 , 14, 317	6
1581	Delayed angiogenesis in aging rats and therapeutic effect of adenoviral gene transfer of VEGF. 2004 , 13, 581	О
1580	Collateralization and the response to obstruction of epicardial coronary arteries. 2004 , 97, 259-72	34
1579	Modification of endothelial NO synthase through protein phosphorylation after forebrain cerebral ischemia/reperfusion. 2004 , 35, 2582-6	29
1578	Exercise-induced overexpression of angiogenic factors and reduction of ischemia/reperfusion injury in stroke. 2004 , 1, 411-20	114
1577	Hirudo medicinalis: avascular tissues for clear-cut angiogenesis studies?. 2004 , 10, 1979-88	20
1576	p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. 2004 , 279, 43352-60	122
1575	Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. 2004 , 10, 1706-16	266
1574	Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. 2004 , 10, 4109-17	171
1573	Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. 2004 , 64, 8643-50	139
1572	Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production. 2004 , 279, 30654-61	38
1571	Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. 2004 , 64, 1712-21	46
1570	Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. 2004 , 90, 245-52	38
1569	Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. 2004 , 64, 2039-46	45
1568	Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. 2004 , 15, 2307-19	23
1567	Differential expression of the vascular endothelial growth factor-receptor system in the gravid uterus of yorkshire and Meishan pigs. 2004 , 71, 163-9	35
1566	The potential role of vascular endothelial growth factor in the central nervous system. 2004 , 15, 293-307	62

(2004-2004)

1565	endothelial growth factor. 2004 , 50, 221-31	40
1564	Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2004,	7
1563	Vascular development in early human embryos and in teratomas derived from human embryonic stem cells. 2004 , 71, 2029-36	41
1562	Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. 2004 , 286, H1881-8	54
1561	A multi-protein complex containing cold shock domain (Y-box) and polypyrimidine tract binding proteins forms on the vascular endothelial growth factor mRNA. Potential role in mRNA stabilization. 2004 , 271, 648-60	66
1560	Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. 2004 , 9, 81-6	56
1559	Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma. 2004 , 19, 648-54	27
1558	Endoglin (CD105) expression in the development of haemorrhoids. 2004 , 34, 107-12	35
1557	The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. 2004, 65, 2003-17	345
1556	Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors. 2004 , 112, 257-63	44
1555	Comparative expression of vascular endothelial growth factor family members, VEGF-B, -C and -D, by normal human keratinocytes and fibroblasts. 2004 , 13, 98-105	50
1554	Local rh-VEGF administration enhances skin flap survival more than other types of rh-VEGF administration: a clinical, morphological and immunohistochemical study. 2004 , 13, 682-90	32
1553	Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. 2004 , 13, 671-81	39
1552	Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. 2004 , 34 Suppl 2, 2-11	21
1551	Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. 2004 , 123, 1151-61	104
1550	VEGF links hippocampal activity with neurogenesis, learning and memory. 2004 , 36, 827-35	661
1549	Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. 2004 , 18, 926-33	84
1548	Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). 2004 , 23, 122-9	55

1547	Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation. 2004 , 23, 5523-31	24
1546	Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. 2004 , 84, 502-12	81
1545	Placental vascular endothelial growth factor receptor system mRNA expression in pigs selected for placental efficiency. 2004 , 554, 194-201	31
1544	Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. 2004 , 288, 149-64	36
1543	Expression of VEGF isoforms by epiphyseal chondrocytes during low-oxygen tension is HIF-1 alpha dependent. 2004 , 12, 433-9	70
1542	IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondrocytes. 2004 , 12, 683-91	70
1541	Cerebrospinal fluid and serum vascular endothelial growth factor and nitric oxide levels in newborns with hypoxic ischemic encephalopathy. 2004 , 26, 283-6	33
1540	Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma. 2004 , 76, 143-52	39
1539	Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. <i>European Journal of Pharmacology</i> , 2004 , 499, 219-28	36
1538	Regulation of angiogenesis by extracellular matrix. 2004 , 1654, 13-22	116
1538 1537	Regulation of angiogenesis by extracellular matrix. 2004 , 1654, 13-22 Cell biology and pathology of liver sinusoidal endothelial cells. 2004 , 37, 208-15	11655
1537	Cell biology and pathology of liver sinusoidal endothelial cells. 2004 , 37, 208-15 VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic	55
1537 1536	Cell biology and pathology of liver sinusoidal endothelial cells. 2004 , 37, 208-15 VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. 2004 , 85, 161-71	55
1537 1536 1535	Cell biology and pathology of liver sinusoidal endothelial cells. 2004, 37, 208-15 VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. 2004, 85, 161-71 Myocardial angiogenesis. 2004, 264, 35-44	55 11 30
1537 1536 1535	Cell biology and pathology of liver sinusoidal endothelial cells. 2004, 37, 208-15 VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. 2004, 85, 161-71 Myocardial angiogenesis. 2004, 264, 35-44 Therapeutic myocardial angiogenesis with vascular endothelial growth factors. 2004, 264, 63-74	55 11 30 44
1537 1536 1535 1534	Cell biology and pathology of liver sinusoidal endothelial cells. 2004, 37, 208-15 VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. 2004, 85, 161-71 Myocardial angiogenesis. 2004, 264, 35-44 Therapeutic myocardial angiogenesis with vascular endothelial growth factors. 2004, 264, 63-74 Integrative signaling in angiogenesis. 2004, 264, 99-102 Gene transfer of CuZn superoxide dismutase enhances the synthesis of vascular endothelial growth	55 11 30 44 52

1529	Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS. 2004, 19, 754-60	19
1528	Forensic application of VEGF expression to skin wound age determination. 2004 , 118, 320-5	67
1527	Molecular basis of gastric cancer development and progression. 2004 , 7, 61-77	137
1526	Systemic and peritoneal angiogenic response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. 2004 , 47, 1670-4	31
1525	Relationship between Co-expression of vascular endothelial growth factor and its receptor, kinase insert domain containing receptor and tumor angiogenesis in invasive carcinoma of the cervix. 2004 , 1, 431-436	
1524	Vascular endothelial growth factor upregulates follistatin in human umbilical vein endothelial cells. 2004 , 9, 201-206	12
1523	Mathematical modeling of tumor-induced angiogenesis. 2004 , 49, 111-87	231
1522	Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. 2004 , 122, 209-15	110
1521	Antiangiogenic strategies, compounds, and early clinical results in breast cancer. 2004 , 49, 91-107	33
1520	Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. 2004 , 202, 313-20	48
1519	Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. 2004 , 202, 367-74	140
1518	Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. 2004 , 203, 721-8	119
1517	Development of the microcirculation of the secondary ossification center in rat humeral head. 2004 , 278, 419-27	23
1516	VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. 2004 , 26, 943-54	423
1515	Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 2004 , 100, 270-8	90
1514	Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. 2004 , 100, 1884-91	59
1513	Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. 2004 , 101, 1364-74	112
1512	Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. 2004 , 101, 2341-50	66

1511	Zebrafish neuropilins are differentially expressed and interact with vascular endothelial growth factor during embryonic vascular development. 2004 , 231, 33-42	50
1510	Homologs of vascular endothelial growth factor and receptor, VEGF and VEGFR, in the jellyfish Podocoryne carnea. 2004 , 231, 303-12	37
1509	NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. 2004 , 108, 181-8	101
1508	Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. 2004 , 110, 343-51	47
1507	VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. 2004 , 200, 351-9	29
1506	Vascular endothelial growth factor in esophageal cancer. 2004 , 87, 95-104	109
1505	The angiogenic status of B-CLL B cells: role of the VEGF receptors. 2004 , 28, 221-2	16
1504	Involvement of nitric oxide in angiogenic activities of vascular endothelial growth factor isoforms. 2004 , 22, 19-28	23
1503	Role of angiogenic growth factors in transplant coronary artery disease. 2004 , 36, 184-93	11
1502	Therapeutic angiogenesis for treatment of peripheral vascular disease. 2004 , 22, 269-79	14
1501	Neoadjuvant therapy for resectable pancreatic cancer. 2004 , 13, 639-61, ix	41
1500	Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. 2004 , 95, 109-16	248
1499	Vascular endothelial growth factor as a target for anticancer therapy. 2004 , 9 Suppl 1, 2-10	462
1498	Vascular endothelial growth factor and angiogenesis. 2004 , 56, 549-80	1342
1497	The vascular endothelial growth factor family and its receptors. 2004 , 18, 951-71, vii	45
1496	Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. 2004 , 171, S30-4; discussion S35	64
1495	Human embryo implantation: current knowledge and clinical implications in assisted reproductive technology. 2004 , 9, 692-715	102
1494	Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. 2004 , 43, 1383-7	57

(2004-2004)

1493	Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel. 2004 , 47, 6363-72		51
1492	From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. 2004 , 25, 971-1010		263
1491	Vascular endothelial growth factor: basic science and clinical progress. 2004 , 25, 581-611		2749
1490	Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). 2004 , 45, 325-37		43
1489	Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. 2004 , 46, 11-9		86
1488	Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. 2004 , 4, 262-7		41
1487	Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer?. 2004 , 6, 48-57		21
1486	Signaling pathways for arsenic-stimulated vascular endothelial growth factor-a expression in primary vascular smooth muscle cells. 2004 , 17, 555-63		31
1485	Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. 2004,		
1484	Angiogenesis with biomaterial-based drug- and cell-delivery systems. 2004 , 15, 701-26		121
1483	Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. 2004, 36, 1-12		636
1482	Dynamic Contrast-Enhanced Magnetic Resonance Imaging Rapidly Indicates Vessel Regression in Human Squamous Cell Carcinomas Grown in Nude Mice Caused by VEGF Receptor 2 Blockade with DC101. 2004 , 6, 213-223		55
1481	The effects of surgery, with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma. 2004 , 25, 68-72		25
1480	Human primary co-culture angiogenesis assay reveals additive stimulation and different angiogenic properties of VEGF and HGF. 2004 , 26, 178-85		28
1479	Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. 2004 , 28, 35-47		66
1478	The PDGF/VEGF receptor controls blood cell survival in Drosophila. 2004 , 7, 73-84		197
1477	Effect of nutrient intake during pregnancy on fetal and placental growth and vascular development. 2004 , 27, 199-217		163
1476	VEGF expression in adult permanent thyroid cartilage: implications for lack of cartilage ossification. Bone, 2004 , 35, 543-52	∤ .7	20

1475	Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. 2004 , 45, 143-63	84
1474	SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. 2004 , 324, 471-80	51
1473	Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45. 2004 , 32, 168-75	44
1472	VEGF regulates PCB 104-mediated stimulation of permeability and transmigration of breast cancer cells in human microvascular endothelial cells. 2004 , 296, 231-44	50
1471	VE-cadherin increases the half-life of VEGF receptor 2. 2004 , 300, 248-56	27
1470	Identification of two novel alternatively spliced Neuropilin-1 isoforms. 2004 , 84, 82-94	64
1469	In vitro evaluation and biodistribution of a 99mTc-labeled anti-VEGF peptide targeting neuropilin-1. 2004 , 31, 575-81	40
1468	GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. 2004 , 21, 831-42	73
1467	Expression of CD44v3 protein in human endothelial cells in vitro and in tumoral microvessels in vivo. 2004 , 68, 110-8	31
1466	Expression of placenta growth factor is regulated by both VEGF and hyperglycaemia via VEGFR-2. 2004 , 68, 239-46	39
1465	Do the signalling proteins for angiogenesis exist as a modular complex? The case for the angosome. 2004 , 63, 675-80	4
1464	Expression of VEGF receptors in cocultured neuroblastoma cells. 2004 , 119, 56-65	18
1463	Elasticity and adhesion force mapping reveals real-time clustering of growth factor receptors and associated changes in local cellular rheological properties. 2004 , 86, 1753-62	138
1462	Possible involvement of p44/p42 MAP kinase in retinoic acid-stimulated vascular endothelial growth factor release in aortic smooth muscle cells. 2004 , 175, 245-51	8
1461	Role of vascular endothelial growth factor receptor 1 in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in mice. 2004 , 82 Suppl 3, 1149-53	21
1460	Expression of human VEGF165 in silkworm (Bombyx mori L.) by using a recombinant baculovirus and its bioactivity assay. 2004 , 111, 253-61	16
1459	Pancreatic cancer. 2004 , 363, 1049-57	1569
1458	Immunohistochemical identification of vascular endothelial growth factor in pig latissimus dorsi musculocutaneous flaps following ischemia-reperfusion injury. 2004 , 53, 398-403	8

(2005-2004)

1457	Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. 2004 , 35, 1715-9	96
1456	Role of Hypoxia/lschemia/VEGF-A, and Strain Differences. 2004 , 115-129	2
1455	Expression of VEGFR-1 and VEGFR-2 in degenerative Achilles tendons. 2004 , 286-91	28
1454	VEGF protects human cerebral hybrid neurons from in vitro ischemia. 2004 , 15, 847-50	23
1453	Respiratory syncytial virus causes increased bronchial epithelial permeability. 2004 , 126, 186-91	25
1452	Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. 2004 , 286, L668-78	180
1451	Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. 2004 , 103, 3883-9	147
1450	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. 2004 , 103, 3474-9	79
1449	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. 2004 , 104, 1159-65	123
1448	Regulators of vascular endothelial growth factor expression in cancer. 2004 , 119, 33-58	3
1447	DNA microarray analysis of neonatal mouse lung connects regulation of KDR with dexamethasone-induced inhibition of alveolar formation. 2004 , 286, L411-9	32
1446	Shear stress and VEGF activate IKK via the Flk-1/Cbl/Akt signaling pathway. 2004 , 286, H685-92	52
1445	Reverse effects of tetraarsenic oxide on the angiogenesis induced by nerve growth factor in the rat cornea. 2004 , 66, 1091-5	11
1444	Carboxyamidotriazole, an Inhibitor of Nonvoltage-Operated Calcium Entry. 2005 , 89-105	1
1443	Constitutive and stimulated production of VEGF by human megakaryoblastic cell lines: effect on proliferation and signaling pathway. 2005 , 18, 445-55	16
1442	16 Role of Immunohistochemical Expression of Vascular Endothelial Growth Factor C and Vascular Endothelial Growth Factor Receptor 2 in Ovarian Cancer. 2005 , 4, 441-447	
1441	Understanding the biology of compressive neuropathies. 2005 , 251-60	22
1440	Acceleration of follicular development by administration of vascular endothelial growth factor in cycling female rats. 2005 , 51, 161-8	35

1439	Hypoxia and angiogenesis in rheumatoid arthritis. 2005 , 17, 293-8	132
1438	Sprouting angiogenesis versus co-option in tumor angiogenesis. 2005 , 65-76	7
1437	Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung. 2005 , 33, 860-6	20
1436	Update on angiogenesis inhibitors. 2005 , 17, 578-83	64
1435	Paradoxical effects of iron chelation on growth of vascular endothelial cells. 2005 , 45, 539-44	7
1434	Immunotherapy and cancer vaccines in the management of breast cancer. 2005 , 11, 3475-83	12
1433	Cytokine profiles in stem cell transplantation: possible use as a predictor of graft-versus-host disease. 2005 , 10, 107-14	31
1432	Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. 2005 , 103, 104-14	55
1431	Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. 2005 , 108, 205-13	261
1430	The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. 2005 , 105, 1383-95	277
1429	Erratum for vol. 104, p. 2368. 2005 , 105, 1395-1395	
1428	Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. 2005 , 106, 2347-55	101
1427	Increased CD133 expression in bone marrow of myelodysplastic syndromes. 2005 , 29, 995-1001	8
1426	A case of vulvar superficial angiomyxoma with necrotizing angiitis-like lesions and expression of granulocyte-colony stimulating factor. 2005 , 201, 145-52	8
1425	Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. 2005 , 1, 451-9	68
1424	Effects of vascular endothelial growth factor (VEGF) and chondroitin sulfate A on human monocytic THP-1 cell migration. 2005 , 43, 216-20	22
1423	The art of arteriogenesis. 2005 , 43, 1-15	59
1422	VEGF as a therapeutic target in cancer. 2005 , 69 Suppl 3, 11-6	450

(2005-2005)

1421	Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. 2005 , 23, 1011-27	2248
1420	Locally applied angiogenic factorsa new therapeutic tool for meniscal repair. 2005, 187, 509-19	47
1419	The influence of biomechanical parameters on the expression of VEGF and endostatin in the bone and joint system. 2005 , 187, 461-72	38
1418	Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. 2005 , 192, 734-41	121
1417	Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. 2005 , 15, 329-36	24
1416	Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. 2005 , 21, 1304-14	171
1415	Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. 2005 , 46, 31-6	153
1414	Effects of cold-water immersion on VEGF mRNA and protein expression in heart and skeletal muscles of rats. 2005 , 183, 389-97	9
1413	The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. 2005 , 128, 303-9	143
1412	Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. 2005 , 139, 575-9	13
1411	Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia. 2005 , 146, 568-75	55
1410	VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. 2005 , 19, 513-23	103
1409	Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. 2005 , 24, 8025-37	78
1408	Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. 2005 , 85, 756-67	50
1407	Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. 2005 , 18, 485-94	48
1406	The role of vasculature and angiogenesis for the pathogenesis of degenerative tendons disease. 2005 , 15, 211-22	166
1405	Modulation of vascular endothelial growth factor receptors in melanocytes. 2005 , 14, 625-33	62
1404	Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. 2005 , 7, 251-61	143

1403	Vascular endothelial growth factor expression and cyclosporine toxicity in renal allograft rejection. 2005 , 5, 766-74	19
1402	Gene activation and protein expression following ischaemic stroke: strategies towards neuroprotection. 2005 , 9, 85-102	48
1401	Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). 2005 , 9, 777-94	528
1400	VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. 2005 , 137, 192-9	52
1399	Animal models of placental angiogenesis. 2005 , 26, 689-708	134
1398	A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. 2005 , 6, 460-3	5
1397	El factor de crecimiento endotelial vascular en los derrames pleurales benignos y malignos. 2005 , 41, 376-379	3
1396	Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. 2005 , 95, 827-39	242
1395	A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. 2005 , 114, 32-8	65
1394	Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. 2005 , 104, 1668-77	49
1393	Expression of angiogenic VEGF-A (soluble isoforms 121, 165) and lymphangiogenic VEGF-C in colorectal cancers with micro-satellite instability. 2005 , 92, 317-25	4
1392	Schwann cells upregulate vascular endothelial growth factor secondary to chronic nerve compression injury. 2005 , 31, 452-60	44
1391	Roles of neuropilins in neuronal development, angiogenesis, and cancers. 2005 , 29, 271-5	39
1390	[Molecular biology approach to explain lymphatic metastasis]. 2005 , 44, 608-13	2
1389	Mast cell-derived VEGF and VEGF receptor type 1, 2, and 3 expression in human term trophoblast cultureinfluence of hypoxia. 2005 , 54 Suppl 1, S82-3	10
1388	[Overload damage to the Achilles tendon: the importance of vascularization and angiogenesis]. 2005 , 34, 533-42	19
1387	Sex steroid regulation of angiogenesis in breast tissue. 2005 , 8, 127-36	18
1386	Vascular endothelial growth factor plays an important autocrine/paracrine role in the progression of osteoarthritis. 2005 , 123, 275-81	96

(2005-2005)

1385	Proanthocyanidins, from Ribes nigrum leaves, reduce endothelial adhesion molecules ICAM-1 and VCAM-1. 2005 , 2, 9	31
1384	Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. 2005 , 205, 41-9	80
1383	Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. 2005 , 10, 1415-39	50
1382	A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 427-34.1	53
1381	Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. 2005 , 19, 2006-19	97
1380	Severe Lower Extremity Arterial Disease. 2005 , 269-292	1
1379	Expression of vascular endothelial growth factor and its receptors in heart tissue following short-term swimming training. 2005 , 3, 91-99	3
1378	Microdialysis - an in vivo technique for studies of growth factors in breast cancer. 2005 , 10, 1329-35	41
1377	Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. 2005 , 46, 4780-7	18
1376	Expression and regulation of latent TGF-beta binding protein-1 transcripts and their splice variants in human glomerular endothelial cells. 2005 , 20, 628-35	1
1375	Crotalid venom vascular endothelial growth factors has preferential affinity for VEGFR-1. Characterization of Protobothrops mucrosquamatus venom VEGF. 2005 , 93, 331-8	16
1374	Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. 2005 , 65, 3185-92	51
1373	Signaling in the Endocrine System. 2005 , 247-273	
1372	Novel therapeutic approaches targeting vascular endothelial growth factor and its receptors in haematological malignancies. 2005 , 5, 573-8	17
1371	Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. 2005 , 174, 5846-55	89
1370	Role of neural guidance signals in blood vessel navigation. 2005 , 65, 629-38	75
1369	A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. 2005 , 30, 249-57	35
1368	PGE1 analog alprostadil induces VEGF and eNOS expression in endothelial cells. 2005 , 289, H2066-72	23

1367	Angioblast-mesenchyme induction of early kidney development is mediated by Wt1 and Vegfa. 2005 , 132, 5437-49	90
1366	Vascular endothelial growth factor receptor-2: counter-regulation by the transcription factors, TFII-I and TFII-IRD1. 2005 , 280, 29856-63	30
1365	Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. 2005 , 44, 721-8	63
1364	Expression of vascular endothelial growth factor and its receptors in the cochlea of various experimental animals. 2005 , 125, 1152-7	12
1363	Important role of apoptosis signal-regulating kinase 1 in ischemia-induced angiogenesis. 2005 , 25, 1877-83	33
1362	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. <i>Molecular Cancer</i> 6.1 <i>Therapeutics</i> , 2005 , 4, 715-25	26
1361	Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. 2005 , 12, 123-8	39
1360	Ectopic norrin induces growth of ocular capillaries and restores normal retinal angiogenesis in Norrie disease mutant mice. 2005 , 25, 1701-10	74
1359	Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells. 2005 , 97, 796-804	49
1358	Real-time reverse transcription-PCR quantification of vascular endothelial growth factor splice variants. 2005 , 51, 1518-20	21
1357	Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor. 2005 , 33, 449-55	43
1356	Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. 2005 , 4, 315-21	64
1355	VEGF-integrin interplay controls tumor growth and vascularization. 2005 , 102, 7589-94	158
1354	Common Molecular Mechanisms Regulating Fetal Bone Formation and Adult Fracture Repair. 2005 , 45-55	3
1353	In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects. 2005 , 4, 1125-32	11
1352	Changes in fetal lung distension alter expression of vascular endothelial growth factor and its isoforms in developing rat lung. 2005 , 58, 30-7	38
1351	Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. 2005 , 6, 603-14	12
1350	[Angiogenesis VEGF165 gene therapy with AdVEGF- a new delay procedure for flaps]. 2005 , 37, 365-74	7

(2005-2005)

1349	Cellular expression and hormonal regulation of neuropilin-1 and -2 messenger ribonucleic Acid in the human and rhesus macaque endometrium. 2005 , 90, 1783-90	21
1348	Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy. 2005 , 5, 681-94	3
1347	The transport barrier in intraperitoneal therapy. 2005 , 288, F433-42	160
1346	Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. 2005 , 22, 513-24	8
1345	Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. 2005 , 93, 1005-10	66
1344	Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. 2005 , 12, 716-24	31
1343	Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate. 2005 , 19, 1-10	31
1342	Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. 2005 , 280, 25369-76	96
1341	A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. 2005 , 280, 3493-9	76
1340	Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy?. 2005 , 65, 8317-23	55
1339	Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. 2005 , 280, 31508-15	129
1338	VEGF-PLCgamma1 pathway controls cardiac contractility in the embryonic heart. 2005 , 19, 1624-34	100
1337	Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. 2005 , 46, 1647-52	63
1336	Mechanisms of Cell Growth Regulation by Heparin and Heparan Sulfate. 2005 , 533-570	5
1335	Molecular pathology of non-small-cell lung cancer. 2005 , 72, 313-30	42
1334	Integration/Interaction of Oncologic Growth. 2005,	3
1333	Comparing whole-genome amplification methods and sources of biological samples for single-nucleotide polymorphism genotyping. 2005 , 51, 1520-3	33
1332	Lower Extremity Arterial Disease. 2005,	1

1331	Margatoxin inhibits VEGF-induced hyperpolarization, proliferation and nitric oxide production of human endothelial cells. 2005 , 42, 368-76	34
1330	Vascular endothelial growth factor induces branching morphogenesis/tubulogenesis in renal epithelial cells in a neuropilin-dependent fashion. 2005 , 25, 7441-8	53
1329	New Functions of Angiogenic Peptides in Osteoarthritic Cartilage. 2005 , 1, 37-43	5
1328	Photoperiod-induced differential expression of angiogenesis genes in testes of adult Peromyscus leucopus. 2005 , 129, 201-9	18
1327	Molecularly targeted therapy for gastrointestinal cancer. 2005 , 5, 171-93	73
1326	A Review of Vasculogenesis Models. 2005 , 6, 1-19	53
1325	Abnormal maturation of the retinal vasculature in type XVIII collagen/endostatin deficient mice and changes in retinal glial cells due to lack of collagen types XV and XVIII. <i>FASEB Journal</i> , 2005 , 19, 1564-6	49
1324	Role of oxygen and vascular development in epithelial branching morphogenesis of the developing mouse lung. 2005 , 288, L167-78	119
1323	Effect of maternal administration of selective cyclooxygenase (COX)-2 inhibitors on renal size, growth factors, proteinases, and COX-2 secretion in the fetal rabbit. 2005 , 87, 246-53	5
1322	Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells. 2005 , 68, 204-11	14
1321	Significance of vascular endothelial growth factor expression in renal tissue of patients with preeclamptic nephropathy. 2005 , 25, 579-85	10
1320	A multipurpose vector system for the screening of libraries in bacteria, insect and mammalian cells and expression in vivo. 2005 , 33, e42	40
1319	Low ambient o(2) enhances ureteric bud branching in vitro. 2005 , 2, 17-21	6
1318	VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise. 2005 , 98, 2137-46	72
1317	Modulation of the expression of vascular endothelial growth factor in human fibroblasts. 2005 , 83, 405-9	52
1316	Responses of keratinocytes to substrate-bound vitronectin: growth factor complexes. 2005 , 305, 221-32	33
1315	SDF-1 is both necessary and sufficient to promote proliferative retinopathy. 2005 , 115, 86-93	182
1314	The future: rehabilitation, gene therapy, optimization of healing. 2005 , 10, 383-97	24

1313	[Vascular endothelial growth factor in benign and malignant pleural effusions]. 2005, 41, 376-9	3
1312	The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. 2005 , 7, 486-96	26
1311	Mechanisms of Angiogenesis. 2005,	5
1310	Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor. 2005 , 15, 1-11	11
1309	VEGF and VEGF receptor expression after experimental brain contusion in rat. 2005, 22, 353-67	111
1308	Oxygen availability causes morphological changes and a different VEGF/FIk-1/HIF-2 expression pattern in sea bass gills. 2005 , 72, 103-111	14
1307	Heparan sulfate: a complex polymer charged with biological activity. 2005 , 105, 2745-64	323
1306	Tendon injury and tendinopathy: healing and repair. 2005 , 87, 187-202	546
1305	An ancient role for a prokineticin domain in invertebrate hematopoiesis. 2005 , 174, 6153-60	150
1304	Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation. 2005 , 70, 179-88	20
1303	Graft serosectomy in adult small bowel transplantation without vascular reconstruction in rats improves graft survival by induction of vascular endothelial growth factor. 2005 , 40, 1881-6	2
1302	Adult stem cell lines in regenerative medicine and reconstructive surgery. 2005 , 124, 201-8	75
1301	Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation. 2005 , 128, 140-6	42
1300	Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid arthritis. 2005 , 66, 864-8	23
1299	Expression and cellular localization of vascular endothelial growth factor A and its receptors in acute and chronic leukemias: an immunohistochemical study. 2005 , 36, 797-805	23
1298	Soluble vascular endothelial growth factor, soluble VEGF receptor Flt-1 and endothelial function in healthy smokers. 2005 , 100, 207-12	28
1297	Transcription regulation of the vegf gene by the BMP/Smad pathway in the angioblast of zebrafish embryos. 2005 , 329, 324-30	51
1296	Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF. 2005 , 32, 206-12	37

1295	Transcriptional regulation of vascular endothelial growth factor in cancer. 2005 , 16, 77-89	100
1294	Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. 2005 , 41, 1291-9	152
1293	Vascular endothelial growth factor counteracts NMDA-induced cell death of adult cholinergic neurons in rat basal nucleus of Meynert. 2005 , 65, 125-31	17
1292	Normal patterning of the coronary capillary plexus is dependent on the correct transmural gradient of FGF expression in the myocardium. 2005 , 279, 378-90	28
1291	Current concepts in the etiology and treatment of Behät disease. 2005 , 50, 297-350	295
1290	New horizons for VEGF. Is there a role for nuclear localization?. 2005 , 106, 405-11	27
1289	Neuropilin-1 expression by endothelial cells and retinal pigment epithelial cells in choroidal neovascular membranes. 2005 , 140, 1044-1050	18
1288	Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. 2005 , 14, 207-21	209
1287	Bioactive glass stimulates the secretion of angiogenic growth factors and angiogenesis in vitro. 2005 , 11, 768-77	299
1286	Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. 2005 , 46, 827-34	147
1285	Osteoclast-forming Activity of Vascular Endothelial Growth Factor. 2005, 47, 105-114	
1284	The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. 2005 , 7, 912-20	27
1283	Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution. 2005 , 42, 1183-9	30
1282	From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. 2005 , 54, 1626-34	468
1281	Reactive oxygen species induce expression of vascular endothelial growth factor in chondrocytes and human articular cartilage explants. 2006 , 8, R189	63
1280	Biomarkers in Breast Cancer. 2006 ,	3
1279	Cell biology of membrane trafficking in human disease. 2006 , 252, 1-69	38
1278	Gonadotropin-releasing hormone antagonists increase follicular fluid insulin-like growth factor-l and vascular endothelial growth factor during ovarian stimulation cycles. 2006 , 22, 289-96	8

1277 Transmembrane Signaling Protocols. 2006,

Differential expression profiling of the blind subterranean mole rat Spalax ehrenbergi superspecies: bioprospecting for hypoxia tolerance. 2006 , 27, 54-64	22
Heterogeneity of capillary endothelial cells for basic fibroblast growth factor-induced paracrine signaling. 2006 , 13, 191-203	4
Role of vascular endothelial growth factor in pulmonary endothelial cell injury by exercise challenge in asthmatic patients. 2006 , 43, 267-71	8
Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response. 2006 , 8, 41-5	9
1272 A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. 2006 , 10, 867-76	71
1271 [Vascular development in inflammatory bowel disease]. 2006 , 29, 414-21	11
1270 Mechanisms of transcoelomic metastasis in ovarian cancer. 2006 , 7, 925-34	320
Genetic susceptibility to retinopathy of prematurity. 2006 , 118, 1858-63	91
1268 CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. 2006 , 203, 941-51	262
Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. 2006 , 187, 423-32	187
1266 Clinical implications for vascular endothelial growth factor in the lung: friend or foe?. 2006 , 7, 128	85
Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. 2006 , 49, 1271-81	78
Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. 2006 , 91, 180-4	95
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. 2006 , 51, 143-58	277
Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites. 2006 , 45, 10319-28	82
Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. 2006 , 82, 99-110	208
Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. 2006 , 83, 1005-16	72

1259	Serum level of vascular endothelial growth factor is increased by estrogen replacement therapy in normotensive and DOCA-Salt hypertensive ovariectomized rats. 2006 , 365, 206-10	8
1258	Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. 2006 , 340, 984-94	61
1257	Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. 2006 , 342, 1396-404	89
1256	The effect of VEGF on blood vessels and blood cells during Xenopus development. 2006 , 344, 339-45	13
1255	Vascular endothelial growth factor increases the intracellular magnesium. 2006 , 347, 496-501	13
1254	Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. 2006 , 349, 31-8	42
1253	Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. 2006 , 235, 229-38	53
1252	Irinotecan in the treatment of colorectal cancer. 2006 , 32, 491-503	111
1251	Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. 2006 , 35, 21-8	90
1250	Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer. 2006 , 42, 101-8	41
1249	Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles. 2006 , 124, 70-6	12
1248	Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes. 2006 , 79, 1214-20	2
1247	Whole-body hyperthermia induces up-regulation of vascular endothelial growth factor accompanied by neovascularization in cardiac tissue. 2006 , 79, 1781-8	24
1246	Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. 2006 , 79, 2370-81	130
1245	Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding. 2006 , 359, 76-85	32
1244	A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. 2006 , 72, 91-100	40
1243	Hypobaric hypoxia induces oxidative stress in rat brain. 2006 , 49, 709-16	163
1242	Vascular endothelial growth factor (VEGF) expression in noise-induced hearing loss. 2006 , 214, 76-83	35

(2006-2006)

1241	The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. 2006 , 37, 190-7	80
1240	The effect of hypertension on serum nitric oxide and vascular endothelial growth factor concentrations. A study in DOCA-Salt hypertensive ovariectomized rats. 2006 , 135, 91-4	9
1239	Calcitonin gene-related peptide regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes by activation of ERK1/2 MAPK. 2006 , 137, 134-9	34
1238	Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. 2006 , 289, 329-35	143
1237	Cigarette smoke exposure impairs VEGF-induced endothelial cell migration: role of NO and reactive oxygen species. 2006 , 41, 275-84	93
1236	Expression and characterization of human vascular endothelial growth factor (VEGF165) in insect cells. 2006 , 46, 503-9	21
1235	Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. 2006 , 20, 154-62	33
1234	A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. 2006 , 24, 6994-7002	32
1233	Flt-1 intraceptor induces the unfolded protein response, apoptotic factors, and regression of murine injury-induced corneal neovascularization. 2006 , 47, 4787-93	18
1232	VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. 2006 , 11, 818-29	145
1232	VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. 2006 , 11, 818-29 [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006 , 69, 756-65	145
1231		
1231	[Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006 , 69, 756-65	1
1231	[Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006 , 69, 756-65 The Role of Microvasculature in Metastasis Formation. 2006 , 31-62	5
1231 1230 1229	[Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006, 69, 756-65 The Role of Microvasculature in Metastasis Formation. 2006, 31-62 Biomolecular markers of breast cancer. 2006, 11, 1818-43 Comano's (Trentino) thermal water interferes with the expression and secretion of vascular endothelial growth factor-A protein isoforms by cultured human psoriatic keratinocytes: A	1 5 51
1231 1230 1229	[Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006, 69, 756-65 The Role of Microvasculature in Metastasis Formation. 2006, 31-62 Biomolecular markers of breast cancer. 2006, 11, 1818-43 Comano's (Trentino) thermal water interferes with the expression and secretion of vascular endothelial growth factor-A protein isoforms by cultured human psoriatic keratinocytes: A potential mechanism of its anti-psoriatic action. 2006, 18, 17 Promotion of ovarian follicular development by injecting vascular endothelial growth factor (VEGF)	1 5 51 1
1231 1230 1229 1228	[Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006, 69, 756-65 The Role of Microvasculature in Metastasis Formation. 2006, 31-62 Biomolecular markers of breast cancer. 2006, 11, 1818-43 Comano's (Trentino) thermal water interferes with the expression and secretion of vascular endothelial growth factor-A protein isoforms by cultured human psoriatic keratinocytes: A potential mechanism of its anti-psoriatic action. 2006, 18, 17 Promotion of ovarian follicular development by injecting vascular endothelial growth factor (VEGF) and growth differentiation factor 9 (GDF-9) genes. 2006, 52, 23-32 Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and	1 5 51 1 30
1231 1230 1229 1228 1227 1226	[Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. 2006, 69, 756-65 The Role of Microvasculature in Metastasis Formation. 2006, 31-62 Biomolecular markers of breast cancer. 2006, 11, 1818-43 Comano's (Trentino) thermal water interferes with the expression and secretion of vascular endothelial growth factor-A protein isoforms by cultured human psoriatic keratinocytes: A potential mechanism of its anti-psoriatic action. 2006, 18, 17 Promotion of ovarian follicular development by injecting vascular endothelial growth factor (VEGF) and growth differentiation factor 9 (GDF-9) genes. 2006, 52, 23-32 Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. 2006, 12, 127-36	1 5 51 1 30 81

1223	Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. 2006 , 29, 981	9
1222	Drug Development for Advanced Colorectal Cancer in the United States. 2006 , 317-336	
1221	The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. 2006 , 107, 3564-71	147
1220	Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. 2006 , 136, 1477-82	121
1219	Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis. 2006 , 29, 357	4
1218	Tumor Angiogenesis. 1087-1106	O
1217	Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. 2006 , 58, 365-72; discussion 365-72	102
1216	Vitreous fluid biomarkers. 2006 , 42, 111-66	9
1215	Review of selected patents for cancer therapy targeting tumor angiogenesis. 2006 , 1, 153-61	4
1214	Angiopoietin-1 and -2 mRNA and protein expression in mouse preimplantation embryos and uteri suggests a role in angiogenesis during implantation. 2006 , 18, 509-16	9
1213	The basic science of wound healing. 2006 , 117, 12S-34S	874
1212	Vascular endothelial growth factor expression in osteosarcoma. 2006 , 448, 193-8	41
1211	Activation of VEGF and FGF induced angiogenesis under influence of low level laser radiation in vitro. 2006 ,	
1210	Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. 2006 , 244, 792-8	87
1209	Current status of genetic modulation of growth factors in wound repair (Review). 2006, 17, 183	О
1208	Role of platelet-derived growth factor-B, vascular endothelial growth factor, insulin-like growth factor-II, mitogen-activated protein kinase and transforming growth factor-beta1 in expansion-induced lung growth in fetal sheep. 2006 , 18, 655-65	13
1207	TLR-2-mediated induction of vascular endothelial growth factor (VEGF) in cartilage in septic joint disease. 2006 , 210, 315-24	32
1206	Vascular endothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. 2006 , 21, 988-93	13

(2006-2006)

1205	Increased serum level of vascular endothelial growth factor in Mycobacterium avium complex infection. 2006 , 11, 407-13	9
1204	Signaling angiogenesis via p42/p44 MAP kinase cascade. 2000 , 902, 187-200	107
1203	Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. 2000 , 902, 249-62; discussion 262-4	201
1202	Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. 2006 , 7, 1270-82	144
1201	Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining. 2006 , 28, 254-8	5
1200	Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. 2006 , 12, 1286-93	273
1199	Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. 2006 , 94, 1710-7	100
1198	Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. 2006 , 19, 701-7	33
1197	Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation. 2006 , 38, 149-56	54
1196	Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. 2006 , 13, 940-7	8
1195	Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors. 2006 , 13, 993-1001	20
1194	Low urinary placental growth factor is a marker of pre-eclampsia. 2006 , 69, 621-4	62
1193	Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. 2006 , 69, 1654-61	131
1192	Abnormal development of glomerular endothelial and mesangial cells in mice with targeted disruption of the lama3 gene. 2006 , 70, 1062-71	28
1191	Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. 2006 , 25, 4257-66	135
1190	The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo. 2006 , 572, 243-57	39
1189	Angiogenesis in malignant gliomaa target for antitumor therapy?. 2006 , 59, 181-93	70
1188	Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). 2006 , 59, 40-50	62

1187	Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. 2006 , 16, 1913-9	9
1186	Improved surgical mesh integration into the rat abdominal wall with arginine administration. 2006 , 27, 758-68	14
1185	Modeling the effects of vasculature evolution on early brain tumor growth. 2006, 243, 517-31	80
1184	Design and synthesis of novel photoaffinity reagents for labeling VEGF receptor tyrosine kinases. 2006 , 47, 2915-2919	10
1183	Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine. 2006 , 7, 837-43	2
1182	Hypoxia-inducible factor-1 (HIF-1). 2006 , 70, 1469-80	1089
1181	Upregulation of VEGF by 15-deoxy-Delta12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells. 2006 , 1090, 375-84	45
1180	Expression of stathmin family genes in the murine uterus during early pregnancy. 2006 , 73, 164-72	21
1179	Circulating Vascular Endothelial Growth Factor. 2006 , 267-292	O
1178	Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. 2006 , 195, 1668-73	76
1177	Peliosis hepatis: microscopic and macroscopic type, time pattern, and correlation with liver cell apoptosis in a model of toxic liver injury. 2006 , 51, 1998-2006	23
1176	Pro-angiogenic cytokines and their role in tumor angiogenesis. 2006 , 25, 373-85	71
1175	Molecular and functional diversity of vascular endothelial growth factors. 2006 , 10, 515-27	183
1174	VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers. 2006 , 113, 487-96	37
1173	Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer. 2006 , 49, 883-94	14
1172	Angiogenic factors in peritoneal adhesion formation. 2006 , 3, 157-167	11
1171	Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf. 2005 , 8, 349-60	28
1170	Angiogenesis - understanding the mathematical challenge. 2006 , 9, 127-38	15

(2006-2006)

1169	Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. 2006 , 297, 425-9	53
1168	Estradiol increases VEGF in human breast studied by whole-tissue culture. 2006 , 325, 245-51	28
1167	Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. 2006 , 16, 129-33	11
1166	Cardiovascular genomics: a current overview of in vivo and in vitro studies. 2006 , 2, 59-66	1
1165	Effects of estradiol-17beta on expression of mRNA for seven angiogenic factors and their receptors in the endometrium of ovariectomized (OVX) ewes. 2006 , 30, 333-42	38
1164	Effects of inhalant nitrites on VEGF expression: a feasible link to Kaposi's sarcoma?. 2006 , 1, 317-22	7
1163	Relationship between prostaglandin E2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells. 2006 , 44, 411-6	39
1162	Gene therapy of the ischemic lower limbTherapeutic angiogenesis. 2006 , 44, 395-405	35
1161	Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. 2006 , 165, 9-19	81
1160	Free radicals, metals and antioxidants in oxidative stress-induced cancer. 2006 , 160, 1-40	4124
1160 1159	Free radicals, metals and antioxidants in oxidative stress-induced cancer. 2006 , 160, 1-40 Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. 2006 , 85, 61-8	4124 26
1159	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from	
1159	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. 2006 , 85, 61-8	26
1159 1158	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. 2006 , 85, 61-8 Understanding the importance of smart drugs in renal cell carcinoma. 2006 , 49, 633-43 A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type	26
1159 1158 1157	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. 2006, 85, 61-8 Understanding the importance of smart drugs in renal cell carcinoma. 2006, 49, 633-43 A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. 2006, 111, 153-64 Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1	26 68 114
1159 1158 1157 1156	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. 2006, 85, 61-8 Understanding the importance of smart drugs in renal cell carcinoma. 2006, 49, 633-43 A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. 2006, 111, 153-64 Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. 2006, 114, 381-8 The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell	26 68 114 78
1159 1158 1157 1156 1155	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. 2006, 85, 61-8 Understanding the importance of smart drugs in renal cell carcinoma. 2006, 49, 633-43 A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. 2006, 111, 153-64 Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. 2006, 114, 381-8 The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. 2006, 42, 337-42	26 68 114 78
1159 1158 1157 1156 1155	Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. 2006, 85, 61-8 Understanding the importance of smart drugs in renal cell carcinoma. 2006, 49, 633-43 A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. 2006, 111, 153-64 Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. 2006, 114, 381-8 The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. 2006, 42, 337-42 Fabrication of endothelialized tube in collagen gel as starting point for self-developing capillary-like network to construct three-dimensional organs in vitro. 2006, 95, 1-7 Role of MSK1 in the signaling pathway leading to VEGF-mediated PAF synthesis in endothelial cells.	26 68 114 78 44

1151	Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. 2006 , 209, 56-66	58
1150	Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1beta. 2006 , 106, 2028-38	29
1149	Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. 2006 , 119, 2054-62	21
1148	Alginate hydrogels as biomaterials. 2006 , 6, 623-33	1282
1147	Glyco-materials: using saccharides and their interactions for designing new biomaterials. 2006 , 6, 575-8	6
1146	Vascular endothelial growth factor induction by rhinovirus infection. 2006 , 78, 666-72	23
1145	Distinct signaling pathways are involved in hypoxia- and IL-1-induced VEGF expression in human articular chondrocytes. 2006 , 24, 1544-54	35
1144	Microvasculature change and placenta growth factor expression in the early stage of a rat remnant kidney model. 2006 , 26, 97-104	4
1143	Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. 2006 , 12, 7294-305	58
1142	Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. 2006 , 21, 1453-60	51
1141	Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes. 2006 , 21, 1846-55	32
1140	Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy. 2006 , 147, 1675-84	84
1139	Integrin regulation by vascular endothelial growth factor in human brain microvascular endothelial cells: role of alpha6beta1 integrin in angiogenesis. 2006 , 281, 40450-60	54
1138	Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases. 2006 , 332, 51-77	71
1137	Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. 2006 , 26, 1051-7	71
1136	Monoclonal antibodies in the management of solid tumors. 2006 , 6, 1687-705	18
1135	Molecular mechanisms involved in chemoprevention of black raspberry extracts: from transcription factors to their target genes. 2006 , 54, 69-78	51
1134	Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. 2006 , 12, 2609-22	123

1133	New technologies and directed agents for applications of cancer imaging. 2006 , 24, 3299-308	81
1132	Renal handling of adipokines. 2006 , 151, 91-105	8
1131	VEGF, a mediator of the effect of experience on hippocampal neurogenesis. 2006 , 3, 29-33	98
1130	Inhaled NO restores lung structure in eNOS-deficient mice recovering from neonatal hypoxia. 2006 , 291, L119-27	82
1129	Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition. 2006 , 290, L897-908	75
1128	Nitric oxide augments fetal pulmonary artery endothelial cell angiogenesis in vitro. 2006 , 290, L1111-6	30
1127	HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation. 2006 , 291, F995-1004	29
1126	Angiogenesis as a therapeutic target in arthritis: lessons from oncology. 2006 , 12, 2631-44	28
1125	Exercise training improves aging-induced downregulation of VEGF angiogenic signaling cascade in hearts. 2006 , 291, H1290-8	84
1124	Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. 2006 , 30, 353-61	174
1123	Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. 2006 , 281, 11322-31	46
1122	High-resolution quantitative computed tomography demonstrating selective enhancement of medium-size collaterals by placental growth factor-1 in the mouse ischemic hindlimb. 2006 , 113, 2445-53	32
1121	Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. 2006 , 12, 800-6	98
1120	Impaired adipose tissue development in mice with inactivation of placental growth factor function. 2006 , 55, 2698-704	84
1119	The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts. 2006 , 66, 3792-801	40
1118	Vascular composition, apoptosis, and expression of angiogenic factors in the corpus luteum during prostaglandin F2alpha-induced regression in sheep. 2006 , 131, 1115-26	63
1117	MicroRNAs modulate the angiogenic properties of HUVECs. 2006 , 108, 3068-71	619
1116	Drugs Affecting Growth of Tumours. 2006 ,	1

1115	Ocular Angiogenesis. 2006,	3
1114	The Diabetic Kidney. 2006,	1
1113	Calpain-2 regulation of VEGF-mediated angiogenesis. <i>FASEB Journal</i> , 2006 , 20, 1443-51 0.9	63
1112	Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A. 2006 , 95, 291-6	3
1111	Is the Vasculature a Potential Therapeutic Target in Arthritis?. 2006 , 2, 151-158	1
1110	Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. 2006 , 6, 455-89	28
1109	Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. 2006 , 104, 314-20	26
1108	Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. 2006 , 281, 5702-10	98
1107	Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. 2006 , 103, 9017-22	170
1106	Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation. 2006 , 177, 5727-35	50
1105	Flow-mediated signaling modulates endothelial cell phenotype. 2006 , 13, 375-84	35
1104	Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells. 2006 , 281, 13503-13512	30
1103	Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and antionagulant forms of antithrombin to proangiogenic heparan sulfate	27
1102	domains. 2006 , 281, 37302-10 Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. 2006 , 177, 7322-31	92
1101	Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. 2006 , 66, 3658-66	124
1100	Neuropilin-1 and neuropilin-2 enhance VEGF121 stimulated signal transduction by the VEGFR-2 receptor. <i>FASEB Journal</i> , 2007 , 21, 915-26	61
1099	Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. 2007 , 282, 28045-56	7 ²
1098	Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer. 2007 , 53, 1433-9	31

(2007-2007)

1097	Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. 2007 , 67, 3310-9	189
1096	Non-invasive detection of acute renal allograft rejection by measurement of vascular endothelial growth factor in urine. 2007 , 35, 442-9	9
1095	Bevacizumab in the management of solid tumors. 2007 , 7, 433-45	42
1094	Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. 2007 , 99, 1551-5	45
1093	Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. 2007 , 292, E1030-40	41
1092	Interactive endogenous small molecule (gaseous) signaling: implications for teratogenesis. 2007 , 13, 2952-78	20
1091	Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate. 2007 , 6, 389-99	34
1090	Role of rat alpha adducin in angiogenesis: null effect of the F316Y polymorphism. 2007 , 75, 608-17	8
1089	Molecular and cellular regulators of cancer angiogenesis. 2007 , 7, 743-58	55
1088	Early rise in serum VEGF and PDGF levels predisposes patients with a normal MBL2 genotype to restenosis after eversion endarterectomy. 2007 , 38, 2247-53	15
1087	WITHDRAWN: High-level expression of recombinant human vascular endothelial growth factor (rhVEGF165) in silkworm larvae (Bombyx mori). 2007 , 1	
1086	Novel insights in the treatment of diabetic nephropathy. 2007 , 62, 278-90	14
1085	Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 in rat hippocampus after transient forebrain ischemia. 2007 , 24, 521-31	19
1084	Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. 2007 , 91, 291-7	109
1083	[Restoration of the continuity of the colon with preservation of an existing colostomy]. 2007 , 132, 151-3; discussion 154	
1082	Inflammatory response in on- versus off-pump myocardial revascularization: is ECC really the culprit?. 2007 , 55, 473-80	16
1081	The Wnt Pathway as a Target for Small Synthetic Anti-Cancer Molecules. 2007, 1, 227-239	
1080	Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule. 2007 , 148, 4734-44	30

1079	Angiogenesis in day-30 bovine pregnancies derived from nuclear transfer. 2007 , 9, 595-607		15
1078	Short-term hyperhomocysteinemia-induced oxidative stress activates retinal glial cells and increases vascular endothelial growth factor expression in rat retina. 2007 , 71, 1203-10		30
1077	Chondrocyte signaling and artificial matrices for articular cartilage engineering. 2006, 585, 67-86		41
1076	Controlled Angiogenic Factor Release from Alginate Gels. 2007 , 342-343, 517-520		1
1075	Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. 2007 , 48, 2030-6		63
1074	Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. 2007 , 177, 489-500		219
1073	Selective adapter recruitment and differential signaling networks by VEGF vs. shear stress. 2007 , 104, 8875-9		37
1072	Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: effect on endothelial progenitor cells and nitric oxide. <i>FASEB Journal</i> , 2007 , 21, 3845-52	0.9	71
1071	Mast cell degranulation in rat uterine cervix during pregnancy correlates with expression of vascular endothelial growth factor mRNA and angiogenesis. 2007 , 133, 1045-55		29
1070	Inducible nitric oxide synthase-vascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents. 2007 , 7, 475-83		23
1069	Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. 2007, 27, 63-9		201
1068	Tendinopathy and Neovascularization in Rheumatology. 2007 , 3, 135-146		О
1067	The influence of physical training on the angiopoietin and VEGF-A systems in human skeletal muscle. 2007 , 103, 1012-20		59
1066	A review of gene expression in porcine endometrial lymphocytes, endothelium and trophoblast during pregnancy success and failure. 2007 , 53, 455-63		39
1065	Effects of antiretroviral therapy on tube-like network formation of human endothelial cells. 2007 , 30, 982-4		3
1064	Duplicate VegfA genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish. 2007 , 110, 3627-36		97
1063	Patterns of late embryonic and fetal mortality and association with several factors in sheep. 2007 , 85, 1274-84		61
1062	Schlemm's canal endothelia, lymphatic, or blood vasculature?. 2007 , 16, 391-405		57

1061	Receptor tyrosine kinases as therapeutic targets in malignant glioma. 2007 , 2, 87-101	19
1060	VEGF, angiopoietin-1 and -2 in bronchial asthma: new molecular targets in airway angiogenesis and microvascular remodeling. 2007 , 1, 1-8	25
1059	The role of apoptosis in respiratory diseases. 2007 , 21, 22-8; quiz 29-30	6
1058	Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. 2007 , 25, 317-21	14
1057	Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness. 2007 , 101, 587-94	35
1056	Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. 2007 , 115, 320-33	42
1055	On the role of placental growth factor in murine adipogenesis. 2007 , 120, 399-405	4
1054	The distribution of the growth factors FGF-2 and VEGF, and their receptors, in growing red deer antler. 2007 , 39, 35-46	16
1053	Angiogenesis induced by novel peptides selected from a phage display library by screening human vascular endothelial cells under different physiological conditions. 2007 , 28, 691-701	22
1052	Developmental and adult phenotyping directly from mutant embryonic stem cells. 2007, 104, 4455-60	157
	Developmental and adult phenotyping directly from mutant embryonic stem cells. 2007 , 104, 4455-60 Structure and Pathology of the BloodBrain Barrier. 2007 , 56-89	157
1051		
1051	Structure and Pathology of the Blood B rain Barrier. 2007 , 56-89	
1051	Structure and Pathology of the BloodBrain Barrier. 2007, 56-89 Activation of growth factor receptors in pancreatic cancer. 2007, 194, S76-S83 Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of	1
1051 1050 1049	Structure and Pathology of the Blood B rain Barrier. 2007 , 56-89 Activation of growth factor receptors in pancreatic cancer. 2007 , 194, S76-S83 Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. 2007 , 33, 1169-76 Age-dependent expression of VEGF isoforms and receptors in the rabbit anterior cruciate ligament.	1 22
1051 1050 1049 1048	Structure and Pathology of the BloodBrain Barrier. 2007, 56-89 Activation of growth factor receptors in pancreatic cancer. 2007, 194, S76-S83 Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. 2007, 33, 1169-76 Age-dependent expression of VEGF isoforms and receptors in the rabbit anterior cruciate ligament. 2007, 1770, 997-1002 Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue	1 22 13
1051 1050 1049 1048	Structure and Pathology of the BloodBrain Barrier. 2007, 56-89 Activation of growth factor receptors in pancreatic cancer. 2007, 194, S76-S83 Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. 2007, 33, 1169-76 Age-dependent expression of VEGF isoforms and receptors in the rabbit anterior cruciate ligament. 2007, 1770, 997-1002 Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. 2007, 1770, 1369-73 Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human	1 1 22 13 10

1043	VEGF modulation of retinal pigment epithelium resistance. 2007 , 85, 762-71	101
1042	Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease. 2007 , 206, 308-17	39
1041	Microinjecting recombinant rainbow trout Ea4-peptide of pro-IGF-I into zebrafish embryos causes abnormal development in heart, red blood cells, and vasculature. 2007 , 145, 39-44	0
1040	Free radicals and antioxidants in normal physiological functions and human disease. 2007, 39, 44-84	8827
1039	Oncostatin M stimulates expression of stromal-derived factor-1 in human mesenchymal stem cells. 2007 , 39, 650-9	19
1038	Vascular endothelial growth factor: biology and therapeutic applications. 2007 , 39, 1349-57	129
1037	Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. 2007, 89, 1234-44	38
1036	Flt-1 tyrosine kinase-deficient homozygous mice result in decreased trabecular bone volume with reduced osteogenic potential. <i>Bone</i> , 2007 , 40, 1494-501	25
1035	Erythropoietin (EPO): EPO-receptor signaling improves early endochondral ossification and mechanical strength in fracture healing. 2007 , 80, 893-900	73
1034	Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. 2007 , 80, 1409-14	49
1033	Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptor. 2007 , 81, 570-6	9
1032	Expression of vascular endothelial growth factor and its receptors after mandibular distraction osteogenesis. 2007 , 36, 338-44	33
1031	Antiangiogenic activity of Diallyl Sulfide (DAS). 2007 , 7, 295-305	35
1030	Expression of vascular endothelial growth factor receptors Flt-1 and Flk-1 in embryonic rat forebrain. 2007 , 425, 131-5	9
1029	VEGF 936 C/T gene polymorphism in renal transplant recipients: association of the T allele with good graft outcome. 2007 , 68, 599-602	17
1028	ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma. 2007 , 38, 86-94	20
1027	Vasa vasorum neovascularization and lesion distribution among different vascular beds in ApoE-/-/LDL-/- double knockout mice. 2007 , 191, 73-81	60
1026	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. 2007 , 7, 551-66	11

1025 Growth factor mediated assembly of cell receptor-responsive hydrogels. 2007 , 129, 3040-1	190
In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter. 2007 , 4, 88	19
Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. 2007 , 333-382	
1022 Angiogenesis. 2007 , 1-6	
Thiram-induced changes in the expression of genes relating to vascularization and tibial dyschondroplasia. 2007 , 86, 2390-5	44
1020 Tissue Engineering. 2007,	6
Controlled release of vascular endothelial growth factor from alginate hydrogels nano-coated with polyelectrolyte multilayer films. 2007 , 18, 775-83	44
1018 The therapeutic potential of VEGF inhibition in diabetic microvascular complications. 2007 , 7, 393-8	23
Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. 2007 , 36, 83-90	18
1016 VEGF: an essential mediator of both angiogenesis and endochondral ossification. 2007 , 86, 937-50	281
VEGF: an essential mediator of both angiogenesis and endochondral ossification. 2007 , 86, 937-50 The Impact of Surgery on Angiogenesis. 2007 , 18, 242-246	281
	281 45
The Impact of Surgery on Angiogenesis. 2007 , 18, 242-246	
The Impact of Surgery on Angiogenesis. 2007, 18, 242-246 1014 Molecular mechanisms of pulmonary vascular development. 2007, 10, 1-17 Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal	45
The Impact of Surgery on Angiogenesis. 2007, 18, 242-246 1014 Molecular mechanisms of pulmonary vascular development. 2007, 10, 1-17 1013 Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats. 2007, 55, 821-30 Vascular endothelial growth factor: an angiogenic factor reflecting airway inflammation in healthy	45 29
The Impact of Surgery on Angiogenesis. 2007, 18, 242-246 1014 Molecular mechanisms of pulmonary vascular development. 2007, 10, 1-17 1013 Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats. 2007, 55, 821-30 1012 Vascular endothelial growth factor: an angiogenic factor reflecting airway inflammation in healthy smokers and in patients with bronchitis type of chronic obstructive pulmonary disease?. 2007, 8, 53 Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery	45 29 31
The Impact of Surgery on Angiogenesis. 2007, 18, 242-246 1014 Molecular mechanisms of pulmonary vascular development. 2007, 10, 1-17 1013 Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats. 2007, 55, 821-30 1012 Vascular endothelial growth factor: an angiogenic factor reflecting airway inflammation in healthy smokers and in patients with bronchitis type of chronic obstructive pulmonary disease?. 2007, 8, 53 1011 Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery. 2007, 2, 38	45 29 31 14

1007	Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. 2007 , 82, 409-13	16
1006	Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis. 2007 , 120, 2096-109	43
1005	Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. 2008 , 122, 1981-6	47
1004	Calcium phosphate bone cements, functionalized with VEGF: release kinetics and biological activity. 2007 , 81, 474-83	71
1003	Endothelial cell response to lactate: implication of PAR modification of VEGF. 2007, 211, 477-85	90
1002	Regulation of plasminogen activators in human thyroid follicular cells and their relationship to differentiated function. 2007 , 212, 643-54	7
1001	Carbohydrate-Based VEGF Inhibitors. 2007, 2007, 6016-6033	8
1000	Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. 2007 , 110, 2519-27	45
999	Biomarker discovery in lung cancerpromises and challenges of clinical proteomics. 2007 , 26, 451-66	47
998	Macrophage depletion alters the blood-nerve barrier without affecting Schwann cell function after neural injury. 2007 , 85, 766-77	37
997	Role of fibroblasts and fibroblast-derived growth factors in periprosthetic angiogenesis. 2007 , 25, 1378-88	23
996	ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. 2007 , 17, 1369-75	12
995	Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. 2007 , 17, 6003-8	17
994	Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein. 2007 , 26, 775-82	20
993	Polymeric protein delivery systems. 2007 , 32, 669-697	328
992	Upregulation of Flk-1 by bFGF via the ERK pathway is essential for VEGF-mediated promotion of neural stem cell proliferation. 2007 , 17, 73-9	76
991	Glycine as a potent anti-angiogenic nutrient for tumor growth. 2007 , 22 Suppl 1, S62-4	12
990	Laser capture microdissection and microarray analysis of dividing neural progenitor cells from the adult rat hippocampus. 2007 , 26, 1079-90	14

989	Tumour-associated angiogenesis in human colorectal cancer. 2007 , 9, 3-14	63
988	Acute renal allograft rejection is associated with increased levels of vascular endothelial growth factor in the urine. 2008 , 13, 73-9	7
987	Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. 2007 , 14, 133-9	45
986	Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. 2007 , 34, 419-29	4
985	Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs. 2007 , 28, 493-502	17
984	Up-regulation of VEGF expression by NGF that enhances reparative angiogenesis during thymic regeneration in adult rat. 2007 , 1773, 1462-72	32
983	VEGFR1 (Flt-1+/-) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. 2007 , 42, 1487-95	32
982	Plasma levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in familial Mediterranean fever. 2007 , 74, 52-5	10
981	Tgf-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro. 2007 , 38, 45-51	41
980	Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer. 2007 , 104, 168-75	52
979	The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. 2007 , 104, 557-63	50
978	Analysis of vascular endothelial growth factor gene 936 C/T polymorphism in patients with familial Mediterranean fever. 2008 , 35, 33-6	6
977	Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A. 2007 , 95, 291-296	
976	Inhibition and reversibility of renal changes: lessons from diabetic kidney disease. 2007 , 95, 83-92	
975	Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. 2007 , 11, 1012-30	133
974	Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation. 2007 , 28, 1049-58	34
973	Exploring the cause of the most ancient clinical sign of medicine: finger clubbing. 2007, 36, 380-5	52
972	Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. 2007 , 100, 263-72	478

971	Vascular endothelial growth factor and bevacitumab in breast cancer. 2007 , 14, 163-73	33
970	Characterization and differential expression of vascular endothelial growth factor isoforms and receptors in swine corpus luteum throughout estrous cycle. 2007 , 74, 163-71	29
969	Mechanisms of disease: angiogenesis and the management of breast cancer. 2007 , 4, 536-50	93
968	Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. 2008 , 61, 179-88	39
967	Targeted polymeric gene delivery for anti-angiogenic tumor therapy. 2007, 15, 100-108	4
966	Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice. 2007 , 32, 2132-41	52
965	Significance of ovarian macrophages in the follicular aspirates from ART patients. 2007, 24, 137-42	O
964	The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. 2007 , 106, 333-42	78
963	Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. 2007, 10, 12-7	51
962	Pancreatic cancer Dutlook: targeted therapy. 2007 , 6, 176-180	
962 961	Pancreatic cancer [Dutlook: targeted therapy. 2007, 6, 176-180 Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. 2007, 10, 243-58	34
	Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer	34
961	Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. 2007 , 10, 243-58 Expression of VEGF-A, Flt-1, and Flk-1 in the arterial endothelial cells of the uterine broad ligament	
961 960	Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. 2007, 10, 243-58 Expression of VEGF-A, Flt-1, and Flk-1 in the arterial endothelial cells of the uterine broad ligament throughout the estrous cycle. 2007, 330, 313-9 Pleural mesothelial cells mediate inflammatory and profibrotic responses in talc-induced	2
961 960 959	Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. 2007, 10, 243-58 Expression of VEGF-A, Flt-1, and Flk-1 in the arterial endothelial cells of the uterine broad ligament throughout the estrous cycle. 2007, 330, 313-9 Pleural mesothelial cells mediate inflammatory and profibrotic responses in talc-induced pleurodesis. 2007, 185, 343-8 Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine	2 22
961 960 959 958	Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. 2007, 10, 243-58 Expression of VEGF-A, Flt-1, and Flk-1 in the arterial endothelial cells of the uterine broad ligament throughout the estrous cycle. 2007, 330, 313-9 Pleural mesothelial cells mediate inflammatory and profibrotic responses in talc-induced pleurodesis. 2007, 185, 343-8 Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. 2007, 8, 15-27 Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers	2 22 98
961960959958957	Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. 2007, 10, 243-58 Expression of VEGF-A, Flt-1, and Flk-1 in the arterial endothelial cells of the uterine broad ligament throughout the estrous cycle. 2007, 330, 313-9 Pleural mesothelial cells mediate inflammatory and profibrotic responses in talc-induced pleurodesis. 2007, 185, 343-8 Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. 2007, 8, 15-27 Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylationeffect of dexamethasone. 2007, 49, 98-110 Serum level of vascular endothelial growth factor in patients with obstructive sleep apnea	2 22 98 19

(2008-2008)

953	Vascular endothelial growth factor immobilized in collagen scaffold promotes penetration and proliferation of endothelial cells. 2008 , 4, 477-89	230
952	Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells. 2008 , 26, 215-22	4
951	Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. 2008 , 13, 227-44	9
950	Association of vascular endothelial growth factor C-634 g polymorphism in taiwanese children with Kawasaki disease. 2008 , 29, 292-6	19
949	Identification of two distinct populations of endothelial progenitor cells differing in size and antigen expression from human umbilical cord blood. 2008 , 87, 87-95	5
948	Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. 2008 , 30, 329-37	51
947	Gender dimorphism of tumor growth: role of gonadal hormones in differential regulation of apoptosis of a murine T cell lymphoma. <i>Journal of Biomedical Science</i> , 2008 , 15, 147-62	15
946	Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. 2008 , 25, 394-9	31
945	Vascular endothelial growth factor and carotid intima-media thickness in patients with Behët's disease. 2008 , 27, 961-6	30
944	Expression of oxygen-regulated protein 150 (ORP150) in skin wound healing and its application for wound age determination. 2008 , 122, 409-14	29
943	Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection. 2008 , 22, 287-97	43
942	The role of tendon microcirculation in Achilles and patellar tendinopathy. 2008, 3, 18	54
941	Poster Presentations. 2008 , 14, 47-194	1
940	Insulin-like growth factors, angiopoietin-2, and pigment epithelium-derived growth factor in the hypoxic retina. 2008 , 86, 702-11	13
939	Modulation of expression of LDH isoenzymes in endothelial cells by laminin: implications for angiogenesis. 2008 , 103, 1808-25	9
938	TGF-beta1 induces rearrangement of FLK-1-VE-cadherin-beta-catenin complex at the adherens junction through VEGF-mediated signaling. 2008 , 105, 1367-73	18
937	Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells. 2008 , 216, 458-68	56
936	Angiogenesis and hypoxic factors in colorectal cancer. 2008 , 204, 501-10	16

935	TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs. 2008 , 18, 2368-72	7
934	Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors. 2008 , 18, 4344-7	8
933	UVB induces a biphasic response of HIF-1alpha in cultured human keratinocytes. 2008 , 17, 335-42	16
932	Cellular responses of rat periodontal ligament cells under hypoxia and re-oxygenation conditions in vitro. 2008 , 43, 322-7	17
931	Chronic tendinopathy tissue pathology, pain mechanisms, and etiology with a special focus on inflammation. 2008 , 18, 3-15	177
930	Rapamycin affects early fracture healing in mice. 2008, 154, 1055-62	48
929	The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis. 2008 , 27, 2989-98	50
928	Mechanisms of angiogenesis. 2008, 73, 751-62	205
927	KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells. 2008 , 22, 826-34	21
926	Melatonin attenuates hypoxia-induced ultrastructural changes and increased vascular permeability in the developing hippocampus. 2008 , 18, 533-47	29
925	Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference. 2008 , 9, 228-37	12
924	Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. 2008 , 18, 499-505	38
923	Genetic polymorphism of VEGF-1154 (A/G) in laryngeal squamous cell carcinoma. 2008 , 39, 209-11	13
922	Vascular endothelial growth factor induces heat shock protein (HSP) 27 serine 82 phosphorylation and endothelial tubulogenesis via protein kinase D and independent of p38 kinase. 2008 , 20, 1375-84	69
921	Targeting angiogenesis in head and neck cancer. 2008 , 35, 274-85	66
920	Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. 2008 , 12, 649-60	53
919	Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. 2008 , 12, 2651-64	66
918	Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3',5'-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells.	21

(2008-2008)

917	The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis?. 2008 , 16, 279-86	120
916	Reactive oxygen species and respiratory plasticity following intermittent hypoxia. 2008, 164, 263-71	64
915	Understanding the mechanisms of viral induced asthma: new therapeutic directions. 2008, 117, 313-53	99
914	Transplantation of human umbilical mesenchymal stem cells from Wharton's jelly after complete transection of the rat spinal cord. 2008 , 3, e3336	174
913	COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats. 2008 , 79, 1062-9	24
912	A hybrid model for three-dimensional simulations of sprouting angiogenesis. 2008 , 95, 3146-60	111
911	Alterations in plasma soluble vascular endothelial growth factor receptor-1 (sFlt-1) concentrations during coronary artery bypass graft surgery: relationships with post-operative complications. 2008 , 3, 16	3
910	Tendinopathy and tendon injury: the future. 2008 , 30, 1733-45	64
909	Angiogenesis and plastic surgery. 2008 , 61, 1425-37	23
908	Human rhinovirus infection enhances airway epithelial cell production of growth factors involved in airway remodeling. 2008 , 121, 1238-1245.e4	98
907	Exercise, vascular wall and cardiovascular diseases: an update (Part 1). 2008, 38, 1009-24	109
906	Differing transcriptional responses to pulsed or continuous estradiol exposure in human umbilical vein endothelial cells. 2008 , 111, 41-9	5
905	Traditional Chinese drug ShuXueTong facilitates angiogenesis during wound healing following traumatic brain injury. 2008 , 117, 473-7	24
904	Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)?. 2008 , 70, 1174-8	14
903	Chronic hydrocephalus-induced hypoxia: increased expression of VEGFR-2+ and blood vessel density in hippocampus. 2008 , 152, 346-59	35
902	A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. 2008 , 21, 178-87	34
901	Vascular endothelial growth factor in chronic rat allograft nephropathy. 2008, 19, 136-44	18
900	Vascular endothelial growth factor expression in cultured periosteal-derived cells. 2008 , 105, 554-60	16

899	Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2. 2008 , 29, 2013-23	49
898	Growth factors and cell therapy in myocardial regeneration. 2008 , 44, 219-27	34
897	Angiogenic response of endothelial cells to heparin-binding domain of fibronectin. 2008, 40, 215-26	19
896	Prevalence, aetiologies and significance of clubbing in a department of general internal medicine. 2008 , 19, 325-9	23
895	2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. 2008 , 172, 534-44	123
894	Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. 2008 , 172, 167-78	47
893	SRG3, a core component of mouse SWI/SNF complex, is essential for extra-embryonic vascular development. 2008 , 315, 136-46	32
892	Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer. 2008 , 17, 357-76, ix	1
891	Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. 2008 , 26, 250-5	15
0	Doptide and protein mediated accombly of hoppinized hydrogole 2009, 4-20-27	
890	Peptide- and protein-mediated assembly of heparinized hydrogels. 2008 , 4, 29-37	63
889	Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. 2008 , 87, 14-32	332
889	Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. 2008 , 87, 14-32 Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast	332
889	Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. 2008 , 87, 14-32 Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis. 2008 , 283, 13905-12 Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in	332
889 888 887	Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. 2008, 87, 14-32 Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis. 2008, 283, 13905-12 Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. 2008, 19, 2278-88 Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and	332 126 40
889 888 887 886	Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. 2008, 87, 14-32 Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis. 2008, 283, 13905-12 Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. 2008, 19, 2278-88 Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. 2008, 121, 3487-95 Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation	332 126 40 247
889 888 887 886 885	Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. 2008, 87, 14-32 Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis. 2008, 283, 13905-12 Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. 2008, 19, 2278-88 Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. 2008, 121, 3487-95 Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. 2008, 14, 321-33	332 126 40 247 150

(2008-2008)

881	Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development. 2008 , 122, 340-6	16
880	A comparative study of gene vaccines encoding different extracellular domains of the vascular endothelial growth factor receptor 2 in the mouse model of colon adenocarcinoma CT-26. 2008 , 7, 502-9	9
879	Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. 2008 , 7, 758-66	83
878	Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. 2008 , 33, 278-91	87
877	Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy. 2008 , 31, 535-40	13
876	Correlation of metabolic syndrome with residual renal function, solute transport rate and peritoneal solute clearance in chronic peritoneal dialysis patients. 2008 , 26, 138-44	18
875	Anti-angiogenic gene therapy for hepatocellular carcinoma mediated by microbubble-enhanced ultrasound exposure: an in vivo experimental study. 2008 , 16, 389-95	41
874	VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. 2008 , 92, 689-93	46
873	The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. 2008 , 14, 2656-63	12
872	Signal Transduction in the Cardiovascular System in Health and Disease. 2008,	
871	Acute ethanol exposure disrupts VEGF receptor cell signaling in endothelial cells. 2008, 295, H174-84	43
870	Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2. 2009 , 19, 229-39	71
869	VEGF promotes vascular sympathetic innervation. 2008 , 294, H2646-52	50
868	Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. 2008 , 16, 1033-40	47
867	Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. 2008 , 294, F928-36	127
866	Time course for expression of VEGF and its receptor and regulator levels of contraction and relaxation in increased vascular permeability of lung induced by phosgene. 2008 , 20, 805-12	9
865	Effects of visual experience on vascular endothelial growth factor expression during the postnatal development of the rat visual cortex. 2008 , 18, 1630-9	40
864	Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. 2008 , 82, 1759-76	59

863	Infectious spleen and kidney necrosis virus ORF48R functions as a new viral vascular endothelial growth factor. 2008 , 82, 4371-83	26
862	X-linked inhibitor of apoptosis protein is an important regulator of vascular endothelial growth factor-dependent bovine aortic endothelial cell survival. 2008 , 102, 896-904	30
861	(+)-Catechin inhibits tumour angiogenesis and regulates the production of nitric oxide and TNF-alpha in LPS-stimulated macrophages. 2008 , 14, 160-74	46
860	Enhanced adult neurogenesis and angiogenesis and altered affective behaviors in mice overexpressing vascular endothelial growth factor 120. 2008 , 28, 14522-36	63
859	Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases. 2008 , 68, 6922-31	99
858	Medikamentße Therapie des kleinzelligen Bronchialkarzinoms (SCLC) - neue molekulare Therapieanstze. 2008 , 29, 81-90	
857	[Drug therapy for small-cell lung cancer (SCLC)new molecular strategies for therapy]. 2008, 62, 23-30	1
856	Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165. 2008 , 26, 125-31	32
855	Plasma levels of vascular endothelial growth factor after treatment for cerebral arteriovenous malformations. 2008 , 39, 2274-9	24
854	Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. 2008 , 108, 979-88	28
853	Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. 2008 , 100, 109-20	137
852	Experimental Study of Human Bone Marrow Mesenchymal Stem Cells Transfected with Vascular Endothelial Growth Factor Gene in Vitro. 2008 ,	
851	Angiogenesis in Osteoarthritis. 2008 , 4, 206-209	2
850	Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. 2008 , 5, 236-45	91
849	Expression and Function of Angiomodulating Cytokines in Rheumatoid Arthritis and Experimental Arthritis: Important Therapeutic Targets. 2008 , 4, 159-167	
848	Carbon monoxide ameliorates renal cold ischemia-reperfusion injury with an upregulation of vascular endothelial growth factor by activation of hypoxia-inducible factor. 2008 , 85, 1833-40	64
847	Vascular endothelial growth factor in central nervous system injuries - a vascular growth factor getting nervous?. 2008 , 5, 246-59	13
846	Angiopoietin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury. 2008 , 36, 262-7	38

845	Ovarian Hyperstimulation Syndrome. 243-257	4
844	Transplantation of adult neural progenitor cells transfected with vascular endothelial growth factor rescues grafted cells in the rat brain. 2007 , 4, 1-7	18
843	Association of Vascular Endothelial Growth Factor Polymorphisms with Asthma in Tunisian Children. 2008 , 2, 117762500800200	1
842	Hypoxia-ischemia and retinal ganglion cell damage. 2008 , 2, 879-89	190
841	Precancerous stem cells can serve as tumor vasculogenic progenitors. 2008 , 3, e1652	81
840	The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins. 2008 , 3, e2543	58
839	Parathyroid hormone-related protein interacts with vascular endothelial growth factor to promote fibrogenesis in the obstructed mouse kidney. 2008 , 295, F415-25	17
838	Evaluation of adenoviral vascular endothelial growth factor-activated chitosan/hydroxyapatite scaffold for engineering vascularized bone tissue using human osteoblasts: In vitro and in vivo studies. 2014 , 29, 748-60	31
837	Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway. 2014 , 29, 263-75	7
836	Soybean Bowman-Birk protease inhibitor (BBI): identification of the mechanisms of BBI suppressive effect on growth of two adenocarcinoma cell lines: AGS and HT29. 2014 , 45, 455-61	20
835	Notch functions in developmental and tumour angiogenesis by diverse mechanisms. 2014 , 42, 1563-8	26
834	HIF-1Hnhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. 2014 , 328, 444-55	20
833	Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure. 2014 , 86, 7305-10	15
832	Hypoxia-inducible factor-1: a possible link between inhalational anesthetics and tumor progression?. 2014 , 52, 70-6	15
831	Effects of selective endothelin (ET)-A receptor antagonist versus dual ET-A/B receptor antagonist on hearts of streptozotocin-treated diabetic rats. 2014 , 111, 6-11	10
830	Leukocyte driven-decidual angiogenesis in early pregnancy. 2014 , 11, 522-37	74
829	Is the mesenchymal stem cell a new hope for the management of COPD?. 2014 , 3, 112-120	1
828	Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. 2014 , 7, 369	8

827	Expression of tumor necrosis factor-alpha and vascular endothelial growth factor in different zones of fetal membranes: a possible relation to onset of labor. 2014 , 45, 243-57	3	
826	Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)-a retrospective case-control study. 2014 , 7, 54	15	
825	Expression and characterization of a soluble VEGF receptor 2 protein. 2014 , 4, 14	6	
824	Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies. 2014 , 14, 621-39	15	
823	Angiogenesis and Anti-Angiogenesis in Hematological Malignancies. 2014,		
822	Seminal plasma induces global transcriptomic changes associated with cell migration, proliferation and viability in endometrial epithelial cells and stromal fibroblasts. 2014 , 29, 1255-70	53	
821	Microfluidics-based single-cell functional proteomics for fundamental and applied biomedical applications. 2014 , 7, 275-95	60	
820	Anti-VEGF therapy for diabetic macular edema. 2014 , 14, 510	49	
819	Transcription of the vascular endothelial growth factor receptor-3 (VEGFR3) gene is regulated by the zinc finger proteins Sp1 and Sp3 and is under epigenetic control: transcription of vascular endothelial growth factor receptor 3. 2014 , 37, 131-45	17	
818	Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate. <i>Journal of Biomedical Science</i> , 2014 , 21, 35	13.3 15	
817	Heparin binding VEGF isoforms attenuate hyperoxic embryonic lung growth retardation via a FLK1-neuropilin-1-PKC dependent pathway. 2014 , 15, 32	6	
816	Ardisia crispa roots inhibit cyclooxygenase and suppress angiogenesis. 2014 , 14, 102	7	
815	Plasmalogens in the retina: from occurrence in retinal cell membranes to potential involvement in pathophysiology of retinal diseases. 2014 , 107 Pt A, 58-65	15	
814	Heparan sulfate proteoglycans and heparin regulate melanoma cell functions. 2014 , 1840, 2471-81	29	
813	Detection of vascular endothelial growth factor based on rolling circle amplification as a means of signal enhancement in surface plasmon resonance. 2014 , 61, 83-7	74	
812	Molecular mechanisms of increased cerebral vulnerability after repeated mild blast-induced traumatic brain injury. 2014 , 3, 22-37	15	
811	miR-126, a new modulator of innate immunity. 2014 , 11, 215-7	22	

(2015-2014)

809	A rapid and simple method to assess the changes of human VEGF mRNA based on dual molecular beacons. 2014 , 6, 4585-4592	1
808	In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs. 2014 , 21, 283-92	34
807	Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy. 2014 , 35, 6776-86	47
806	Erythropoietin promotes retinal angiogenesis in a mouse model. 2014 , 10, 2979-84	6
805	Diabetes and Health Care. 2014 , 1-129	1
804	Gelatin-chondroitin-6-sulfate-hyaluronic acid scaffold seeded with vascular endothelial growth factor 165 modified hair follicle stem cells as a three-dimensional skin substitute. 2014 , 5, 118	35
803	Simultaneous assessment of hepatocyte growth factor and vascular endothelial growth factor in epithelial lining fluid from patients with COPD. 2014 , 146, 1159-1165	17
802	Arnebin-1 promotes angiogenesis by inducing eNOS, VEGF and HIF-1\(\text{Lexpression}\) through the PI3K-dependent pathway. 2015 , 36, 685-97	28
801	Effect of microRNA-155 on angiogenesis after cerebral infarction of rats through AT1R/VEGFR2 pathway. 2015 , 8, 829-35	18
800	Characterization of two types of vascular endothelial growth factor from Litopenaeus vannamei and their involvements during WSSV infection. 2015 , 47, 824-32	11
799	Renal Cell Carcinoma and Targeted Therapy. 2015 , 287-295	1
798	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. 2015 , 125, 3153-63	86
797	Divergent selection for residual feed intake affects the transcriptomic and proteomic profiles of pig skeletal muscle. 2015 , 93, 2745-58	58
796	The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression. 2015 , 15, 619-33	2
795	Apoptosis and reduced microvascular density of the lamina propria during tooth eruption in rats. 2015 , 227, 487-96	8
794	Aberrant astrocytes impair vascular reactivity in Huntington disease. 2015 , 78, 178-92	54
793	Investigating the effect of hypoxic culture on the endothelial differentiation of human amniotic fluid-derived stem cells. 2015 , 227, 767-80	6
792	Procyanidin B2 3,3?-di-O-gallate inhibits endothelial cells growth and motility by targeting VEGFR2 and integrin signaling pathways. 2015 , 15, 14-26	14

791	Tumour Angiogenesis and Angiogenic Inhibitors: A Review. 2015 , 9, XE01-XE05	88
790	Functionalized Biomaterials - Oxygen Releasing Scaffolds. 2015 , 05,	1
789	Angiotensin 1-7 promotes cardiac angiogenesis following infarction. 2015 , 13, 37-42	18
788	Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. 2015 , 2015, 646853	34
787	Strategies to Stimulate Mobilization and Homing of Endogenous Stem and Progenitor Cells for Bone Tissue Repair. 2015 , 3, 79	62
786	Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. 2015 , 16, 26880-913	110
785	Conjugation of Polymer-Coated Gold Nanoparticles with Antibodies-Synthesis and Characterization. 2015 , 5, 1297-1316	24
784	Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. 2015 , 9, 2355-71	30
783	The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis. 2015 , 10, e0124909	28
782	(2-Hydroxypropyl)-ECyclodextrin Is a New Angiogenic Molecule for Therapeutic Angiogenesis. 2015 , 10, e0125323	6
781	Intramembranous bone healing process subsequent to tooth extraction in mice: micro-computed tomography, histomorphometric and molecular characterization. 2015 , 10, e0128021	73
78o	Atherogenic Cytokines Regulate VEGF-A-Induced Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Endothelial Cells. 2015 , 2015, 498328	16
779	The effect of tou nong san on transplanted tumor growth in nude mice. 2015 , 2015, 518454	7
778	Circulating soluble neuropilin-1 in patients with early cervical cancer and cervical intraepithelial neoplasia can be used as a valuable diagnostic biomarker. 2015 , 2015, 506428	8
777	. 2015,	2
776	Effect of taurine on prostate-specific antigen level and migration in human prostate cancer cells. 2015 , 803, 203-14	9
775	Effects of bisphenol A and 17 estradiol on vascular endothelial growth factor A and its receptor expression in the non-cancer and cancer ovarian cell lines. 2015 , 31, 187-97	12
774	Association between ultrasound findings and serum levels of vascular endothelial growth factor in ampullary pregnancy. 2015 , 103, 734-7	3

(2015-2015)

773	C57BL/6 mice. 2015 , 128, 39-46	7
77²	Cancer of the corpus uteri. 2015 , 131 Suppl 2, S96-104	56
771	VEGF Signaling: Methods and Protocols. Preface. 2015 , 1332, v-vi	3
770	VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature. 2015 , 53, 199-208	55
769	Hypoxia-induced fibroblast growth factor 11 stimulates capillary-like endothelial tube formation. 2015 , 34, 2745-51	24
768	The anticancer effect of Huaier (Review). 2015 , 34, 12-21	53
767	Teleost soluble CSF-1R modulates cytokine profiles at an inflammatory site, and inhibits neutrophil chemotaxis, phagocytosis, and bacterial killing. 2015 , 49, 259-66	16
766	Contrasting biofunctionalization strategies for the enhanced endothelialization of biodegradable vascular grafts. 2015 , 16, 437-46	57
765	Assessment of serum biomarkers in rats after exposure to pesticides of different chemical classes. 2015 , 282, 161-74	25
764	Immunological effects and therapeutic role of C5a in cancer. 2015 , 11, 255-63	14
763	Recombinant Human Keratinocyte Growth Factor Induces Akt Mediated Cell Survival Progression in Emphysematous Mice. 2015 , 51, 328-37	6
763 762		6
	Emphysematous Mice. 2015 , 51, 328-37 One type of VEGFR is involved in WSSV infection to the Pacific whiteleg shrimp Litopenaeus	
762	Emphysematous Mice. 2015 , 51, 328-37 One type of VEGFR is involved in WSSV infection to the Pacific whiteleg shrimp Litopenaeus vannamei. 2015 , 50, 1-8	13
762 761	Emphysematous Mice. 2015, 51, 328-37 One type of VEGFR is involved in WSSV infection to the Pacific whiteleg shrimp Litopenaeus vannamei. 2015, 50, 1-8 Brown and beige fat: the metabolic function, induction, and therapeutic potential. 2015, 9, 162-72 Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth	13
762 761 760	One type of VEGFR is involved in WSSV infection to the Pacific whiteleg shrimp Litopenaeus vannamei. 2015, 50, 1-8 Brown and beige fat: the metabolic function, induction, and therapeutic potential. 2015, 9, 162-72 Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent. 2015, 33, 75-85 Characterization of endothelial colony-forming cells from peripheral blood samples of adult horses.	13 23 6
762 761 760 759	One type of VEGFR is involved in WSSV infection to the Pacific whiteleg shrimp Litopenaeus vannamei. 2015, 50, 1-8 Brown and beige fat: the metabolic function, induction, and therapeutic potential. 2015, 9, 162-72 Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent. 2015, 33, 75-85 Characterization of endothelial colony-forming cells from peripheral blood samples of adult horses. 2015, 76, 174-87 Comparison of the early host immune response to two widely diverse virulent strains of	132367

755	IL-4 regulates specific Arg-1(+) macrophage sFlt-1-mediated inhibition of angiogenesis. 2015 , 185, 2324-35	26
754	Chemiluminescence detection of a protein through the aptamer-controlled catalysis of a porphyrin probe. 2015 , 87, 8336-41	40
753	Aflibercept a new target therapy in cancer treatment: a review. 2015 , 96, 569-76	19
752	Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. 2015 , 20, 742-51	13
751	Syngeneic transplantation of newborn splenocytes in a murine model of neonatal ischemia-reperfusion brain injury. 2015 , 28, 842-7	3
750	The tetrapeptide Arg-Leu-Tyr-Glu inhibits VEGF-induced angiogenesis. 2015 , 463, 532-7	7
749	Lipoxins exert antiangiogenic and anti-inflammatory effects on Kaposi's sarcoma cells. 2015 , 166, 111-33	21
748	Inhibition of Caspase-1 Activation in Endothelial Cells Improves Angiogenesis: A NOVEL THERAPEUTIC POTENTIAL FOR ISCHEMIA. 2015 , 290, 17485-94	68
747	Postinfarction Cardiac Remodeling Proceeds Normally in Granulocyte Colony-Stimulating Factor Knockout Mice. 2015 , 185, 1899-911	3
746	Polyphenols in Health and Disease. 2015 , 73, 649-64	26
746 745	Polyphenols in Health and Disease. 2015, 73, 649-64 Corneal neovascularization and contemporary antiangiogenic therapeutics. 2015, 78, 323-30	26 27
745	Corneal neovascularization and contemporary antiangiogenic therapeutics. 2015 , 78, 323-30 Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral	27
745 744	Corneal neovascularization and contemporary antiangiogenic therapeutics. 2015 , 78, 323-30 Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats. 2015 , 351, 78-87 Effect and possible mechanism of monocyte-derived VEGF on monocyte-endothelial cellular	27 41
745 744 743	Corneal neovascularization and contemporary antiangiogenic therapeutics. 2015 , 78, 323-30 Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats. 2015 , 351, 78-87 Effect and possible mechanism of monocyte-derived VEGF on monocyte-endothelial cellular adhesion after electrical burns. 2015 , 41, 825-32 Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-B activity and	27 41 9
745 744 743 742	Corneal neovascularization and contemporary antiangiogenic therapeutics. 2015, 78, 323-30 Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats. 2015, 351, 78-87 Effect and possible mechanism of monocyte-derived VEGF on monocyte-endothelial cellular adhesion after electrical burns. 2015, 41, 825-32 Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-B activity and Nrf2-dependent induction of HO-1 expression. 2015, 39, 1189-98 The MAPK signaling pathway mediates the GPR91-dependent release of VEGF from RGC-5 cells.	27 41 9
745 744 743 742 741	Corneal neovascularization and contemporary antiangiogenic therapeutics. 2015, 78, 323-30 Anti-apoptotic, anti-oxidant, and anti-inflammatory effects of thalidomide on cerebral ischemia/reperfusion injury in rats. 2015, 351, 78-87 Effect and possible mechanism of monocyte-derived VEGF on monocyte-endothelial cellular adhesion after electrical burns. 2015, 41, 825-32 Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-B activity and Nrf2-dependent induction of HO-1 expression. 2015, 39, 1189-98 The MAPK signaling pathway mediates the GPR91-dependent release of VEGF from RGC-5 cells. 2015, 36, 130-8	27 41 9 21 29

(2015-2015)

737	properties. 2015 , 25, 2425-8	5
736	Soluble Flt-1 links microvascular disease with heart failure in CKD. 2015 , 110, 30	28
735	Recombinant Human Keratinocyte Growth Factor Induces Akt Mediated Cell Survival Progression in Emphysematous Mice. 2015 , 51, 328-337	3
734	Robust Differences in p16-Dependent Oropharyngeal Squamous Cell Carcinoma Distant Metastasis: Implications for Targeted Therapy. 2015 , 153, 209-17	10
733	Quantification of VEGFRs, NRP1, and PDGFRs on Endothelial Cells and Fibroblasts Reveals Serum, Intra-Family Ligand, and Cross-Family Ligand Regulation. 2015 , 8, 383-403	22
73 ²	Novel vascular endothelial growth factor blocker improves cellular viability and reduces hypobaric hypoxia-induced vascular leakage and oedema in rat brain. 2015 , 42, 475-84	4
731	Psychological stress impairs ischemia-induced neovascularization: Protective effect of fluoxetine. 2015 , 241, 569-78	10
730	In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation. 2015 , 898, 28-33	10
729	Stimulus-responsive ultrasound contrast agents for clinical imaging: motivations, demonstrations, and future directions. 2015 , 7, 111-23	9
728	Chemotactic Migration of Endothelial Cells Towards VEGF-A II2015 , 1332, 151-7	4
727	The pre-vascularisation of a collagen-chondroitin sulphate scaffold using human amniotic fluid-derived stem cells to enhance and stabilise endothelial cell-mediated vessel formation. 2015 , 26, 263-73	23
726	Direct renin inhibition with aliskiren improves ischemia-induced neovascularization: blood pressure-independent effect. 2015 , 242, 450-60	13
725	The VEGF Receptor Family. 2015, 821-841	
724	Challenges and opportunities for non-antibody scaffold drugs. 2015 , 20, 1271-83	147
723	Research in the Early Twenty-First Century: The Year-Round Research Program Comes of Age. 2015 , 995-1064	
722	Impact of cigarette smoke extract and hyperglycemic conditions on blood-brain barrier endothelial cells. 2015 , 12, 18	43
721	Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration. 2015 , 78, 635-41	17
720	Pristimerin inhibits angiogenesis in adjuvant-induced arthritic rats by suppressing VEGFR2 signaling pathways. 2015 , 29, 302-313	26

719	Molecular Mechanisms for Exercise Training-Induced Changes in Vascular Structure and Function: Skeletal Muscle, Cardiac Muscle, and the Brain. 2015 , 135, 227-57	32
718	Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. 2015 , 8, 111-8	13
717	Circulating levels of inflammatory cytokines in patients with psoriasis vulgaris of different Chinese medicine syndromes. 2015 , 21, 108-14	10
716	Inhibition of the VEGF signalling pathway and glomerular disorders. 2015 , 30, 1449-55	42
715	The role of hypoxia related angiogenesis in uterine smooth muscle tumors. 2015 , 90, 102-10	10
714	Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis. 2015 , 95, 211-7	8
713	Generation of scFv specific to human VEGFR-3 from the neutralizing mAb BDD073. 2015, 28, 19-22	
712	Inflammatory breast cancer: an overview. 2015 , 93, 116-26	80
711	Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. 2015,	4
710	Soluble VEGFR1 concentration in the serum of patients with colorectal cancer. 2015 , 45, 215-20	6
709	Prognostic value of VEGF mRNA expression in short-term follow-up of patients with acute coronary syndrome. 2015 , 24, 133-137	
708	Interactions of oxidative stress and neurovascular inflammation in the pathogenesis of traumatic brain injury. 2015 , 51, 966-79	248
707	Platelet rich plasma enhances the immunohistochemical expression of platelet derived growth factor and vascular endothelial growth factor in the synovium of the meniscectomized rat models of osteoarthritis. 2015 , 197, 38-49	15
706	Biomimetic 3D Tissue Models for Advanced High-Throughput Drug Screening. 2015 , 20, 201-15	100
705	Critical regulators of endothelial cell functions: for a change being alternative. 2015 , 22, 1212-29	4
704	Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia. 2015 , 71, 385-93	77
703	Effect of brain-derived neurotrophic factor on mesenchymal stem cell-seeded electrospinning biomaterial for treating ischemic diabetic ulcers via milieu-dependent differentiation mechanism. 2015 , 21, 928-38	13
702	Hypoxia and angiogenesis: from primary tumor to bone metastasis. 2015 , 177-189	1

(2016-2015)

701	Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF. 2015 , 97, 13-8	12
700	VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. 2015 , 34, 3107-19	163
699	Associations of total arsenic in drinking water, hair and nails with serum vascular endothelial growth factor in arsenic-endemic individuals in Bangladesh. 2015 , 120, 336-42	26
698	A comparative study of short chain and long chain mercapto acids used in biosensor fabrication: A VEGF-R1-based immunosensor as a model system. 2016 , 44, 462-70	10
697	Schlemm's Canal: The Outflow №essel□ 2016 ,	
696	EGR1, EGFR and IGF1R protein expressions in non-small cell lung cancer and their clinical significances. 2016 , 11, S123-S130	
695	Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy. 2016 , 17, 214	9
694	Selection, Analysis and Improvement of Anti-Angiogenesis Compounds Identified by an Anti-HIF-1∃ Screening and Validation System. 2016 , 7, 1926-1938	6
693	Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy. 2016 , 7, 84965-84980	11
692	Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. 2016 , 2016, 7590245	14
691	Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies. 2016 , 2016, 7954580	21
690	Synergistic Effects of Vascular Endothelial Growth Factor on Bone Morphogenetic Proteins Induced Bone Formation In Vivo: Influencing Factors and Future Research Directions. 2016 , 2016, 2869572	48
689	Ischemia-induced Angiogenesis is Attenuated in Aged Rats. 2016 , 7, 326-35	15
688	Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis. 2016 , 11, 4643-4656	5
687	Paeonol enhances thrombus recanalization by inducing vascular endothelial growth factor 165 via ERK1/2 MAPK signaling pathway. 2016 , 13, 4853-8	8
686	[Target Therapy in Unresectable or Metastatic Colorectal Cancer]. 2016 , 68, 303-311	5
685	Effect of ximenynic acid on cell cycle arrest and apoptosis and COX-1 in HepG2 cells. 2016 , 14, 5667-5676	4
684	Human adipose-derived mesenchymal stem cell could participate in angiogenesis in a mouse model of acute hindlimb ischemia. 2016 , 3,	5

683	Pre-eclampsia: its pathogenesis and pathophysiolgy. 2016 , 27, 71-8	170
682	Shear stress-induced angiogenesis in mouse muscle is independent of the vasodilator mechanism and quickly reversible. 2016 , 218, 153-166	13
681	Design of a Novel Composite H2 S-Releasing Hydrogel for Cardiac Tissue Repair. 2016 , 16, 847-58	38
680	The roles of vascular endothelial growth factor in bone repair and regeneration. <i>Bone</i> , 2016 , 91, 30-8 4.7	247
679	Electrochemically triggered aptamer immobilization via click reaction for vascular endothelial growth factor detection. 2016 , 16, 550-559	15
678	Transcription of Inflammatory Cytokine TNF II s Upregulated in Retinal Angiogenesis under Hyperoxia. 2016 , 39, 573-83	5
677	Elevated Preoperative Serum Gamma-glutamyltranspeptidase Predicts Poor Prognosis for Hepatocellular Carcinoma after Liver Transplantation. 2016 , 6, 28835	30
676	Nkx2-5 Is Expressed in Atherosclerotic Plaques and Attenuates Development of Atherosclerosis in Apolipoprotein E-Deficient Mice. 2016 , 5,	6
675	Pathogenesis of Microvascular Complications. 2016 , 541-553	
674	Transfection of chondromodulin I into human breast cancer cells and its effect on the inhibition of cancer cell growth. 2016 , 13, 4303-8	5
673	Oxalomalate reduces expression and secretion of vascular endothelial growth factor in the retinal pigment epithelium and inhibits angiogenesis: Implications for age-related macular degeneration. 2016 , 10, 211-220	10
672	Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015). 2016 , 7, 82	134
671	Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Malignant and Benign Biliary Obstructions. 2016 , 351, 259-64	9
670	Growth Factors and Cytokines in Skeletal Muscle Development, Growth, Regeneration and Disease. 2016 ,	1
669	Vascular Growth Factors and Glomerular Disease. 2016 , 78, 437-61	62
668	Endothelial differentiation of canine yolk sac cells transduced with VEGF. 2016 , 104, 71-6	9
667	Epigenetic Advancements in Cancer. 2016 ,	1
666	Endothelial Cell Response to Fusobacterium nucleatum. 2016 , 84, 2141-2148	20

(2016-2016)

665	Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. 2016 , 8, 892-904	28
664	Biocompatibility Assessment of a New Biodegradable Vascular Graft via In Vitro Co-culture Approaches and In Vivo Model. 2016 , 44, 3319-3334	16
663	A natural food sweetener with anti-pancreatic cancer properties. 2016 , 5, e217	16
662	Role of miR-21 in alkalinity stress tolerance in tilapia. 2016 , 471, 26-33	15
661	Pharmacogenomics of Drugs in Ocular Therapeutics. 2016 , 65-82	
660	Comment: Gene-environment interactions in dementia-: Not just another fish story. 2016 , 86, 2069	2
659	Tumor suppressor microRNAs: Targeted molecules and signaling pathways in breast cancer. 2016 , 81, 305-317	24
658	Ranibizumab interacts with the VEGF-A/VEGFR-2 signaling pathway in human RPE cells at different levels. 2016 , 83, 210-216	12
657	Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis. 2016 , 37, 14341-14354	15
656	Applications of Platelet-Rich Plasma in Lymphedema. 2016 , 14, 206-209	6
655	Sphingosine-1-phosphate restores endothelial barrier integrity in ovarian hyperstimulation syndrome. 2016 , 22, 852-866	11
654	VEGF Requires the Receptor NRP-1 To Inhibit Lipopolysaccharide-Dependent Dendritic Cell Maturation. 2016 , 197, 3927-3935	31
653	Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. 2016 , 15, 1013-1030	78
652	Pro- and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases. 2016 , 49, 366-372	5
651	Vascular toxicity of silver nanoparticles to developing zebrafish (Danio rerio). 2016, 10, 1363-72	23
650	A mutation within the SH2 domain of slp-76 regulates the tissue distribution and cytokine production of iNKT cells in mice. 2016 , 46, 2121-36	1
649	Fluorescence-based retention assays reveals sustained release of vascular endothelial growth factor from bone grafts. 2016 , 104, 283-90	7
648	Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. 2016 , 31, 911-24	112

647	Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer. 2016 , 12, 232-240	4
646	Promotion of adhesion and proliferation of endothelial progenitor cells on decellularized valves by covalent incorporation of RGD peptide and VEGF. 2016 , 27, 142	12
645	Developmental Therapeutics for Gynecologic Cancers: An Overview. 2016 , 99-125	
644	Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. 2016 , 21, 576-85	27
643	Human Genetic Variation, Sport and Exercise Medicine, and Achilles Tendinopathy: Role for Angiogenesis-Associated Genes. 2016 , 20, 520-7	25
642	Erythropoietin-activated mesenchymal stem cells promote healing ulcers by improving microenvironment. 2016 , 205, 464-473	24
641	Evidence for Pro-angiogenic Functions of VEGF-Ax. 2016 , 167, 275-284.e6	39
640	Identification and function analysis of a novel vascular endothelial growth factor, LvVEGF3, in the Pacific whiteleg shrimp Litopenaeus vannamei. 2016 , 63, 111-20	11
639	The effect of heparinized decellularized scaffolds on angiogenic capability. 2016 , 104, 3021-3030	22
638	Gynecological Cancers. 2016 ,	
638 637	Exogenous avian leukosis virus-induced activation of the ERK/AP1 pathway is required for virus replication and correlates with virus-induced tumorigenesis. 2016 , 6, 19226	14
	Exogenous avian leukosis virus-induced activation of the ERK/AP1 pathway is required for virus	14
637	Exogenous avian leukosis virus-induced activation of the ERK/AP1 pathway is required for virus replication and correlates with virus-induced tumorigenesis. 2016 , 6, 19226	
637	Exogenous avian leukosis virus-induced activation of the ERK/AP1 pathway is required for virus replication and correlates with virus-induced tumorigenesis. 2016 , 6, 19226 CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery. 2016 , 515, 431-440 Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous	29
637 636 635	Exogenous avian leukosis virus-induced activation of the ERK/AP1 pathway is required for virus replication and correlates with virus-induced tumorigenesis. 2016, 6, 19226 CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery. 2016, 515, 431-440 Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas. 2016, 11, 399-404 Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma	29 9
637 636 635	Exogenous avian leukosis virus-induced activation of the ERK/AP1 pathway is required for virus replication and correlates with virus-induced tumorigenesis. 2016, 6, 19226 CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery. 2016, 515, 431-440 Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas. 2016, 11, 399-404 Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis. 2016, 6, 31398 A 3D Poly(ethylene glycol)-based Tumor Angiogenesis Model to Study the Influence of Vascular	29 9 16
637636635634633	Exogenous avian leukosis virus-induced activation of the ERK/AP1 pathway is required for virus replication and correlates with virus-induced tumorigenesis. 2016, 6, 19226 CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery. 2016, 515, 431-440 Immunohistochemical expression of vascular endothelial growth factor in canine oral squamous cell carcinomas. 2016, 11, 399-404 Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis. 2016, 6, 31398 A 3D Poly(ethylene glycol)-based Tumor Angiogenesis Model to Study the Influence of Vascular Cells on Lung Tumor Cell Behavior. 2016, 6, 32726	29 9 16 50

(2016-2016)

629	Inhibition of angiopoietin-1 (ANGPT1) affects vascular integrity in ovarian hyperstimulation syndrome (OHSS). 2016 , 28, 690-9	10
628	Expression of factors involved in the regulation of angiogenesis in the full-term human placenta: Effects of in vitro fertilization. 2016 , 16, 104-12	5
627	Current targeted therapies in the treatment of advanced colorectal cancer: a review. 2016 , 8, 276-93	65
626	Epigenetics and Angiogenesis in Cancer. 2016 , 145-176	1
625	Genes and Musculoskeletal Soft-Tissue Injuries. 2016 , 61, 68-91	15
624	Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases. 2016 , 16, 915-26	14
623	Impact of 2.45 GHz microwave radiation on the testicular inflammatory pathway biomarkers in young rats: The role of gallic acid. 2016 , 31, 1771-1784	21
622	The relationship between synovial fluid VEGF and serum leptin with ultrasonographic findings in knee osteoarthritis. 2016 , 19, 233-40	12
621	A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study. 2016 , 36, 63-71	11
620	The cartilage extracellular matrix as a transient developmental scaffold for growth plate maturation. 2016 , 52-54, 363-383	48
619	Hsp90 inhibitor celastrol reinstates growth plate angiogenesis in thiram-induced tibial dyschondroplasia. 2016 , 45, 187-93	32
618	Co-expression of fibulin-5 and VEGF165 increases long-term patency of synthetic vascular grafts seeded with autologous endothelial cells. 2016 , 23, 237-46	7
617	Ten years of anti-vascular endothelial growth factor therapy. 2016 , 15, 385-403	507
616	MART-10, the new brand of $1\cancel{D}$ 5(OH)2D3 analog, is a potent anti-angiogenic agent in vivo and in vitro. 2016 , 155, 26-34	7
615	Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. 2016 , 380, 216-26	32
614	Function of Membrane-Associated Proteoglycans in the Regulation of Satellite Cell Growth. 2016 , 900, 61-95	2
613	Microtubule-associated protein 4 is an important regulator of cell invasion/migration and a potential therapeutic target in esophageal squamous cell carcinoma. 2016 , 35, 4846-56	26
612	Angiogenesis in melanoma: an update with a focus on current targeted therapies. 2016 , 69, 472-83	46

611	Differential immunohistochemical expression profiles of perlecan-binding growth factors in epithelial dysplasia, carcinoma in situ, and squamous cell carcinoma of the oral mucosa. 2016 , 212, 426-36	6
610	[Xenon: From rare gaz to doping product]. 2016 , 45, 422-30	2
609	Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. 2016 , 109, 371-9	33
608	Estimating binding free energy of a putative growth factors EGF-VEGF complex - a computational bioanalytical study. 2016 , 34, 1717-24	4
607	Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. 2016 , 104, 93-109	56
606	Paracrine CCL20 loop induces epithelial-mesenchymal transition in breast epithelial cells. 2016 , 55, 1175-86	27
605	Selenium Induces an Anti-tumor Effect Via Inhibiting Intratumoral Angiogenesis in a Mouse Model of Transplanted Canine Mammary Tumor Cells. 2016 , 171, 371-379	21
604	Interleukin-4 and granulocyte-macrophage colony-stimulating factor mediates the upregulation of soluble vascular endothelial growth factor receptor-1 in RAW264.7 cells-a process in which p38 mitogen-activated protein kinase signaling has an important role. 2016 , 49, 344-51	6
603	Hydrogels for therapeutic cardiovascular angiogenesis. 2016 , 96, 31-9	58
602	Gelatin-based hydrogel for vascular endothelial growth factor release in peripheral nerve tissue engineering. 2017 , 11, 459-470	64
601	Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). 2017 , 30, 171-180	23
600	Blocking elevated VEGF-A attenuates non-vasculature Fragile X syndrome abnormalities. 2017 , 77, 14-25	7
599	Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone?. 2017 , 15, 1-8	22
598	Preconditioning in neuroprotection: From hypoxia to ischemia. 2017 , 157, 79-91	106
597	Spatiotemporal expression of Vascular Endothelial Growth Factor-C in mice fetal-maternal tissues during periimplantation (D4D7). 2017 , 22, 115-124	1
596	Vascular Endothelial Growth Factor (VEGF) Promotes Assembly of the p130Cas Interactome to Drive Endothelial Chemotactic Signaling and Angiogenesis. 2017 , 16, 168-180	19
595	Protein-crystal interface mediates cell adhesion and proangiogenic secretion. 2017 , 116, 174-185	10
594	Percutaneous microwave ablation (MWA) increased the serum levels of VEGF and MMP-9 in Stage I non-small cell lung cancer (NSCLC). 2017 , 33, 435-439	6

593	Traumatized muscle-derived multipotent progenitor cells recruit endothelial cells through vascular endothelial growth factor-A action. 2017 , 11, 3038-3047	2
592	Retinal oxygen: from animals to humans. 2017 , 58, 115-151	109
591	Novel Therapies for Advanced Cervical Cancer. 2017 , 263-299	2
590	Cell-instructive starPEG-heparin-collagen composite matrices. 2017 , 53, 70-80	12
589	CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. 2017 , 108, 469-477	24
588	Expression of vascular endothelial growth factor (VEGF) and factor VIII in the gilt placenta and its relation to fetal development. 2017 , 92, 63-68	9
587	Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNAs promote matrix metalloproteinases (MMPs) expression and pro-angiogenic cytokine secretion in endothelial cells. 2017 , 89, 1274-1280	10
586	The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD). 2017 , 18, 20	52
585	Sulfated Hyaluronan Alters Endothelial Cell Activation in Vitro by Controlling the Biological Activity of the Angiogenic Factors Vascular Endothelial Growth Factor-A and Tissue Inhibitor of Metalloproteinase-3. 2017 , 9, 9539-9550	21
584	MicroRNA-150 Modulates Ischemia-Induced Neovascularization in Atherosclerotic Conditions. 2017 , 37, 900-908	39
583	Considerations for management of patients with diabetic macular edema: Optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration. 2017 , 126, 1-9	4
582	Tumor Angiogenesis. 2017 , 1-32	
581	Kidney development and perspectives for organ engineering. 2017 , 369, 171-183	10
580	Trimodal rescue of hind limb ischemia with growth factors, cells, and nanocarriers: fundamentals to clinical trials. 2017 , 95, 1125-1140	O
579	Peripheral artery disease, redox signaling, oxidative stress - Basic and clinical aspects. 2017 , 12, 787-797	61
578	Targeting Vascular Endothelial Growth Factor. 2017 , 99-139	
577	Selenium nanoparticles: potential in cancer gene and drug delivery. 2017 , 12, 1075-1089	118
576	The Effects of Voluntary Physical Exercise-Activated Neurotrophic Signaling in Rat Hippocampus on mRNA Levels of Downstream Signaling Molecules. 2017 , 62, 142-153	9

575	Splicing regulatory factors, ageing and age-related disease. 2017 , 36, 165-170	30
574	VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016). 2017 , 27, 987-1004	54
573	SEMA3A partially reverses VEGF effects through binding to neuropilin-1. 2017 , 22, 70-78	14
572	The antimicrobial peptide derived from insulin-like growth factor-binding protein 5, AMP-IBP5, regulates keratinocyte functions through Mas-related gene X receptors. 2017 , 88, 117-125	4
571	Physiological importance of polyamines. 2017 , 25, 244-255	55
570	Applications of vacuum sealing drainage in treating seawater-immersed sulfur mustard injury. 2017 , 99, 975-986	1
569	Photo-controlled aptamers delivery by dual surface gold-magnetic nanoparticles for targeted cancer therapy. 2017 , 80, 88-92	17
568	Vertical bone regeneration using rhBMP-2 and VEGF. 2017 , 13, 11	33
567	Gene Therapy for Amyotrophic Lateral Sclerosis. 2017 , 167-205	1
566	Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. 2017 , 214, 1029-1047	25
565	Diabetic Retinopathy. 2017,	0
564	In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome. 2017 , 23, 417-427	7
563	Reduced expression of let-7f activates TGF-ALK5 pathway and leads to impaired ischaemia-induced neovascularization after cigarette smoke exposure. 2017 , 21, 2211-2222	20
562	Oxidative injury of the pulmonary circulation in the perinatal period: Short- and long-term consequences for the human cardiopulmonary system. 2017 , 7, 55-66	17
561	The Role of Proteomics in the Study of Kidney Diseases and in the Development of Diagnostic Tools. 2017 , 119-223	2
560	Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization. 2017 , 24, 33-37	17
559	Stimuli-Responsive Polymer Materials for Creation of Biointerfaces. 2017 , 229-253	
558	Enhanced regeneration potential of mobilized dental pulp stem cells from immature teeth. 2017 , 23, 620-628	16

557	neonatal exposure to high oxygen levels leads to impaired ischemia-induced neovascularization in adulthood. 2017 , 7, 14143	4
556	Expression and association of VEGF-Notch pathways in infantile hemangiomas. 2017 , 14, 3737-3743	5
555	Imaging of Integrin Expression in Lung Cancers and Brain Tumors Using Single-Photon Emission Computed Tomography with a Novel Radiotracer Tc-IDA-D-[c(RGDfK)]. 2017 , 32, 288-296	6
554	Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke. 2016 , 6, 107-119	21
553	A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. 2017 , 80, 755-763	26
552	Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis. 2017 , 11, 349-358	25
551	Gastroblastoma harbors a recurrent somatic MALAT1-GLI1 fusion gene. 2017 , 30, 1443-1452	49
550	Chemical constituents from the rare mushroom Calvatia nipponica inhibit the promotion of angiogenesis in HUVECs. 2017 , 27, 4122-4127	12
549	Animal models of ocular angiogenesis: from development to pathologies. FASEB Journal, 2017, 31, 4665-4681	75
548	Regulator of Calcineurin 3 Ameliorates Autoimmune Arthritis by Suppressing Th17 Cell Differentiation. 2017 , 187, 2034-2045	9
547	Polymyalgia Rheumatica and Giant Cell Arteritis. 2017,	1
546	A mammalian mirtron miR-1224 promotes tube-formation of human primary endothelial cells by targeting anti-angiogenic factor epsin2. 2017 , 7, 5541	11
545	Neocortical developmental analysis of vasculature and their growth factors offer new insight into fragile X syndrome abnormalities. 2017 , 77, 1321-1333	2
544	RNA SEQ Analysis Indicates that the AE3 Cl/HCO Exchanger Contributes to Active Transport-Mediated CO Disposal in Heart. 2017 , 7, 7264	3
543	The role of vascular endothelial growth factor-B in metabolic homoeostasis: current evidence. 2017 , 37,	16
542	Angiogenic growth factors in myocardial infarction: a critical appraisal. 2017 , 22, 665-683	15
541	Hypothermie und ihr Einfluss auf das Tumorwachstum. 2017 , 31, 222-227	
540	MicroRNA-433 Inhibits the Proliferation and Migration of HUVECs and Neurons by Targeting Hypoxia-Inducible Factor 1 Alpha. 2017 , 61, 135-143	14

539	Stimuli-Responsive Interfaces. 2017,	2
538	Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds. 2017 , 241, 6-9	19
537	Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro. 2017 , 21, 1979-1988	20
536	Extracellular matrix proteomics in schizophrenia and Alzheimer's disease. 2017 , 409, 379-394	52
535	Do Demodex mites play a role in pterygium development?. 2017 , 98, 6-10	11
534	Vascularization and VEGF expression altered in bovine yolk sacs from IVF and NT technologies. 2017 , 87, 290-297	4
533	VEGF and the diabetic kidney: More than too much of a good thing. 2017 , 31, 273-279	39
532	A new 3D concentration gradient maker and its application in building hydrogels with a 3D stiffness gradient. 2017 , 11, 256-264	19
531	Corneal Angiogenesis: Etiologies, Complications, and Management. 2017,	1
530	Histopathological study with immunohistochemical expression of vascular endothelial growth factor in placentas of hyperglycemic and diabetic women. 2017 , 9, 227-233	5
529	The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis. 2017 , 10, 1725-1734	5
528	Developing a deeper insight into reproductive biomarkers. 2017 , 44, 159-170	5
527	Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer. 2017, 9,	46
526	Refined Deep-Sea Water Suppresses Inflammatory Responses via the MAPK/AP-1 and NF-B Signaling Pathway in LPS-Treated RAW 264.7 Macrophage Cells. 2017 , 18,	18
525	Morphological Plasticity of Emerging Purkinje Cells in Response to Exogenous VEGF. 2017, 10, 2	8
524	4.13 Peptide- and Protein-Modified Surfaces ?. 2017 , 200-220	1
523	Alopecia and platelet-derived therapies. 2017 , 4, 88	19
522	Overexpression of Kinesin Family Member 20A Correlates with Disease Progression and Poor Prognosis in Human Nasopharyngeal Cancer: A Retrospective Analysis of 105 Patients. 2017 , 12, e0169280	24

521	A hypoxia response element in the Vegfa promoter is required for basal Vegfa expression in skin and for optimal granulation tissue formation during wound healing in mice. 2017 , 12, e0180586	14
520	Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. 2017 , 17, 714	13
519	Therapeutic approaches for corneal neovascularization. 2017 , 4, 28	42
518	Trinucleotide Repeat Expansion in the Transcription Factor 4 (TCF4) Gene Leads to Widespread mRNA Splicing Changes in Fuchs' Endothelial Corneal Dystrophy. 2017 , 58, 343-352	48
517	Anti-VEGF Therapy in Cancer: A Double-Edged Sword. 2017 ,	4
516	Delivery of sodium morrhuate to hemangioma endothelial cells using immunoliposomes conjugated with anti-VEGFR2/KDR antibody. 2017 , 12, 6963-6972	4
515	Intraocular Delivery of miR-146 Inhibits Diabetes-Induced Retinal Functional Defects in Diabetic Rat Model. 2017 , 58, 1646-1655	29
5 ¹ 4	Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation. 2017 , 2, 95	7
513	Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer. 2017 , 8, 11990-12002	46
512	A study of vascular endothelial growth factor in the cord blood of pre-eclamptics and healthy pregnant women. 2017 , 8, 21-25	
511	Systemic therapy for advanced hepatocellular carcinoma: an update. 2017 , 8, 243-255	45
510	A Systematic Review of Placental Biomarkers Predicting Small-for-Gestational-Age Neonates. 2018 , 20, 272-283	6
509	Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways. 2018 , 15, 6029-6035	7
508	The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. 2018 , 102, 1127-1144	27
507	Perspectives: MRI of angiogenesis. 2018 , 292, 99-105	2
506	Sensing Native Protein Solution Structures Using a Solid-state Nanopore: Unraveling the States of VEGF. 2018 , 8, 1017	25
505	Wu-Tou Decoction Inhibits Angiogenesis in Experimental Arthritis by Targeting VEGFR2 Signaling Pathway. 2018 , 21, 442-455	10
504	Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1EVEGF pathway in oxygen-induced retinopathy mice. 2018 , 64, e12473	42

503	"All-in-one" in vitro selection of collagen-binding vascular endothelial growth factor. 2018 , 161, 270-27	78	7
502	Platelet indices as markers of inflammation in systemic sclerosis patients: Relation to vascular endothelial growth factor and flow mediated dilatation. 2018 , 40, 239-242		6
501	Evaluation of Vascular Endothelial Growth Factor (VEGF) and Its Family Member Expression After Peripheral Nerve Regeneration and Denervation. 2018 , 301, 1646-1656		26
500	Secretomes of mesenchymal stem cells induce early bone regeneration by accelerating migration of stem cells. 2018 , 30, 445-451		10
499	Elevated serum vascular endothelial growth factor and development of cardiac allograft vasculopathy in children. 2018 , 37, 1075-1082		4
498	Fucoidan/VEGF-based surface modification of decellularized pulmonary heart valve improves the antithrombotic and re-endothelialization potential of bioprostheses. 2018 , 172, 14-29		40
497	Association between the ratio of anti-angiogenic isoform of VEGF-A to total VEGF-A and adverse clinical outcomes in patients after acute myocardial infarction. 2018 , 19, 3-7		8
496	Correlation between circulating VEGF levels and disease activity in rheumatoid arthritis: a´meta-analysis. 2018 , 77, 240-248		16
495	Mathematical Modeling of Cellular Cross-Talk Between Endothelial and Tumor Cells Highlights Counterintuitive Effects of VEGF-Targeted Therapies. 2018 , 80, 971-1016		13
494	Effects of electrical stimulation on cell proliferation and apoptosis. 2018 , 233, 1860-1876		54
493	Fucoidan-induced osteogenic differentiation promotes angiogenesis by inducing vascular endothelial growth factor secretion and accelerates bone repair. 2018 , 12, e1311-e1324		25
492	Protective effect of Salvianolic acid A on ischaemia-reperfusion acute kidney injury in rats through protecting against peritubular capillary endothelium damages. 2018 , 32, 103-114		15
491	Expression of vascular endothelial growth factor and its correlation with clinical symptoms and endoscopic findings in patients with chronic radiation proctitis. 2018 , 20, 321-330		3
490	The skeletal vascular system - Breathing life into bone tissue. <i>Bone</i> , 2018 , 115, 50-58	4.7	46
489	CCR6 promotes tumor angiogenesis via the AKT/NF-B/VEGF pathway in colorectal cancer. 2018 , 1864, 387-397		31
488	Autologous Mesenchymal Stem Cell and Islet Cotransplantation: Safety and Efficacy. 2018 , 7, 11-19		32
487	Local blood flow in peripheral nerves and their ganglia: Resurrecting key ideas around its measurement and significance. 2018 , 57, 884-895		14
486	Biology and pathological implications of brown adipose tissue: promises and caveats for the control of obesity and its associated complications. 2018 , 93, 1145-1164		14

485	Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1. 2018 , 192, 54-67	9
484	Effects of dexmedetomidine post-treatment on BDNF and VEGF expression following cerebral ischemia/reperfusion injury in rats. 2018 , 17, 6033-6037	8
483	A fresh look at angiogenesis in juvenile idiopathic arthritis. 2018 , 43, 325-330	9
482	The Lymphatic System in Health and Disease. 2018 , 10, i-89	
481	Salivary VEGF - A Potential Breast Cancer Marker. 2018, 7, 11	
480	Interaction study of cancer cells and fibroblasts on a spatially confined oxygen gradient microfluidic chip to investigate the tumor microenvironment. 2018 , 143, 5431-5437	11
479	FOXC1, the new player in the cancer sandbox. 2018 , 9, 8165-8178	31
478	Hox Genes in Adult Tissues and Their Role in Endothelial Cell Differentiation and Angiogenesis. 2018 ,	3
477	The association between circulating endostatin levels and incident myocardial infarction. 2018 , 52, 315-319	3
476	Tumor necrosis factor- Ir egulates angiogenesis of BeWo cells via synergy of PlGF/VEGFR1 and VEGF-A/VEGFR2 axes. 2018 , 74, 20-27	10
476 475		10
	VEGF-A/VEGFR2 axes. 2018, 74, 20-27 The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the	
475	VEGF-A/VEGFR2 axes. 2018, 74, 20-27 The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster. 2018, 13, e0202838 Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma	10
475 474	VEGF-A/VEGFR2 axes. 2018, 74, 20-27 The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster. 2018, 13, e0202838 Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis. 2018, 13, e0207019 Gain of affinity for VEGF165 binding within the VEGFR2/NRP1 cellular complex detected by an	10
475 474 473	VEGF-A/VEGFR2 axes. 2018, 74, 20-27 The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster. 2018, 13, e0202838 Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis. 2018, 13, e0207019 Gain of affinity for VEGF165 binding within the VEGFR2/NRP1 cellular complex detected by an HTRF-based binding assay. 2018, 158, 45-59	10
475 474 473 472	VEGF-A/VEGFR2 axes. 2018, 74, 20-27 The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster. 2018, 13, e0202838 Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis. 2018, 13, e0207019 Gain of affinity for VEGF165 binding within the VEGFR2/NRP1 cellular complex detected by an HTRF-based binding assay. 2018, 158, 45-59 Role of Tyrosine Kinases in Gastrointestinal Malignancies. 2018,	10
475 474 473 472 471	The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster. 2018, 13, e0202838 Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis. 2018, 13, e0207019 Gain of affinity for VEGF165 binding within the VEGFR2/NRP1 cellular complex detected by an HTRF-based binding assay. 2018, 158, 45-59 Role of Tyrosine Kinases in Gastrointestinal Malignancies. 2018,	10 3 6

467	Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment. 2018 , 32, 296-302	11
466	In vitro growth and development of isolated secondary follicles from vitrified caprine ovarian cortex. 2018 , 30, 359-370	6
465	Inflammatory breast cancer and chest wall disease: The oncologist perspective. 2018, 44, 1142-1147	4
464	Different angiogenesis modes and endothelial responses in implanted porous biomaterials. 2018 , 10, 406-418	3
463	Follicular fluid vascular endothelial growth factor is associated with type of infertility and interferon alpha correlates with endometrial thickness in natural cycle in vitro fertilization. 2018 , 18, 289-294	3
462	Angiogenesis in Brain Tumors. 2018 , 27-47	
461	The Role of Limbal Epithelial Stem Cells in Regulating Corneal (Lymph)angiogenic Privilege and the Micromilieu of the Limbal Niche following UV Exposure. 2018 , 2018, 8620172	26
460	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. 2018 , 10, 58	13
459	The Fibrin Cleavage Product BiChannels Endothelial and Tubular Regeneration in the Post-acute Course During Murine Renal Ischemia Reperfusion Injury. 2018 , 9, 369	1
458	Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review. 2018 , 9, 428	23
457	Clinical efficiency and safety of Hsp90 inhibitor Novobiocin in avian tibial dyschondroplasia. 2018 , 41, 902-911	9
456	Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators. 2018 , 8, 955-979	15
455	VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. 2018 , 19,	42
454	Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase. 2018 , 15, 2165-2173	6
453	Targeting the Microenvironment in High Grade Serous Ovarian Cancer. 2018, 10,	14
452	Biodistribution and Internal Radiation Dosimetry of Tc-IDA-D-[c(RGDfK)] (BIK-505), a Novel SPECT Radiotracer for the Imaging of Integrin Expression. 2018 , 33, 396-402	6
451	Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer. 2018 , 9, 1287-1300	5
450	Therapeutic aptamers in discovery, preclinical and clinical stages. 2018 , 134, 51-64	25

449	Soluble VEGFR1 signaling guides vascular patterns into dense branching morphologies. 2018 , 456, 261-278	5
448	Expression and localization of VEGFR-2 in hair follicles during induced hair growth in mice. 2018 , 310, 591-598	7
447	Morphological and Molecular Analysis of In Vitro Tubular Structures from Bovine Yolk Sac-Derived MSCs. 2019 , 2019, 5073745	
446	Contribution of the VEGF system to the follicular persistence associated with bovine cystic ovaries. 2019 , 138, 52-65	6
445	Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase-positive lung cancer. 2019 , 7, e00454	6
444	A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis. 2019 , 28, 949-965.e7	25
443	MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma. 2019, 11,	7
442	Role of angiogenesis in melanoma progression: Update on key angiogenic mechanisms and other associated components. 2019 , 59, 175-186	22
441	Carrier-Enhanced Anticancer Efficacy of Sunitinib-Loaded Green Tea-Based Micellar Nanocomplex beyond Tumor-Targeted Delivery. 2019 , 13, 7591-7602	30
440	Mammaglobin-A, VEGFR3, and Ki67 in Human Breast Cancer Pathology and Five Year Survival. 2019 , 13, 1178223419858957	6
439	Migration of endothelial cells into photo-responsive hydrogels with tunable modulus under the presence of pro-inflammatory macrophages. 2019 , 6, 259-267	8
438	Potential of targeted drug delivery systems in treatment of rheumatoid arthritis. 2019 , 53, 101217	2
437	Cancer Biomarkers in Body Fluids. 2019 ,	1
436	Induced Expression of VEGFC, ANGPT, and EFNB2 and Their Receptors Characterizes Neovascularization in Proliferative Diabetic Retinopathy. 2019 , 60, 4084-4096	11
435	Ardisia crispa root hexane fraction suppressed angiogenesis in human umbilical vein endothelial cells (HUVECs) and in vivo zebrafish embryo model. 2019 , 118, 109221	5
434	Antiangiogenic Human Monoclonal Antibody Ramucirumab Radiolabelling: Evaluation on VEGFR2-positive Cell Lines. 2019 , 39, 735-744	2
433	Mapping Tyrosine Kinase Receptor Dimerization to Receptor Expression and Ligand Affinities. 2019 , 7, 288	2
432	Sitagliptin protects diabetic rats with acute myocardial infarction through induction of angiogenesis: role of IGF-1 and VEGF. 2019 , 97, 1053-1063	10

431	Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. 2019 , 8, 4709-4721	104
430	Vascular endothelial growth factor gene polymorphisms in patients with rosacea: A case-control study. 2019 , 81, 348-354	10
429	Tendon and Ligament Injuries in Elite Rugby: The Potential Genetic Influence. 2019, 7,	5
428	Vascular endothelial growth factor-loaded elastin-hydrogel modification of the pericardium improves endothelialization potential of bioprosthetic heart valves. 2019 , 34, 451-459	3
427	Longitudinal Changes of PAI-1, MMP-2, and VEGF in Peritoneal Effluents and Their Associations with Peritoneal Small-Solute Transfer Rate in New Peritoneal Dialysis Patients. 2019 , 2019, 2152584	5
426	VEGFA From Early Osteoblast Lineage Cells (Osterix+) Is Required in Mice for Fracture Healing. 2019 , 34, 1690-1706	17
425	CD147 participates in the activation function of circulating angiogenic T cells in patients with rheumatoid arthritis. 2019 , 38, 2621-2628	5
424	Ellagic Acid, Kaempferol, and Quercetin from : Promising Combined Drug With Multiple Mechanisms of Action. 2019 , 5, 255-280	14
423	Clinical characteristics and genetic analysis of gene mutations in a Chinese pedigree with Peutz-Jeghers syndrome. 2019 , 7, 735-739	1
422	Alternative Splicing in Angiogenesis. 2019 , 20,	32
421	Hybrid Pericardium with VEGF-Loaded Hyaluronic Acid Hydrogel Coating to Improve the Biological Properties of Bioprosthetic Heart Valves. 2019 , 19, e1800390	8
420	Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. 2019 , 37, 2090-2098	3
419	Arachidonic Acid Derived Lipid Mediators Influence Kaposi's Sarcoma-Associated Herpesvirus Infection and Pathogenesis. 2019 , 10, 358	11
418	Effects of Platelet-Rich Plasma on Fat and Nanofat Survival: An Experimental Study on Mice. 2019 , 43, 1085-1094	10
417	Tumor Neovascularization and Developments in Therapeutics. 2019 , 11,	46
417 416	Tumor Neovascularization and Developments in Therapeutics. 2019 , 11, Andrographolide binds to ATP-binding pocket of VEGFR2 to impede VEGFA-mediated tumor-angiogenesis. 2019 , 9, 4073	46 17
	Andrographolide binds to ATP-binding pocket of VEGFR2 to impede VEGFA-mediated	ŕ

413	Genetic Basis of Vasculitides with Neurologic Involvement. 2019 , 37, 219-234	2
412	Cold and Exercise: Therapeutic Tools to Activate Brown Adipose Tissue and Combat Obesity. 2019 , 8,	28
411	Activation of oxygen-responsive pathways is associated with altered protein metabolism in Arctic char exposed to hypoxia. 2019 , 222,	1
410	Exosomes from conditioned media of bone marrow-derived mesenchymal stem cells promote bone regeneration by enhancing angiogenesis. 2019 , 14, e0225472	73
409	Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism. 2019 , 9, 17429	7
408	The use of apatinib in treating primary pleural synovial sarcoma: A case report. 2019 , 98, e18382	2
407	Current treatment of optic nerve gliomas. 2019 , 30, 356-363	22
406	Polyethylenimine: A new differentiation factor to endothelial/cardiac tissue. 2018, 120, 1511	13
405	Expression of a functional recombinant vascular endothelial growth factor 165 (VEGF165) in Arabidopsis thaliana. 2019 , 44, 254-260	2
404	Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. 2018 , 20,	20
403	Tipping the Balance from Angiogenesis to Fibrosis in Chronic Kidney Disease. 2019 , 419-449	
402	VEGF-A regulates angiogenesis during osseointegration of Ti implants via paracrine/autocrine regulation of osteoblast response to hierarchical microstructure of the surface. 2019 , 107, 423-433	16
401	Role of Neuronal VEGF Signaling in the Prefrontal Cortex in the Rapid Antidepressant Effects of Ketamine. 2019 , 176, 388-400	40
400	Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease. 2019 , 88, 1-33	9
399	Assembly of Bifunctional Aptamer-Fibrinogen Macromer for VEGF Delivery and Skin Wound Healing. 2019 , 31, 1006-1015	26
398	Narrative review of the effects of antidiabetic drugs on albuminuria. 2019 , 234, 5786-5797	11
397	Intestinal fibrosis. 2019 , 65, 100-109	34
396	Intravitreal Delivery of VEGF-A-loaded PLGA Microparticles Reduces Retinal Vaso-Obliteration in an In Vivo Mouse Model of Retinopathy of Prematurity. 2019 , 44, 275-286	10

395	Heparan sulfate proteoglycan - A common receptor for diverse cytokines. 2019 , 54, 115-121	33
394	Identification and characterization of two novel vascular endothelial growth factor genes in Litopenaeus vannamei. 2019 , 84, 259-268	3
393	Novel calcitonin gene-related peptide/chitosan-strontium-calcium phosphate cement: Enhanced proliferation of human umbilical vein endothelial cells in vitro. 2019 , 107, 19-28	14
392	Effects of Pituitary Adenylate Cyclase Activating Polypeptide in Human Proximal Tubule Cells Against Gentamicin Toxicity. 2019 , 25, 257-264	3
391	Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT. 2020 , 23, 82-94	13
390	DRG2 supports the growth of primary tumors and metastases of melanoma by enhancing VEGF-A expression. 2020 , 287, 2070-2086	7
389	Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization. 2020 , 12, 92-100	14
388	Development of hydrogel-like biomaterials via nanoparticle assembly and solid-hydrogel transformation. 2020 , 318, 185-196	7
387	Higher level of acute serum VEGF and larger infarct volume are more frequently associated with post-stroke cognitive impairment. 2020 , 15, e0239370	9
386	Predictive Markers for Malignant Urothelial Transformation in Balkan Endemic Nephropathy: A Case-Control Study. 2020 , 12,	
385	A polyoxyethylene sorbitan oleate modified hollow gold nanoparticle system to escape macrophage phagocytosis designed for triple combination lung cancer therapy via LDL-R mediated endocytosis. 2020 , 27, 1342-1359	5
384	Role of oxylipins generated from dietary PUFAs in the modulation of endothelial cell function. 2020 , 160, 102160	5
383	RNase A Treatment Interferes With Leukocyte Recruitment, Neutrophil Extracellular Trap Formation, and Angiogenesis in Ischemic Muscle Tissue. 2020 , 11, 576736	4
382	VEGF-A in Cardiomyocytes and Heart Diseases. 2020 , 21,	35
381	Spontaneous delivery is associated with increased endothelial activity in cord blood compared to elective cesarean section. 2020 , 251, 229-234	1
380	Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model. 2020 , 11, 901	15
379	Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents. 2020 , 353, e2000022	4
378	Effects of VEGF Inhibitor Conbercept on Corneal Neovascularization Following Penetrating Keratoplasty in Rabbit Model. 2020 , 14, 2185-2193	2

377	Hormetic modulation of angiogenic factors by exercise-induced mechanical and metabolic stress in human skeletal muscle. 2020 , 319, H824-H834	2
376	Tetragonia tetragonoides (Pall.) Kuntze Restores Blood Perfusion from Hind-Limb Ischemic Mice. 2020 , 10, 8562	
375	Anti-angiogenic effect of tripterygium glycosides tablets in animal models of rheumatoid arthritis: A systematic review and meta-analysis. 2020 , 7, 291-300	2
374	MiR-21-5p regulates extracellular matrix degradation and angiogenesis in TMJOA by targeting Spry1. 2020 , 22, 99	23
373	Platelet-derived growth factor B restores vascular barrier integrity and diminishes permeability in ovarian hyperstimulation syndrome. 2020 , 26, 585-600	О
372	Early growth response gene mediates in VEGF and FGF signaling as dissected by CRISPR in corpus luteum of water buffalo. 2020 , 10, 6849	4
371	Soluble overexpression, high-level production and purification of receptor binding domain of human VEGF8-109 in E. coli. 2020 , 96, 228-238	
370	The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1⊞ 2020 , 304, 30-38	6
369	Different influence of sulfated chitosan with different sulfonic acid group sites on HUVECs behaviors. 2020 , 31, 1237-1253	2
368	Hydrophobic ion pair loaded self-emulsifying drug delivery system (SEDDS): A novel oral drug delivery approach of cromolyn sodium for management of bronchial asthma. 2020 , 585, 119494	10
367	Humidity-Triggered Relaxation of Polyelectrolyte Complexes as a Robust Approach to Generate Extracellular Matrix Biomimetic Films. 2020 , 9, e2000381	9
366	Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration. 2020 , 12, 79	3
365	CASIN and AMD3100 enhance endothelial cell proliferation, tube formation and sprouting. 2020 , 130, 104001	5
364	Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. 2020 , 57, 2461-2478	72
363	ube3d, a New Gene Associated with Age-Related Macular Degeneration, Induces Functional Changes in Both In Vivo and In Vitro Studies. 2020 , 20, 217-230	4
362	Uncovering the Physiological Mechanisms Underlying the Roe Deer () Testicular Cycle: Analyses of Gelatinases and VEGF Patterns and Correlation with Testes Weight and Testosterone. 2020 , 10,	2
361	Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta. 2020 , 10,	31
360	Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept. 2020 , 45, 1467-1476	3

359	Role of FOXO Transcription Factors in Cancer Metabolism and Angiogenesis. 2020 , 9,	14
358	Developments and Novel Approaches in Biomechanics and Metamaterials. 2020,	3
357	Corneal neovascularization is inhibited with nucleolin-binding aptamer, AS1411. 2020 , 193, 107977	5
356	Inorganic Biomaterials for Regenerative Medicine. 2020 , 12, 5319-5344	69
355	Animal Models and Renal Biomarkers of Diabetic Nephropathy. 2021 , 1307, 521-551	2
354	StarD13: a potential star target for tumor therapeutics. 2020 , 33, 437-443	6
353	Impact of growth factor content on proliferation of mesenchymal stromal cells derived from adipose tissue. 2020 , 15, e0230265	4
352	Smoke exposure from chronic biomass burning induces distinct accumulative systemic inflammatory cytokine alterations compared to tobacco smoking in healthy women. 2020 , 131, 155089	9
351	The binding of kaempferol-3-O-rutinoside to vascular endothelial growth factor potentiates anti-inflammatory efficiencies in lipopolysaccharide-treated mouse macrophage RAW264.7 cells. 2021 , 80, 153400	8
350	Signaling pathways in hepatocellular carcinoma. 2021 , 149, 63-101	8
349	Epsins in vascular development, function and disease. 2021 , 78, 833-842	6
348	Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants. 2021 , 53, 126-139	66
347	A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy. 2021 , 20, 83-98	4
346	Structure Activity Relationship of Key Heterocyclic Anti-Angiogenic Leads of Promising Potential in the Fight against Cancer. 2021 , 26,	4
345	Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy. 2021 , 22,	11
344	A biomimetic orthogonal-bilayer tubular scaffold for the co-culture of endothelial cells and smooth muscle cells 2021 , 11, 31783-31790	3
343	Tiny miRNAs Play a Big Role in the Treatment of Breast Cancer Metastasis. 2021, 13,	3
342	Arginine, Agmatine, and Polyamines: Key Regulators of Conceptus Development in Mammals. 2021 , 1332, 85-105	5

341	Receptors Structural and Functional Insights of VEGF and Its Receptors. 2021, 286-293	1
340	Enhanced Angiogenesis in Salivary Duct Carcinoma Ex-Pleomorphic Adenoma. 2020 , 10, 603717	3
339	Evaluation of stemness properties of cells derived from granulation tissue of peri-implantitis lesions. 2021 , 7, 739-753	4
338	Co- localization of Flt1 and tryptase of mast cells in skin wound of rats with type I diabetes: Initial studies. 2021 , 123, 151680	2
337	A novel vascular endothelial growth factor-trap KP-VR2 with enhanced ligand blocking.	
336	SDF-1Æene-Activated Collagen Scaffold Restores Pro-Angiogenic Wound Healing Features in Human Diabetic Adipose-Derived Stem Cells. 2021 , 9,	10
335	Identification of HIF-dependent alternative splicing in gastrointestinal cancers and characterization of a long, coding isoform of SLC35A3. 2021 , 113, 515-529	O
334	Growth factors in the fetus and pre-adolescent offspring of hyperglycemic rats. 2021 , 18, 1479164121101102	50
333	Screening of novel alkaloid inhibitors for vascular endothelial growth factor in cancer cells: an integrated computational approach. 2021 , 19, e6	1
332	Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. 2021 , 54, e13009	19
332	Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. 2021 , 54, e13009 A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. 2021 , 13,	19 5
	A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast	
331	A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. 2021 , 13, Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89	5
331	A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. 2021 , 13, Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. 2021 , 64, 262-270 Oxidative Stress, Inflammation, and Activators of Mitochondrial Biogenesis: Tempol Targets in the	5
331 330 329	A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. 2021, 13, Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. 2021, 64, 262-270 Oxidative Stress, Inflammation, and Activators of Mitochondrial Biogenesis: Tempol Targets in the Diaphragm Muscle of Exercise Trained- Mice. 2021, 12, 649793 Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. 2021,	5 1 2
331 330 329 328	A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. 2021, 13, Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. 2021, 64, 262-270 Oxidative Stress, Inflammation, and Activators of Mitochondrial Biogenesis: Tempol Targets in the Diaphragm Muscle of Exercise Trained- Mice. 2021, 12, 649793 Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. 2021, 78, 4867-4891	5 1 2
331 330 329 328 327	A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action. 2021, 13, Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. 2021, 64, 262-270 Oxidative Stress, Inflammation, and Activators of Mitochondrial Biogenesis: Tempol Targets in the Diaphragm Muscle of Exercise Trained- Mice. 2021, 12, 649793 Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. 2021, 78, 4867-4891 Effect of heparinization on promoting angiogenesis of decellularized kidney scaffolds. 2021, 109, 1979-1989 Nanotechnology: revolutionizing the delivery of drugs to treat age-related macular degeneration.	5 1 2 4 5

323	Regulation of docosahexaenoic acid-induced apoptosis of confluent endothelial cells: Contributions of MAPKs and caspases. 2021 , 1866, 158902	2
322	Translational Studies on the Potential of a VEGF Nanoparticle-Loaded Hyaluronic Acid Hydrogel. 2021 , 13,	3
321	Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases. 2021 , 22,	6
320	Hypoxia-dependent drivers of melanoma progression. 2021 , 40, 159	11
319	Graphene Oxide Normal (GO + Mn) and Ultrapure: Short-Term Impact on Selected Antioxidant Stress Markers and Cytokines in NHDF and A549 Cell Lines. 2021 , 10,	0
318	Inhibition effects of 7-phloro-eckol from Ecklonia cava on metastasis and angiogenesis induced by hypoxia through regulation of AKT/mTOR and ERK signaling pathways. 2021 , 14, 103187	4
317	Dynamics of Metabolic Parameters and the Level of VEGF in Blood Serum of Patients with Diabetic Kidney Disease under Complex Nephroprotective Therapy. 2021 , 6, 199-205	
316	Systematic Review on the Association of Radiomics with Tumor Biological Endpoints. 2021 , 13,	1
315	Prevention of Hypertensive Disorders of Pregnancy-Is There a Place for Metformin?. 2021, 10,	4
314	The Effect of Miana (Coleus Scutellariodes [L]) on Vascular Endothelial Growth Factor Expression in Balb/C Mice Infected with Mycobacterium Tuberculosis. 2021 , 14, 525-532	4
313	Epigenetic down-regulation of microRNA-126 in scleroderma endothelial cells is associated with impaired responses to VEGF and defective angiogenesis. 2021 , 25, 7078-7088	3
312	Single-cell RNA-seq analysis reveals penaeid shrimp hemocyte subpopulations and cell differentiation process. 2021 , 10,	15
311	VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience. 2021 , 25, 1193-1202	1
310	Ultrasonic microbubble VEGF gene delivery improves angiogenesis of senescent endothelial progenitor cells. 2021 , 11, 13449	3
309	Up-to-date role of aflibercept in the treatment of colorectal cancer. 2021 , 21, 1315-1324	1
308	Single-cell analysis of the cellular heterogeneity and interactions in the injured mouse spinal cord. 2021 , 218,	21
307	Upregulation of long non-coding RNA SNHG16 promotes diabetes-related RMEC dysfunction via activating NF-B and PI3K/AKT pathways. 2021 , 24, 512-527	7
306	Silencing VEGFR-2 Hampers Odontoblastic Differentiation of Dental Pulp Stem Cells. 2021 , 9, 665886	1

305	Tetrastigma hemsleyanum leaf flavones have anti-NSCLC ability by triggering apoptosis using the Akt-mTOR pathway. 2021 , 41, 100914	2
304	Correlation Between Vascular Endothelial Growth Factor and Long-Term Occurrence of HCV-Related Hepatocellular Carcinoma After Treatment with Direct-Acting Antivirals. 2021 , 39, 653-660	1
303	Netrin-1 in Glioblastoma Neovascularization: The New Partner in Crime?. 2021 , 22,	2
302	A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers. 2021 , 88, 713-722	1
301	Impact of perlecan, a core component of basement membrane, on regeneration of cartilaginous tissues. 2021 , 135, 13-26	3
300	Alternative Splicing: A Key Mediator of Diabetic Vasculopathy. 2021 , 12,	О
299	Alternative Splicing: A New Cause and Potential Therapeutic Target in Autoimmune Disease. 2021 , 12, 713540	2
298	TLR2 signaling contributes to the angiogenesis of oxygen-induced retinopathy. 2021 , 210, 108716	1
297	Vitamin D3/phospholipid complex decorated caseinate nanomicelles for targeted delivery of synergistic combination therapy in breast cancer. 2021 , 607, 120965	O
296	Histological investigation of the protective effect of metformin on testis and sperm parameters in obese rats with type 2 diabetes mellitus. 2021 , 5, 954-959	
295	Angiogenesis induction in breast cancer: A paracrine paradigm. 2021 , 39, 860-873	3
294	Schlemm's canal: the outflow 'vessel'. 2021 ,	2
293	A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers. 2021 ,	2
292	Oral wound healing models and emerging regenerative therapies. 2021 , 236, 17-34	9
291	Construction of nanofibrous scaffolds with interconnected perfusable microchannel networks for engineering of vascularized bone tissue. 2021 , 6, 3254-3268	21
290	Missing data handling technique in joint modeling context. 2021 , 2, 100012	
289	The Fovea - Pages 187-241. 2022 , 187-241	
288	Development of the fovea. 2022 , 123-138	

287	Transcriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients. 2021 , 70, 1877-1891	3
286	Single-cell RNA-seq analysis reveals penaeid shrimp hemocyte subpopulations and cell differentiation process.	Ο
285	Adaptive response triggered by the repeated SCUBA diving is reflected in cardiovascular, muscular, and immune biomarkers. 2021 , 9, e14691	2
284	Pathogenesis of Diabetic Microvascular Complications.	1
283	Lymphangiogenesis: Recapitulation of Angiogensis in Health and Disease. 2006 , 159-202	4
282	VEGF Signaling: A Therapeutic Target for Cardiovascular Disease. 2008 , 301-326	2
281	Semaphorin signaling in vascular and tumor biology. 2007 , 600, 118-31	38
2 80	Long-Term Peritoneal Dialysis Patients. 2009 , 757-780	7
279	Pulmonary Vascular Development. 2011 , 25-60	2
278	Morphogenesis of embryonic CNS vessels. 2004 , 117, 33-50	10
277	Molecular Mechanisms of VEGF-Induced Angiogenesis. 2004 , 19-25	1
276	Vascularization of the Placenta. 2002 , 239-273	3
275	Vascular Development of the Brain and Spinal Cord. 2002 , 157-191	5
274	Angiogenesis, Vascular Imaging, and Therapeutic Approaches in Ovarian Tumors. 2001 , 187-205	1
273	Vascular Morphogenesis in the Ovary: Introduction and Overview. 2001 , 109-130	1
272	Growth Factors During Ovarian Angiogenesis. 2001 , 131-147	4
271	Heparin-Functionalized Materials in Tissue Engineering Applications. 2012 , 225-250	4
270	The role of neuropilin in vascular and tumor biology. 2002 , 515, 33-48	161

(2004-2002)

269	The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. 2002 , 515, 81-90	127
268	Vascular endothelial growth factor. 2002 , 513, 375-94	15
267	Hypoxia-inducible factor-1alpha accumulation in the rat brain in response to hypoxia and ischemia is attenuated during aging. 2003 , 510, 337-41	34
266	Recent Advances in the Development of Cell Culture Models for the Blood-Brain- and Blood-CSF-Barrier. 2001 , 45-62	1
265	Transforming Growth Factor-land other Cytokines in Experimental and Human Nephropathy. 2000 , 313-338	2
264	Leukocyte-endothelial interactions in environmental hypoxia. 2001 , 502, 39-60	36
263	Nuclear Functions of Receptor Tyrosine Kinases. 2015 , 77-109	1
262	mTOR Signaling in Angiogenesis. 2009 , 49-74	1
261	A Model of Integrin and VEGF Receptors Recruitment on Endothelial Cells. 2020 , 163-198	1
2 60	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. 2019 , 211-226	3
259	Laparoscopy and Immunology. 2011 , 69-82	1
258	Arteriogenesis and Collateral Formation. 2015 , 167-189	O
257	Therapeutische Angiogenese. 2002 , 363-373	1
256	Innate immune responses in viral encephalitis. 2002 , 265, 63-94	10
255	The angiogenic drive in chronic inflammation: Hypoxia and the cytokine milieu. 2008, 15-28	3
254	Intraocular Neovascularization. 2006 , 2403-2411	1
253	Molecular Determinants of Embryonic Vascular Development. 2004 , 621-634	1
252	Nonclassical Endocrinology. 2004 , 61-100	2

251	Angiogenesis, Basic Mechanisms, and Role in Head and Neck Squamous Cell Carcinoma. 2003, 81-100	1
250	Schnurri-3 regulates BMP9-induced osteogenic differentiation and angiogenesis of human amniotic mesenchymal stem cells through Runx2 and VEGF. 2020 , 11, 72	12
249	Regeneration of testis tissue after ectopic implantation of porcine testis cell aggregates in mice: improved consistency of outcomes and in situ monitoring. 2020 , 32, 594-609	6
248	Prospective Preliminary Investigation of a Magnetic Iron Oxide Nanoparticle Conjugated with Ligand CD80 and VEGF Antibody As a Targeted Drug Delivery System for the Induction of Cell Death in Rodent Osteosarcoma Cells. 2016 , 5, 299-307	9
247	Adeno-associated virus-mediated vascular endothelial growth factor gene transfer into cardiac myocytes. 2000 , 36, 438-43	12
246	Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene. 2000 , 36, 498-502	19
245	VASCULAR ENDOTHELIAL GROWTH FACTOR PROMOTES PROLIFERATION AND MIGRATION OF CAVERNOUS SMOOTH MUSCLE CELLS. 2001 , 354-360	1
244	The effect of vascular endothelial growth factor on a rat model of traumatic arteriogenic erectile dysfunction. 2002 , 167, 761-7	27
243	. 2000 , 8, 104-109	15
242	Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor. 2000 , 8, 104-9	11
241	Upregulation of P53 promoted G1 arrest and apoptosis in human umbilical cord vein endothelial cells from preeclampsia. 2016 , 34, 1380-8	32
240	Lysine as a potential low molecular weight angiogen: its clinical, experimental and in-silico validation- A brief study.	2
239	Single cell analysis of the cellular heterogeneity and interactions in the injured mouse spinal cord.	3
238	Notch signaling is essential for vascular morphogenesis in mice. 2000 , 14, 1343-1352	557
237	Angiostatin's partners. 1999 , 284, 433-4	14
236	Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. 2002 , 109, 327-336	327
235	Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. 2000, 106, 1311-9	831
234	Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. 2004 , 114, 104-111	129

233	Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. 2004 , 113, 885-894	264
232	Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. 2008 , 118, 2062-75	65
231	Osteopenia and decreased bone formation in osteonectin-deficient mice. 2000 , 105, 915-23	196
230	The basic helix-loop-helix transcription factor, dHAND, is required for vascular development. 2000 , 105, 261-70	123
229	IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. 2000 , 106, 783-91	130
228	Molecular-Targeted Agents in Pancreatic Cancer. 2004 , 11, 32-38	7
227	Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. 2000 , 95, 2630-2636	20
226	Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. 2000 , 96, 1525-1530	6
225	In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. 2000 , 96, 3181-3187	3
224	Plasticity of endothelial cells during arterial-venous differentiation in the avian embryo. 2001 , 128, 3359-3370	177
223	The forkhead transcription factor Foxf1 is required for differentiation of extra-embryonic and lateral plate mesoderm. 2001 , 128, 155-166	219
222	Abnormal lymphatic vessel development in neuropilin 2 mutant mice. 2002 , 129, 4797-4806	432
221	Insufficient VEGFA activity in yolk sac endoderm compromises haematopoietic and endothelial differentiation. 2002 , 129, 1881-1892	116
220	Skeletal defects in VEGF120/120 mice reveal multiple roles for VEGF in skeletogenesis. 2002 , 129, 1893-1904	320
219	HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model. 2010 , 5, e9945	30
218	Distinct effects of unfractionated heparin versus bivalirudin on circulating angiogenic peptides. 2012 , 7, e34344	11
217	Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells. 2013, 8, e50964	30
216	Lysophosphatidic acid enhances stromal cell-directed angiogenesis. 2013 , 8, e82134	8

215	Microparticles from kidney-derived mesenchymal stem cells act as carriers of proangiogenic signals and contribute to recovery from acute kidney injury. 2014 , 9, e87853	65
214	Evolution of proliferation and the angiogenic switch in tumors with high clonal diversity. 2014 , 9, e91992	6
213	Evolutionary emergence of angiogenesis in avascular tumors using a spatial public goods game. 2017 , 12, e0175063	5
212	Bone marrow mesenchymal stem cell-derived vascular endothelial growth factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a and miRNA-92a in a rat model of myocardial infarction. 2017 , 12, e0179972	28
211	Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. 2003 , 8, 37-52	92
210	Measuring Stability of Vascular Endothelial Growth Factor using an Immobilization Technique. 2013 , 2, 130-136	11
209	Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. 2001 , 12, 1734-1741	122
208	Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF- B regulated gene products in multiple myeloma xenograft mouse model. 2014 , 5, 634-48	120
207	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. 2010 , 1, 515-529	12
206	Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma. 2017 , 8, 106551-106564	10
205	Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway. 2018 , 9, 31958-31970	18
204	Glucose-regulated protein 94 mediates progression and metastasis of esophageal squamous cell carcinoma via mitochondrial function and the NF-kB/COX-2/VEGF axis. 2018 , 9, 9425-9441	15
203	TENDON INJURY AND TENDINOPATHY. 2005 , 87, 187-202	26
202	Diminished Pulmonary Expression of Hypoxia-Inducible Factor 2- Vascular Endothelial Growth Factor and Hepatocyte Growth Factor in Chickens Exposed to Chronic Hypobaric Hypoxia. 2012 , 49, 205-211	3
201	Angiogenesis in cancer. 2006 , 2, 213-9	772
200	Effects of VEGF on Ca(2+)-transient in cultured lymphatic endothelial cells and mechanical activity of isolated lymph vessels. 2000 , 50, 343-55	6
199	Anti-VEGF Treatment in Corneal Diseases. 2020 , 21, 1159-1180	9
198	Advances in Targeted Gene Delivery. 2019 , 16, 588-608	8

197	The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis. 2019 , 15, 99-109	6
196	Formation of new periodontal ligament around transplanted teeth with proliferating tissue in periodontal osseous defect under barrier membrane. 2004 , 25, 179-187	11
195	Coconut shell derived bioactive compound Oxyresveratrol mediates regulation of Matrix metalloproteinase 9. 2017 , 8,	1
194	Relationships between Lymph Node Metastasis and Expression of CD31, D2-40, and Vascular Endothelial Growth Factors A and C in Papillary Thyroid Cancer. 2012 , 5, 150-5	19
193	ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models. 2020 , 22,	6
192	Hierarchical Capillary Coating to Biofunctionlize Drug-Eluting Stent for Improving Endothelium Regeneration. 2020 , 2020, 1458090	8
191	A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo. 2004 , 10, 2039-44	7
190	Significance of vascular endothelial growth factor expression and its correlation with inducible nitric oxide synthase in gastric cancer. 2004 , 10, 1250-5	7
189	Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma. 2005 , 11, 1167-71	30
188	Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. 2006 , 12, 4937-42	46
187	Risk factors for small bowel angioectasia: The impact of visceral fat accumulation. 2015 , 21, 7242-7	8
187 186	Risk factors for small bowel angioectasia: The impact of visceral fat accumulation. 2015 , 21, 7242-7 Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. 1999 , 5, 296-300	8
,	Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension.	
186	Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. 1999, 5, 296-300 Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor	31
186 185	Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. 1999, 5, 296-300 Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy. 2001, 7, 22-7 VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell	31 17
186 185 184	Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. 1999, 5, 296-300 Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy. 2001, 7, 22-7 VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. 2002, 8, 44-8 Angiogenesis effect on rat liver after administration of expression vector encoding vascular	31 17 31
186 185 184 183	Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. 1999, 5, 296-300 Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy. 2001, 7, 22-7 VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. 2002, 8, 44-8 Angiogenesis effect on rat liver after administration of expression vector encoding vascular endothelial growth factor D. 2003, 9, 312-5 The Clinical Utility of Vascular Endothelial Growth Factor as Predictive Marker for Systemic Lupus	31 17 31 6

179	Consequences of Hypoxia-Reoxygenation Phenomena in Patients with Obstructive Sleep Apnea Syndrome. 2011 , 31, 14-18	2
178	1,2-Dichloropropane (1,2-DCP)-Induced Angiogenesis in Dermatitis. 2019 , 35, 361-369	4
177	Serum concentration of vascular endothelial growth factor and depth of trophoblastic invasion in ampullary ectopic pregnancy. 2016 , 71, 699-702	2
176	Pathologic sequelae of vascular cognitive impairment and dementia sheds light on potential targets for intervention. 2021 , 2, 100030	O
175	The evolving view of thermogenic adipocytes - ontogeny, niche and function. 2021, 17, 726-744	9
174	Thymosin-4, and Human Vitronectin peptides Grafted to Collagen Tune Adhesion or VEGF Gene Expression in Human Cell Lines**. 2021 , 6, 10160-10164	
173	DNA methylation in promoter region of immune related genes STAT3 and VEGF and biochemical parameters change in muscle of Japanese flounder under acute hypoxia. 2021 , 129, 104295	1
172	Hemangioblastic precursors in the avian embryo. 2000 , 251, 83-90	6
171	An Update on the Role of Growth Factors in the Development of Diabetic Kidney Disease. 2000 , 295-311	
170	Anti-angiogene Therapie mit einem neutralisierenden Anti-VEGF Antiktper reduziert Tumorgr ë und Metastasierung in einem orthotopen Pankreas-Karzinommodell. 2000 , 85-88	
169	Poxvirus Homologues of Cellular Genes. 2000 , 111-133	
168	Applications of developmental biology to medicine and animal agriculture. 2000 , 54, 213-56	
167	Molecular approaches to receptors as targets for drug discovery. 2000 , 89, 123-39	4
166	The Role of Angiogenesis in Breast Cancer Progression. 2001 , 41-62	
165	Vascular Endothelial Growth Factor: A Key Regulator of Physiologic Angiogenesis. 2001, 149-165	
164	Growth Factor Regulation of Physiologic Angiogenesis in the Mammary Gland. 2001 , 25-40	
163	Bophaguskarzinom 1,2. 2002 , 125-163	
162	Stand der Gentherapie und der lokalen Medikamentenapplikation im kardiovaskulfen Bereich. 2002 , 135-179	

161	Neuropilins.
160	Extracellular Matrix in the Regulation of Angiogenesis. 2002 , 67-95
159	Reproduktionsmedizin. 2002 , 239-305
158	Angiogenesis Research. 2002 , 497-525
157	A New Paradigm for Vascular Endothelial Cell Growth Factor Receptor Signaling in Adult Endothelium. 2003 , 153-166
156	Anti-angiogenic Therapy in Acute Myeloid Leukemia. 2003 , 186-192
155	Cardiovascular Gene Therapy. 2003,
154	N/A. 2003 , 11, 1755-1759
153	Role of Alveolar Type II Epithelial Cells in Pulmonary Fibrosis. 2003 , 573-608
152	The Combination of Angiogenesis Inhibitors and Radiotherapy for the Treatment of Primary Tumors. 2004 , 431-438
151	Vascular Endothelial Growth Factor C and Vascular Endothelial Growth Factor D: Biology, Functions and Role in Cancer. 2004 , 145-162
150	Targeting VEGF in Pancreatic Cancer. 2004 , 107-116
149	Preconditioning and Myocardial Angiogenesis. 2004 , 417-438
148	VEGF and Its Receptors. 2004, 1-11
147	Autoimmunity [Rheumatoid Arthritis. 2005, 481-493
146	Angiogenic Switch. 2007 , 365-388
145	Marine Polysaccharides and Angiogensis. 2007 , 651-672
144	Antiangiogenic Therapy for Lung Cancer: Antibodies and Other Novel Agents. 2007, 73-80

143	Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease. 2008 , 285-299	
142	Placental implantation and development. 2008 , 27-39	
141	Tumor Microvasculature and Microenvironment: Therapeutic Targets for Inhibition of Tumor Angiogenesis and Metastasis. 2009 , 1-47	
140	Molecular Basis of Human Malignancy. 2009 , 41-55	1
139	RAS Oncogenes and Tumor-Vascular Interface. 2010 , 133-165	1
138	Investigational Angiogenesis Inhibitors. 2010 , 225-232	
137	Vascular-Targeted Molecular Therapy. 401-419	
136	Inhibitors of Tumor Angiogenesis. 2011 , 331-340	
135	Roles of Endothelium-Derived Vasoactive and Mitogenic Factors in the Development of Chronic Hypoxia-Mediated Pulmonary Hypertension. 2011 , 695-711	
134	Adrenomedullin administration alters vascular endothelial growth factor levels in rats in cold stress. 2010 , 4, 955-958	
133	Molecular Determinants of Embryonic Vascular Development. 2011 , 704-718	
132	Growth Factors Signaling. 2011 , 69-85	
131	Functional Designs of the Gas Exchangers. 2011 , 141-221	0
130	Effect of Saponin with Antioxidant Activity on Matrix Metalloproteinase in Human Dermal Fibroblasts. 2011 , 21, 1266-1273	2
129	Molecular Regulation of Endothelial Cell Tight Junctions and the Blood-Retinal Barrier. 2012, 123-141	
128	Potential Therapeutic Targets for Cerebral Resuscitation After Global Ischemia. 2012 , 417-450	
127	Pathogenesis of Malignant Effusions. 2012 , 11-21	
126	Regular Endurance Exercise Decreases Blood Pressure via Enhancement of Angiogenesis and VEGF Expression in Spontaneously Hypertensive Rats. 2012 , 22, 665-670	

Growth Factors, Stem Cells, Scaffolds and Biomaterials for Tendon Regeneration. 2012, 327-344 125 Engineering the Pluripotent Stem Cell Niche for Directed Mesoderm Differentiation. 2012, 1-26 124 Molecular Mechanisms of Tumor Metastasis. 2013, 213-228 123 Oxidative Stress and Angiogenesis in Tumor Progression. 2013, 394-425 122 Stem Cell-Based Antiangiogenic Therapies for Brain Tumors. 87-101 121 Arteriogenesis and Collateral Formation. 2014, 1-26 120 Free Flap Revascularisation Process. 2014, 103-116 119 118 Lung Vasculogenesis and Angiogenesis. 2015, 25-41 Hypertension and Vascular Endothelial Growth Factors. 2015, 695-707 117 1 Noninvasive Early Biomarkers in Fallopian Tube Carcinoma. 2015, 413-436 116 Asarone Modulates Activity of Matrix Metalloproteinase as well as Antioxidant Activity. 2015, 25, 1000-1006 115 Retinopathy of Prematurity. 2016, 1-38 114 Ih-silico studies of facilitated VEGF(s) IVEGFR(s) bindings for assessment of Lysine as an indirect 113 Low-Mol-Wt angiogen: Experimental validation of a potential synthetic Low-Mol-Wt angiogen[] Positive Mediators of Cell Proliferation in Neoplasia: Growth Factors and Receptors. 2017, 159-182 112 Melanoma. 2017, 81-94 111 Chest Wall Disease: The Clinical Continuum Between Inflammatory and Lymphangitic Breast 110 Cancer. 2017, 719-727 Genetic Factors in Giant Cell Arteritis and Polymyalgia Rheumatica. 2017, 57-68 109 Retinopathy of Prematurity. 2018, 2349-2386 108

107	Retinopathy of Prematurity. 2018 , 1-39	
106	REGENERATION OF POST-TRAUMATIC SEGMENTAL BONE DEFECTS IN DISTAL FEMUR BY MASQUELET TECHNIQUE- AN OBSERVATIONAL STUDY. 2018 , 7, 207-210	
105	The Value of Anti-angiogenics in Cervical Cancer Therapy. 2018 , 1-22	
104	The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster.	
103	SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS IN NORMAL EARLY PREGNANCIES AND RECURRENT ABORTION PATIENTS. 2018 , 7, 4994-4996	
102	The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. 2019 , 1-16	
101	Ovarian Cancer Biomarkers in Proximal Fluids. 2019 , 191-209	
100	Role of Chemical Exposure in Oxidant-Mediated Lung Diseases. 2019 , 171-183	
99	The Value of Anti-angiogenics in Cervical Cancer Therapy. 2019 , 545-566	
98	Signalling Underlying Wound Healing. 1-12	
97	Could Vitamin D Be Effective in Prevention of Preeclampsia?. 2021 , 13,	
		3
96	Bioactive gelatin cryogels with BMP-2 biomimetic peptide and VEGF: A potential scaffold for synergistically induced osteogenesis. 2021 ,	1
96 95		
	synergistically induced osteogenesis. 2021 ,	
95	Synergistically induced osteogenesis. 2021, Drug Targets for Biologics. 2020, 71-88	
95 94	Synergistically induced osteogenesis. 2021, Drug Targets for Biologics. 2020, 71-88 Characterisation of HIF-dependent alternative isoforms in pancreatic cancer. Vascular endothelial growth factor and epithelial cell adhesion molecule immunoexpression in	
95 94 93	Drug Targets for Biologics. 2020, 71-88 Characterisation of HIF-dependent alternative isoforms in pancreatic cancer. Vascular endothelial growth factor and epithelial cell adhesion molecule immunoexpression in enzootic nasal adenocarcinoma of goats.	

89	Anti-angiogenesis agents. 2006 , 167-183
88	Gastric Cancer: Overexpression of Hypoxia-Inducible Factor 1 as a Prognostic Factor. 2008 , 171-180
87	Vascular and Neuronal Effects of VEGF in the Nervous System. 2006 , 245-264
86	Ocular Inflammation and Neovascularization. 2006 , 291-305
85	Vascular Endothelial Growth Factor as a Determinant of Diabetic Nephropathy. 2006 , 187-199
84	Vascular Endothelial Growth Factor Family and Its Receptors. 2008 , 3-26
83	VEGF in the Adult. 2008 , 245-259
82	Molecular Targets in Ovarian Cancer and Endometrial Cancer. 2008 , 291-308
81	The Role of the Neuropilins and Their Associated Plexin Receptors in Tumor Angiogenesis and Tumor Progression. 2008 , 135-153
80	Ischemic Stroke and Depression Biomarkers: Are There Specific Markers for Post-Stroke Depression?. 2020 , 14, 353-361
79	Effect of ligustrazine on bone marrow microenvironment and signal transduction path in irradiation injured mice. 2002 , 8, 295-298
78	Prolonged release of VEGF and Ang1 from intralesionally implanted hydrogel promotes perilesional vascularization and functional recovery after experimental ischemic stroke 2022 , 271678X211069927
77	The diagnostic value of cytokines for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine 2021 , 150, 155782
76	Antiangiogenese-Anstze in der Tumortherapie. 2000 , 32, 251-254
75	Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies 2022 , 89, 165
74	Gene therapy with Pellino-1 improves perfusion and decreases tissue loss in Flk-1 heterozygous mice but fails in MAPKAP Kinase-2 knockout murine hind limb ischemia model 2022 , 141, 104311
73	Antibody-Incorporated Nanomedicines for Cancer Therapy 2022 , e2109210 6
72	TRAF6 regulates the signaling pathway influencing colorectal cancer function by ubiquitination mechanisms 2022 ,

Bone metabolism parameters and their relation to cytogenetics in multiple myeloma.. 2022, 71 The Changes of HIF-1 and ICAM-1 Expression after Miana (Coleus Scutellariodes [L]) Treatment in 70 Balb/C Mice with Mycobacterium Tuberculosis Infection. 2022, 15, 73-81 Placenta crucially affects formation of fetal congenital heart disease. 2022, 16, 66-72 69 A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and 68 6 lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy.. 2022, 1 Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: 67 1 Current Status in Preclinical and Clinical Studies and Future Directions.. 2022. A review on inflammation and angiogenesis as key mechanisms involved in the pathogenesis of 66 bovine cystic ovarian disease.. 2022, 186, 70-85 The Biological Functions and Regulatory Mechanisms of Fatty Acid Binding Protein 5 in Various 65 O Diseases.. 2022, 10, 857919 Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under 64 5.3 normoxia and hypoxia.. European Journal of Pharmacology, 2022, 922, 174907 Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic 63 2 tumors.. 2022, 25, 78-97 Vascular Endothelial Growth Factor Signaling in Models of Oxygen-Induced Retinopathy: Insights 62 1 Into Mechanisms of Pathology in Retinopathy of Prematurity.. 2021, 9, 796143 Microfluidic-Based Droplets for Advanced Regenerative Medicine: Current Challenges and Future 61 1 Trends.. 2021, 12, Platelets, thrombo-inflammation and cancer. 2022, 15, 755-776 60 CircLATS2 Regulates miR-520a-3p/E2F7/p-VEGFR2 Signaling Pathway to Promote Hepatocellular 59 Carcinoma Progression and Angiogenesis.. 2022, 2022, 3744560 Image_1.TIF. 2018, 58 Image_2.PDF. 2018, 57 56 Image_3.PDF. **2018**, Image_4.PDF. **2018**, 55 Image_1.tiff. 2020, 54

53	Image_2.tiff. 2020 ,			
52	Table_1.pdf. 2020 ,			
51	Table_2.pdf. 2020 ,			
50	VEGF-A -Induced Endothelial Cells Chemotactic Migration and Invasion Assays 2022 , 2475, 205-214			
49	The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization 2022 , 41, 9603271221084674		О	
48	Role of synovial lymphatic function in osteoarthritis 2022,		O	
47	Puerarin suppresses hypoxia-induced vascular endothelial growth factor upregulation in human retinal pigmented epithelial cells by blocking JAK2/STAT3 pathway 2022 , 13, 11636-11645			
46	Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review 2022,			
45	Personalized management of hypertensive patients: focus on prognostic biomarkers. 2022 , 27, 5017			
44	Personalized management of hypertensive patients: focus on prognostic biomarkers. 2022 , 27, 5017			
43	The Vascular Microenvironment in Glioblastoma: A Comprehensive Review. 2022 , 10, 1285		O	
42	Lysyl Oxidase Family Enzymes and Their Role in Tumor Progression. 2022 , 23, 6249		Ο	
41	VEGF Profile in Early Undifferentiated Arthritis Cohort. 2022 , 58, 833		0	
40	Neuroprotective Effects of VEGF in the Enteric Nervous System. 2022, 23, 6756		1	
39	Activated Serum Increases In Vitro Cellular Proliferation and Growth Factor Expression of Musculoskeletal Cells. 2022 , 11, 3442			
38	Regulation of Aortic Morphogenesis and VE-Cadherin Dynamics by VEGF.			
37	Role of growth factors and cytokines in therapeutic angiogenesis. 2022, 85-111			
36	Serum vascular endothelial growth factor as a marker for tubal pregnancy. <i>Revista Da Associd</i> o <i>Mdica Brasileira</i> , 2022 , 68, 860-865	1.4	0	

35	Introducing blood flow in kidney explants by engraftment onto the chick chorioallantoic membrane is not sufficient to induce arterial smooth muscle cell development. <i>Biology Open</i> , 2022 , 11,	2.2	
34	Protective role of VEGF/VEGFR2 signaling against high fatality associated with hepatic encephalopathy via sustaining mitochondrial bioenergetics functions. <i>Journal of Biomedical Science</i> , 2022 , 29,	13.3	O
33	KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1639-1649	6.1	23
32	Neuropilin-1 in the pathogenesis of preeclampsia, HIV-1, and SARS-CoV-2 infection: A Review. <i>Virus Research</i> , 2022 , 198880	6.4	1
31	Novel artemisinin derivative FO8643 with anti-angiogenic activity inhibits growth and migration of cancer cells via VEGFR2 signaling. <i>European Journal of Pharmacology</i> , 2022 , 175158	5.3	1
30	VEGFA from osteoblasts is not required for lamellar bone formation following tibial loading. <i>Bone</i> , 2022 , 163, 116502	4.7	O
29	Direct Interaction between N-Acetylcysteine and Cytotoxic Electrophile An Overlooked In Vitro Mechanism of Protection. 2022 , 11, 1485		0
28	Healing the Broken Hearts: A Glimpse on Next Generation Therapeutics. 2022 , 3, 96-116		1
27	Regulatory Role of JMJD6 in Placental Development. 1-12		0
26	Effect of RNAi-mediated survivin and Hypoxia-inducible factor 1日 ene silencing on proliferation, invasion, migration and apoptosis of gastric cancer BGC-823 cells.		O
25	Vascular Modulation of Antitumor Immunity: A Crosstalk Between Immune Cells and the Tumor Vasculature. 2022 , 1-27		0
24	The antibiotics supplemented bone cement improved the masquelet's induced membrane in a rat femur critical size defect model. 2022 ,		O
23	Serum Levels of VEGF-A and Its Receptors in Patients in Different Phases of Hemorrhagic and Ischemic Strokes. 2022 , 44, 4888-4901		1
22	RNAseq Analysis of Brown Adipose Tissue and Thyroid of Newborn Lambs Subjected to Short-Term Cold Exposure Reveals Signs of Early Whitening of Adipose Tissue. 2022 , 12, 996		О
21	Tumor Angiogenesis. 1-30		0
20	Cellular and molecular basis of therapeutic approaches to breast cancer. 2023 , 101, 110492		O
19	Vascular Endothelial Growth Factor Receptor 2: Molecular Mechanism and Therapeutic Potential in Preeclampsia Comorbidity with Human Immunodeficiency Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Infections. 2022 , 23, 13752		О
18	Altered Immunomodulatory Responses in the CX3CL1/CX3CR1 Axis Mediated by hMSCs in an Early In Vitro SOD1G93A Model of ALS. 2022 , 10, 2916		O

17	Biomarkers for anti-vascular endothelial growth factor drugs. 2022, 24,	0
16	Single dose S-ketamine rescues transcriptional dysregulation of Mtor and Nrp2 in the prefrontal cortex of FSL rats 1hour but not 14 days post dosing. 2022 , 65, 56-67	o
15	Vascular Endothelial Growth Factor (VEGF) is Expressed During Articular Cartilage Growth and Re-expressed in Osteoarthritis. 2010 , 39, 399-403	1
14	Preeclampsia and ObesityThe Preventive Role of Exercise. 2023 , 20, 1267	o
13	Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. 2022 , 18, 755-767	O
12	Novel VEGFR-2 Kinase Inhibitors as Anticancer Agents: A Review Focusing on SAR and Molecular Docking Studies (2016\(\textbf{\textit{0}} 021 \)).	O
11	Diabetic endothelial microangiopathy and pulmonary dysfunction. 14,	O
10	Regulation of aortic morphogenesis and VE-cadherin dynamics by VEGF. 2023, 497, 1-10	o
9	The extract of Curcumae Longae Rhizoma suppresses angiogenesis via VEGF-induced PI3K/Akt-eNOS-NO pathway. 2023 , 308, 116299	0
8	Stimulation of soluble guanylate cyclase activity with riociguat promotes angiogenesis and improves neovascularization after limb ischemia. 2023 , 372, 32-40	o
7	Vascular Endothelial Growth Factor as Molecular Target for Bronchopulmonary Dysplasia Prevention in Very Low Birth Weight Infants. 2023 , 24, 2729	1
6	A Novel Nanoemulsion Formula for an Improved Delivery of a Thalidomide Analogue to Triple-Negative Breast Cancer; Synthesis, Formulation, Characterization and Molecular Studies. Volume 18, 1219-1243	0
5	Evaluation of serum VEGF-A and interleukin 6 as predictors of angiogenesis during peri-implantation period assessed by Transvaginal Doppler Ultrasonography amongst women of prior reproductive failure: a cross-sectional analytical study 12, 284	0
4	Comparative transcriptome analysis of endothelial progenitor cells of HbSS patients with and without proliferative retinopathy. 153537022311579	o
3	Effect of algal metabolites in the inhibition of angiogenic channels for breast tumour.	0
2	A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity. 2023, e15152	0
1	Quantum evaluation and therapeutic activity of (E)-N-(4-methoxyphenyl)-2-(4-(3-oxo-3-phenylprop-1-en-1-yl) phenoxy)acetamide and its modified derivatives against EGFR and VEGFR-2 in the treatment of triple-negative cancer via in silico approach. 2023 , 29,	0